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ABSTRACT 
 Epilepsy is a brain disease defined by having recurrent and spontaneous 
seizures. The susceptibility to seizure is determined by seizure threshold, which 
describes the balance between excitatory and inhibitory neurotransmission in the brain. 
Epileptogenesis, the transition from normal brain to epileptic brain, is accompanied by a 
progressive reduction of seizure threshold and has been shown to have genetic 
influences. Expression of neuronal cyclooxygenase-2 (COX-2) gene, PTGS2, a primary 
gene that regulates prostaglandin synthesis in the normal brain, is enhanced by 
excitatory neurotransmission and is under tight regulation of N-Methyl-D-Aspartate type 
glutamate receptor (NMDAR) activity in cortical neurons. The 3’ untranslated region 
(3’UTR) of PTGS2 gene was found to be a key site of post-transcriptional regulation by 
NMDAR activity. However, deletion of T-cell intracellular antigen-1 (TIA-1), an RNA 
binding protein of COX-2 mRNA 3’UTR, did not affect COX-2 protein expression in 
mouse brain. Although TIA-1 deletion did not alter innate seizure threshold, it facilitated 
the acquisition of epilepsy and enhanced epileptogenesis-associated mortality. Further 
investigation revealed that TIA-1 knockout mice have an altered transcriptome in their 
hippocampi. Together, my findings illustrate an NMDAR-dependent regulatory 
mechanism of a known modulator of seizure threshold (COX-2) in neurons, and provide 
insight into the regulation of epileptogenesis by a novel genetic modifier (TIA-1).
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CHAPTER 1 Background 
1.1 Epilepsy 
 Epilepsy is a chronic debilitating neurological disease that the World Health 
Organization estimates affects 40-50 million people worldwide1,2. It is defined by a state 
of having recurrent and spontaneous seizures3, which are periods of abnormal, 
synchronous excitation of a population of neurons. Epilepsy is often associated with 
cognitive and learning deficits, psychosocial problems, and sudden unexplained death4-
8. In United States, it is estimated that epilepsy affects 1 in 26 Americans in their 
lifetime. Although seizures can be effectively suppressed with antiepileptic drugs 
(AEDs) in many cases, a significant percentage of patients exhibit pharmacoresistance 
during the course of their frequently lifelong condition9. 
1.1.1 Classifications of seizure and epilepsy 
 According to the most recent announcement from International League Against 
Epilepsy (ILAE)10, seizures and epilepsies are classified on three levels. On the first 
level, seizures are defined by their clinical mechanisms. Focal onset seizures are 
seizures that affect only one hemisphere of the brain, and generalized onset seizures 
are seizures that involve both sides of the brain. Seizures can be further classified into 
motor or non-motor. Motor seizures occur when electrical activity involves the motor 
area of the cerebral cortex and induces behaviors such as spasms, myoclonic jerks or 
tonic contraction of muscles, whereas non-motor seizure occur when electrical activity 
involves the sensory area of the cerebral cortex and induces non-motor outcomes such 
as emotional or cognitive alteration. When such seizures are associated with loss of 
consciousness, they are described as “absence” seizures. In a recent modification of 
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seizure and epilepsy classification announced by ILAE11, the terms “simple”, “complex” 
and “secondarily generalized seizure”, which have been used to describe the conscious 
level of a focal seizure or the propagation from focal seizure to a generalized seizure, 
have been replaced by “without” or “with impaired consciousness or awareness” and 
“evolving to a bilateral, convulsive seizure” respectively. On the second level, epilepsies 
are categorized by the type of seizures. For example, focal epilepsy is epilepsy with 
focal onset seizures. Finally, on the third level, epilepsy syndromes are defined by a 
combination of specific features other than seizure types. These features include onset 
age and the course of the disease in a patient (acute/chronic/recurrent), neuroimaging 
or their EEG characteristics. For example, Dravet syndrome is diagnosed typically in the 
first year of life in a normal child with various types of seizures. During the course of 
Dravet syndrome, children may demonstrate cognitive and behavior impairments. It is 
worth mentioning that genetic generalized epilepsy (GGE, adapted from “idiopathic 
generalized epilepsy” to reflect the knowledge that clinical genetic studies demonstrate 
a genetic basis for these epilepsies), which used to be categorized under epilepsy 
syndrome, now only refers to four specific types of epilepsy syndromes including 
childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy and 
generalized tonic–clonic seizures10.  
1.1.2 The hippocampal formation and epileptogenesis of temporal lobe epilepsy 
 The concept of epileptogenesis refers to the process occurs in brain that results 
in the development of epilepsy. It is known that certain brain pathologies as well as 
genetic factors all may contribute to epileptogenesis. A good example is temporal lobe 
epilepsy (TLE), the most common type of intractable (drug resistant) epilepsy. Onset of 
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recurrent seizures occurs after a latent period that can be as long as 5–10 years 12. 
Evidence suggests that the initial insults such as stroke, brain tumor or trauma facilitate, 
if not begin, the epileptogenesis process, which ultimately leads to recurrent seizures. 
The fact that a delay exists between the initial insult and the first seizure suggests that a 
progression of changes may occur in the brain during epileptogenesis. Specifically, TLE 
associates with limbic system dysfunction, and neurons located within limbic structures 
such as the hippocampus and amygdala have been shown to be more vulnerable to 
epileptogenic insults13.  
 The hippocampus is one of the most intensely studied structures of the brain. 
This is due to its role in learning and memory, its ability to form new neurons 
(neurogenesis), and its unique layered organization of neurons. The hippocampal 
formation consists of three sub-regions: dentate gyrus (DG), CA3 and CA1. The signal 
relay in the hippocampal formation, also known as the trisynaptic circuit14, is made up of 
three major cell groups collectively: granule cells in the DG, pyramidal neurons in CA3, 
and pyramidal neurons in CA1. In its simplest view, the entorhinal cortex transmits its 
signals to the DG via granule cell fibers known collectively as the perforant path. The 
DG then synapses on pyramidal cells in CA3 via mossy fibers. CA3 then fires to CA1 
via Schaffer collaterals. The DG has long been a focal point for studies on the 
molecular, cellular, and network mechanisms responsible for epileptogenesis in TLE15. 
Animal models of epileptogenesis reveal several major plasticity changes in the 
hippocampal formation. These changes include severe neuronal death 16, rewiring of 
axons of excitatory neurons17, abnormal neurogenesis18 and gliosis19, and altered 
channel properties of inhibitory neurotransmitter receptors20. These neurobiological 
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changes may alter the ion concentration in the brain, disrupting the balance between 
excitatory versus inhibitory synaptic transmission and facilitating synchronized firing of 
populations of excitatory neurons, which eventually support recurrent seizures21. 
Understanding how cellular alterations (e.g. selective loss of inhibitory neurons in the 
hilar region of the DG and sprouting of mossy fibers) influence functional properties is of 
vital importance for understanding fundamental aspects of epileptogenesis, such as the 
consequences of primary initial injuries, mechanisms underlying network 
synchronization, and progression of intractability. 
1.1.3 Genetic basis of epilepsy 
 Epilepsy has long been recognized to have a genetic basis. Epidemiologic 
studies have clearly shown an increased risk of being diagnosed with epilepsy in first-
degree relatives of people with idiopathic or non-lesional focal epilepsy, whereas twin 
studies have revealed higher concordance in monozygotic than dizygotic pairs 22. The 
genetic contribution to epilepsy has been emphasized as our knowledge in epilepsy 
etiology has increased. Many epilepsies that were considered “idiopathic” (a seemingly 
affirmative diagnosis with the underlying cause being unknown) in the past, have now 
been recognized as autoimmune-related (epilepsy caused by auto-antibodies against 
ion channels, receptors and accessory proteins important in governing the electrical 
activity of the brain23) and epilepsies with lesions that are only detectable by MRI 24. 
Importantly, many epilepsies idiopathic in nature have been reclassified as possessing 
a genetic basis.  Even epilepsies resulting from trauma, stroke, neoplasm, infection or 
congenital malformations, which have long been categorized as acquired epilepsies, are 
now known to have genetic contributions25. 
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 Genetic contributions to epilepsy have also been demonstrated in mice. As an 
example, mice from different strains presented different levels of sensitivity to seizure 
induction. Specifically, studies have demonstrated that DBA/2J mice displayed a much 
lower seizure threshold than C57BL/6J mice in response to electroconvulsive stimuli26 
and chemoconvulsant27. Further analysis through quantitative trait locus revealed a 
significant contributing locus on the distal arm of chromosome 1 27, and a loss-of-
function study using a transgenic mouse line suggested the gene Kcnj10 is responsible 
for the distinction in seizure susceptibility between strains28. This gene encodes a 
subunit of inward rectifying potassium channel Kir4.1 which is found predominantly in 
brain astrocytes. Indeed, potassium and glutamate buffering are significantly impaired in 
astrocytes from DBA/2J mice compared to those from C57BL/6J mice29. In fact, 
conditional knockout of Kir4.1 led to glial membrane depolarization and inhibition of 
potassium and glutamate uptake, as well as premature death resulting from stress-
induced seizures30. 
 However, certain forms of epilepsies are not associated with hereditary traits. For 
instance, idiopathic generalized epilepsies did not show 100% concordance in 
monozygotic twin studies31, implicating other influences, such as gene/environmental 
interactions in their etiologies. Indeed, genome-wide epigenetic alterations including 
DNA methylation, histone modifications, and microRNAs may account for functional and 
structural changes within the brain circuits, thus determining the onset or progression of 
epilepsies. For example, in human TLE, alteration in DNA promoter methylation and 
increased expression of DNA methyltransferase have been identified32. In addition, 
epigenetic profiling in rodent models of acquired epilepsies identified genome-wide 
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changes in DNA methylation as well 33. Posttranscriptional modification of histones, 
including transient and sustained changes in phosphorylation or acetylation of core 
histone proteins have also been reported in rodent models of acquired epilepsies34,35. 
Finally, it has been shown that noncoding RNAs, including microRNA and long 
noncoding RNA, played important roles in regulating brain excitability and seizure 
thresholds36. Together, these studies provide evidence of epigenetic influence on gene 
expression in epilepsy and hint on novel therapeutic approaches in treating or 
preventing epilepsy. 
1.1.4 Hypotheses of genetic architecture of epilepsies 
 Hypotheses made on genetic architecture of epilepsies include the “common 
disease, common variant hypothesis” or “common disease, rare variant hypothesis” 22. 
The “common variant” hypothesis believes that common mutations such as recurrent 
mutations in channel proteins are responsible for prevalence of epilepsies in the 
population, whereas “rare variant” hypothesis believes that epilepsies are phenotypes 
shared by distinct rare genetic mutations. Despite the discovery of some common 
genetic mutations, numerous evidence support the “rare variant” hypothesis as well. 
Accumulating evidence of association between genetically “complex” epilepsies with 
rare micro deletions emphasizes this contribution of rare variants. With this respect, 
de novo mutation has increasingly been revealed as an important mechanism in 
epileptic encephalopathies 25. However, unsuccessful early attempts to identify common 
variants through linkage and association studies argue against that common variants 
play an important role in genetically “complex” epilepsies 37. In addition, a combination 
of the two models is also possible. Not only common mutations (observed frequently 
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and exhibiting polymorphisms among the population) in channel protein genes can lead 
to significant phenotypic effects, rare mutations 37 can also induce functional deficiency 
in electrophysiological properties of these channels.  
 Current genetic and genomic technologies for mutation identification are 
changing the landscape of genetics research and generating an enormous amount of 
information regarding the contributions of genetics to common complex epilepsies. To 
date (March 2018), 9 meta-analysis studies, 7 large scale genome-wide association 
studies, and numerous family-based linkage/association studies have been conducted 
according to the online Epilepsy Genetic Association Database (epiGAD, 
http://www.epigad.org/), providing evidence for both the “common variant” and “rare 
variant” hypotheses. 
1.1.4.1 Common genetic variants of epilepsies 
 Many common genetic variants of epilepsies have been identified in monogenic 
epilepsies. In humans, a small proportion (~1%) of epilepsies exhibit a clear familial 
pattern of Mendelian inheritance and can be classified into Mendelian/monogenic 
epilepsies. These monogenic epilepsies, often heritable, share similar phenotypes in a 
pedigree and have been shown to be associated with mutation(s) in a single gene. 
Linkage analysis, a strategy to detect cosegregation between a phenotype and the 
underlying causative gene locus, on these rare monogenic forms of epilepsy have 
identified more than 20 genes with a major effect on susceptibility 22. The majority are 
genes directly coding for ion channel subunit proteins 38 (e.g. voltage-gated 
calcium/sodium/potassium channels, GABAA receptor, nicotinic acetylcholine receptor, 
etc.), with the remainder being genes that encode protein that interact with channel 
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proteins. For instance, the leucine-rich glioma-inactivated 1 gene (LGI1), which is a 
susceptible gene in familial temporal lobe epilepsy39, encodes a protein with a role in 
the synapse as a regulator of potassium channels and of glutamate α-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid receptor (AMPAR). The EF-Hand Domain 
Containing 1 (EFHC1) gene, commonly mutated in Juvenile Myoclonic Epilepsy (an 
epilepsy syndrome characterized by myoclonic seizures and generalized convulsions 
that have onset between eight to 25 years of age) 40, encodes a protein that interacts 
with the R-type voltage-dependent calcium channel (Cav2.3) and is involved in 
neurotransmitter release. Other genes have more or less been associated with brain 
development and/or receptor signaling. Many of these genes have now been applied as 
clinical tools in genetic testing of epilepsies 25,37,38.  
 Other common genetic variants have been identified as copy number variance 
(CNV). CNVs are chromosomal rearrangements including deletions, duplications or 
insertions that range in size from approximately one kilobase to several megabases. 
CNVs can be defined into two groups: private and recurrent 25. Compared to private 
CNVs, which are rare and randomly located across the genome, recurrent CNVs occur 
at genomic hot spots and are thought to arise de novo repeatedly in a population. While 
many CNVs have unknown functional ramification and are dispersed throughout the 
genomes of healthy individuals at high frequency, others could result in significant 
alteration of gene expression and/or function 37. CNVs can be detected by gene 
targeted studies using probes directed to specific genetic regions of known epilepsy 
genes 37. Meanwhile, array comparative genomic hybridization (Array CGH) and Single 
Nucleotide Polymorphism (SNP) genotyping arrays are genome-wide methods to detect 
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CNVs. These technologies can also be targeted to specific chromosomal regions 37. 
Array CGH as a type of whole genome analysis is capable of detecting genomic 
rearrangements of kilobases in size. Compared to conventional karyotyping, which has 
a resolution of megabase level, Array CGH significantly increases the yield of the 
screening. It is powerful in cases when CNVs have boundaries extending beyond the 
target gene 37. In the clinic, Array CGH has largely replaced karyotyping as a key 
genetic diagnosis tool, although karyotyping is still widely used as a validation strategy 
in research41. Using Array CGH, a micro deletion at 15q13.3 has been recurrently 
detected in cohorts of subjects who are resistant to antiepileptic medication 42,43. This 
micro deletion was first characterized in a number of patients with intellectual disability, 
most of whom suffered from seizures 37. It is one of the most prevalent genetic risk 
factors identified for the genetic generalized epilepsy syndromes and has an unusually 
high frequency in epilepsy cohorts. Seven genes are located within this lesion region, 
with the nicotinic acetylcholine receptor α7 (CHRNA7) gene being the most likely 
pathogenic factor. 
1.1.4.2 Rare genetic variants of epilepsies 
 Although recurrent CNVs have been identified as common mutations in 
epilepsies, other studies suggest that rare non-recurrent CNVs are also likely to play a 
role in the genetic etiology of epilepsy. In one study, array CGH identified 24 non-
polymorphic mutations including 2 rare deletions in a cohort of 102 patients with various 
types of epilepsy with or without additional neurodevelopmental abnormalities 44. Two 
recent genome-wide studies also discovered rare CNVs in epilepsies: Enrichment of 
large (>1 Mb) deletions were found in a diverse spectrum of sporadic epilepsy 
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syndromes 45, the majority of which were seen in one individual each. Ten percent of 
subjects tested in another study carried one or more rare CNV(s) that have not been 
previously found to be enriched in controls46. 
 De novo mutations defines novel mutations that often occur in a parental 
germline or during embryogenesis. With the rapid advances in sequencing technology, 
next-generation sequencing (NGS) techniques including whole exome and whole 
genome sequencing have been used to identify genetic contribution to epilepsies. Due 
to their high sequencing resolution, these techniques are frequently used to identify de 
novo mutation in epilepsy etiology. Dravet syndrome, an epileptic encephalopathy 
(sclerosis accompanied by epileptiform activity), has been shown to be primarily caused 
by de novo mutations occurring during the early stages of embryonic development. 
Most Dravet syndrome cases are caused by mutations in the SCN1A gene, which 
encodes the α-subunit of the type 1 voltage-gated sodium channel 25. Using SNP array, 
the PCDH19 gene, which encodes proto-cadherin 19 on chromosome X, has also been 
associated with Dravet-like syndrome or familial epilepsy and mental retardation that 
was limited to females. Fifteen novel point mutations were identified after screening 150 
unrelated patients with febrile and afebrile seizures, suggesting de novo mutations in 
PCDH19 gene should be carefully examined in this Dravet-like syndrome, even in the 
absence of family history and/or mental retardation 47. Although epileptic 
encephalopathies are typically monogenic epilepsies and are rare at the population 
level, correct explanation of the cause of epileptic encephalopathies is critical in 
expanding our knowledge in epilepsy genetics and susceptible gene pools. New genes 
in which de novo mutations can produce an epileptic encephalopathy are consistently 
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being identified25, including Syntaxin binding protein 1 (STXBP1), PCDH19, Sodium 
voltage-gated channel alpha subunit 2 (SCN2A) and Cyclin dependent kinase-like 5 
(CDKL5). Sequencing technologies have identified new epilepsy genes in other forms of 
epilepsies 48. A 3.2 Mb segment was found within 16p13.3 through linkage analysis in a 
large family that has focal epilepsy and intellectual disability with autosomal recessive 
inheritance 49. Targeted capture and sequencing of the mapped interval identified a de 
novo mutation in TBC1 domain family member 24 (TBC1D24) gene, a gene of unknown 
function. Acknowledging the risk of potential false positive findings, whole-genome 
sequencing has demonstrated strong power in detecting de novo mutation from limited 
sample sizes. In one case of severe epileptic encephalopathy with early-onset seizures, 
whole-genome sequencing of the affected patient and her unaffected parents and 
sibling50 successfully identified a single novel de novo missense mutation in SCN8A 
gene, which encodes the voltage-gated sodium channel Nav1.6. 
1.1.4.3 Insufficient finding of common genetic variants of epilepsies from 
genome-wide association studies 
 In many common diseases, including several with heritability estimates lower 
than those of epilepsies, robust evidence from genome-wide association studies 
(GWAS) has demonstrated that common polymorphisms increase the risk of disease, 
although the individual attributable risk is relatively small 25. To date, however, results 
obtained from GWAS in epilepsy have been relatively limited and a clear picture of the 
role of common polymorphisms has not yet emerged.  
 Although linkage analysis has been successful in some monogenic epilepsies, 
early linkage/association studies in genetic “complex” epilepsy, whose genetic 
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architecture is no doubt far more complicated than initially thought, has been notoriously 
unsuccessful. Unlike monogenic epilepsies, most epilepsies present without a 
significant family history. Thus, the majority of familial epilepsies do not exhibit 
Mendelian inheritance. Rather, the inheritance pattern is complex, suggesting that the 
phenotype is multifactorial in origin, and is caused by the interaction of a few (i.e. 
oligogenic) or multiple (i.e. polygenic) genetic variants, possibly with a further influence 
from environmental factors. Characterization of epilepsies with a polygenic basis is thus 
a genetically “complex” major challenge. Initial efforts in association mapping of 
epilepsy genetic loci have been underpowered and have focused on several candidate 
genes 51, thus yielding few findings. Initial attempts of genome-wide association studies 
also failed to identify valuable candidates, even with considerable sample size 52.  
 To date, seven epilepsy GWAS could be found in PubMed. The initial two studies 
focused on focal epilepsy which has long been proposed to have a strong genetic 
component. The first GWAS study in 2010 included more than 6,000 controls and more 
than 3,000 individuals with focal epilepsies 52 whose phenotypes distributed across a 
broad spectrum. Although the study was sufficiently powered for detecting associations 
of variants with modest effects, none reached the significance required by genome-wide 
analyses. The author concluded that it is unlikely that common SNPs account for risk in 
broadly defined focal epilepsies, at least in the European population examined.  
 A second GWAS, published in 2012, also focused on focal epilepsy in subjects 
from the Han Chinese population 53. This study examined 1,087 focal epilepsy patients 
with acquired or unknown etiology and 3,444 controls. These patients were further 
divided into a discovery cohort and a replication cohort to achieve a two-stage 
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approach. Through combined meta-analysis of the two stages, a single SNP was 
identified. The SNP is located on chromosome 1q32.1 within the CAMSAP1L1 gene, 
which encodes a calmodulin-regulated spectrin-associated cytoskeletal protein.  
 Other groups using GWAS focused on the analysis of genetic generalized 
epilepsy (GGE). Previous family-based genome-wide linkage studies of GGE had 
limited impact given that most studies had relatively small sample sizes. Thus, a recent 
genome-wide linkage meta-analysis conducted by the EPICURE Consortium attempted 
to overcome the power issue by using a much larger sample size 54. The study 
consisted of 379 GGE multiplex families including 982 relatives with GGEs. They still 
failed to detect any significant linkages, but the broad phenotype definition was rather 
broad. However, when phenotypes were further specified into GGE subtypes, a 
significant linkage was found for myoclonic and absence seizures at 2q34 and 13q31.3, 
emphasizing the importance of phenotype stratification on the ability to detect potential 
genetic contributions in GWAS.  
 It is somewhat disappointing that even with a greatly expanded sample size, 
genome-wide studies in complex epilepsy have only identified a handful of susceptibility 
loci. A recent study conducted by the International League Against Epilepsy Consortium 
on Complex Epilepsies combined genome-wide association data from 12 cohorts of 
individual datasets with ethnically matched controls and cases. Epilepsies were grouped 
into GGE, focal epilepsy, or unclassified epilepsy. Although the sample sizes of the 
combined meta-analysis were 8,696 cases and 26,157 controls, the study identified only 
2 loci, SCN1A and PCDH7 genes (2q24.3 and 4p15.1, respectively) that reached 
genome-wide significance in epilepsy cohort (regardless of the epilepsy subtype). Both 
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genes had been identified in previous association studies of epilepsy or epileptic 
encephalopathy. For the cohort of GGE patients, a single signal at 2p16.1 was also 
detected whereas no SNP achieved genome-wide significance for focal epilepsy. 
Nonetheless, the data suggest that specific loci (SCN1A) can increase risk for epilepsy 
broadly, or can have effects limited to a specific epilepsy subtype (e.g. Dravet 
Syndrome).  
 Another group focused on identifying single nucleotide variants (mutation of 
single nucleotide that is not shared among a population) in epilepsy using exome 
sequencing, instead of looking at SNPs 55. In this study, the authors compared the 
exome sequences from subjects of European ancestry consisting of 242 controls and 
118 individuals with GGE, including Juvenile Myoclonic Epilepsy and Absence Epilepsy. 
However, no significant association was obtained when searching for shared genetic 
mechanisms between GGE subtypes. The authors argued that the impact of any 
individual single-nucleotide variant in epilepsy is possibly small. They then suggested a 
gene-based approach (such as SNP-based method, in which each genotyped SNP is 
tested for association) in future sequencing studies of epilepsy predisposition. However, 
in a previous study using exome sequencing of large cohorts of people with GGE, even 
when the researchers focused specifically on finding mutations in genes encoding ion 
channel proteins, they were unable to find any mutation in a single major unidentified 
gene which accounts for epilepsy phenotypes 56. 
 In summary, results from GWAS and genome-wide linkage in the most common 
forms of epilepsies suggest an extremely complex genetic architecture in these 
genetically “complex” epilepsies. These may involve both rare and common variants 
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that could be either disease predisposing or protective. These variants would most likely 
contribute to small effects.  A complicated multi-genetic or gene-environment interaction 
may further elevate the complexity. This is possible considering the known variability of 
penetrance (i.e. the proportion of individuals with a mutation who exhibit clinical 
symptoms) observed in monogenic epilepsies 48.  
1.1.5 Future of genetic studies of epilepsy 
 The genetic architecture of genetic “complex” epilepsies, like other disorders, are 
believed to be highly polygenic with heritability distributed across many hundreds of loci. 
Even where rare variants have been confirmed, as in the case of rare CNVs, they 
present with only partial penetrance, thus suggesting the co-existence of genetic 
variants that each may contribute to only a small fraction of the overall heritability. 
Hence, enormous sample sizes have been required before individual genes begin to 
stand out from the background. The importance of study scale can be seen from the 
success in genome-wide studies of certain psychiatric disorders. Recent analysis of 
schizophrenia risk by the Psychiatric Genomics Consortium encompassed data from 52 
study cohorts totaling 82,000 individual human genomes 57. The size of such studies 
enabled identification of 100 more loci that reach a genome-wide significance, 
regardless of potential genotyping error and variant population substructure. Large-
scale meta-analyses have identified 20 risk loci of late-onset Alzheimer’s disease 
(sample size of 72,000 genomes) and 10 more loci affecting bipolar disorder (sample 
size of 15,000 genomes). 
 On the other hand, the depth of genome wide studies can be enhanced by 
application of exome and whole-genome sequencing methods to large cohorts of 
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affected and unaffected individuals. Early rational biological candidate-gene studies in 
psychiatric disorders, which attempted to nominate candidate genetic variants for 
association studies by known disease biology, have been largely unsuccessful 57. A 
similar idea was to use targeted panels of genes consisting of those previously found to 
be associated with disease 58. However, excessive focus on limited known candidates 
hinders the progression toward revealing the underlying genetic mechanisms. An 
extreme example would be schizophrenia, in which more than 1,400 candidate-gene 
studies have been published, with half of them focused on the same 18 genes 57. While 
exome sequencing may still not be comprehensive enough because it overlooks 
regulatory sequences, innovations in NGS technology have started to allow such 
studies to be pursued on a large scale. In schizophrenia and autism, large scale studies 
based on exome or whole genome sequencing in large numbers of cases and their 
relatives have taken place. In epilepsy, a large-scale international collaborative effort 
(Epi4k project) has also been launched to sequence epilepsy genomes 59. 
 Besides expanding the scale and depth of genome wide studies to identify new 
genes that are associated with epilepsy, effort should also be spent on studying known 
modulators of epileptogenesis. Since numerous genes including channel protein genes 
and neuromodulator genes have already been identified as potential regulators of 
epileptogenesis, understanding the mechanisms through which these commonly 
discovered genes regulate disease progression is equally important. A well-studied 
pathway that has been associated with epilepsy is the arachidonic acid pathway of 
prostaglandin synthesis. 
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1.2 The role of cyclooxygenase-2 gene in seizure generation and epileptogenesis 
 Prostaglandins (PGs) are potent paracrine and autocrine lipid mediators that 
contribute to a broad spectrum of physiological and pathophysiological activities that 
range from gastric acid secretion60 and blood flow61 to inflammation62 and tumor 
growth63. Cyclooxygenase-2 (COX-2) is one of two isoforms of COX that catalyze the 
first committed step in the metabolism of arachidonic acid (AA) to PGs 64. COX-
dependent PG production increases rapidly and transiently in the brain following acute 
convulsive seizures65,66 and pharmacological inhibitors of COX-2 activity reduce the 
seizure threshold 67-69, an effect that is likely due to the loss of anti-convulsive PGs 67. 
This section will introduce the COX-dependent production of PGs, as well as the 
regulation of COX-2 gene expression and activity, and finally, how COX-2 may 
contribute to seizure generation and epileptogenesis. 
1.2.1 The arachidonic acid pathway of prostaglandin synthesis 
 Synthesis of PGs is mediated via the AA pathway (Fig.1.1) 64. Excitatory synaptic 
activity triggers release of AA from membrane phospholipid stores via activation of 
phospholipase A2 (PLA2). Of the many members of this large family of enzymes 70, 
basal and activity-dependent release of AA from neurons is specifically catalyzed by the 
group IV cytosolic phospholipase A2α isozyme (cPLA2α) 71. Free AA can then be rapidly 
metabolized by the cyclooxygenase enzymes to produce prostaglandin G2 (PGG2), an 
intermediate product that is subsequently reduced to prostaglandin H2 (PGH2). PGH2 is 
the substrate for various prostaglandin synthases (PGSs) each producing specific 
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bioactive PG. The nature of the biological responses elicited by these PGs is dictated by 
specific membrane G protein-coupled receptors (GPCRs)72.  
 
Fig. 1.1 Synthesis of PGs 
 
 COX enzymes are homodimers, with each monomer comprising three domains: 
a N-terminal EGF-like domain (serves as a dimerization domain holding the monomers 
together), a membrane-binding domain and a C-terminus catalytic domain that 
comprises approximately 80% of the protein and contains the two distinct but 
structurally and functionally interconnected catalytic sites64. Thus, COX enzymes 
catalyze two reactions: 1) a cyclooxygenase reaction in which AA plus two molecules of 
dioxygen are converted to PGG2 and 2) a peroxidase reaction in which PGG2 is reduced 
to PGH2 by two electrons. COX enzymes are integrated via their membrane binding 
domains into a single leaflet of the lipid bilayer on the luminal side of the endoplasmic 
reticulum and the nuclear envelope. Four alpha helices of the membrane-binding 
		19	
structure create the entrance to a hydrophobic channel that provides the access route 
for AA released from the hydrophobic core of the lipid bilayer, where the 
cyclooxygenase reaction occurs. The peroxidase reaction occurs at the heme-
containing active site located near the protein surface64.  
1.2.2 Regulation of COX-2 gene expression  
 In general, whereas the isozyme cyclooxygenase-1 (COX-1) is constitutively 
expressed throughout the body, constitutive COX-2 expression is only detected 
primarily in kidney, gastrointestinal tract, and thymus, with the most prominent 
expression found within the brain 73. In the central nervous system (CNS), COX-2 is 
expressed constitutively in discrete subpopulations of glutamatergic neurons, where it is 
localized to somata and dendritic arborizations, particularly in the primary neurons of the 
CA3 region of the hippocampus, cortical layers 2/3, and lateral amygdala 74. While the 
regulation of COX-2 expression has been studied extensively in non-neuronal cell 
types, much less is known about its regulation in neurons. 
1.2.2.1 COX (PTGS) genes and protein structure 
 COX1 and COX-2 are homologous ER-resident N-glycoprotein isozymes that are 
produced from different genes (PTGS1 and PTGS2, respectively, in the human 
genome) located on different chromosomes64. COX-1 is present in many cell types in a 
constitutive manner whereas COX-2 expression is typically transient. Although both 
genes can be induced by phorbol esters or growth factors, COX-2 mRNA can be 
induced by a variety of other stimuli. This is likely due to the sequence difference 
between PTGS genes. The promoter region of PTGS1 gene contains three Sp1 sites 
and lacks a TATA or CAAT box 75. In contrast, the PTGS2 gene promoter contains a 
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TATA box motif and a number of cis-acting elements that are recognized by various 
transcription factors. The 3’ untranslated region (3’UTR) of COX-2 mRNA is a second 
regulatory region that has the capacity to bind numerous RNA binding proteins (RBPs) 
that can affect stability and/or translation of the transcript 76. In contrast, COX-1 mRNA 
is very stable and its 3’UTR lacks the sequence elements that bind to these RBPs77. 
The properties of COX-2 regulation are characteristics of “immediate early genes”. 
Moreover, COX-2 but not COX-1 protein, contains a unique segment near its C-
terminus78, which renders additional control over COX-2 protein stability (discussed 
later).  
 Subtle interspecies differences exist in the sequences of PTGS genes between 
humans and other mammals, whereas COX isoforms from invertebrates have 
enormous cross-species differences79, suggesting that duplication events of COX 
isoforms occurred independently in lower organisms. The fact that COX evolved 
multiple isoforms in all organisms known to express it suggests distinct regulatory 
mechanisms and biological roles for PTGS genes. In support of this, when the coding 
sequence of the mouse Ptgs2 gene was replaced by that of Ptgs1 in a transgenic 
mouse line, although the latter could be induced in a manner analogous to COX-2, it 
only partially compensated for the renal and female reproductive phenotypes associated 
with loss of COX-2, indicating distinct roles of COX enzymes80. 
1.2.2.2 Multi-dimensional regulation of COX-2 expression and activity 
 COX-2 gene expression is regulated through transcriptional, post-transcriptional, 
and posttranslational mechanisms 75,81. On top of that, COX-2 enzymatic activity is also 
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tightly regulated (discussed below), resulting in a multi-dimensional and complex set of 
mechanisms to control PGs level.  
 Numerous transcriptional regulatory proteins are known to bind to cis-acting 
elements in the 5’ regulatory region of the PTGS2 gene. These proteins regulate both 
the induced and constitutive expression of COX-2. As an example, Cyclic AMP 
response element binding (CREB) protein mediated both transient COX-2 transcription 
in neurons and long-lasting COX-2 transcription in astrocytes and microglia induced by 
pilocarpine82. Genetic inhibition of CREB markedly attenuated status epilepticus-
induced COX-2 up-regulation in hippocampal neurons82. Moreover, recent evidence 
from cultures of cortical neurons indicated that basal COX-2 expression is modulated 
transcriptionally by both CREB and Sp1 83.  
 The COX-2 mRNA 3’UTR, which in the mouse is >2kb in length, was initially 
proposed and subsequently shown to possess cis-acting elements that regulated RNA 
stability and translation efficiency 76,84,85. These and other studies identified an 
Adenylate/Uridylate (AU)-rich element (ARE) located within 80 bases of the coding 
sequence stop codon that is a key RBP recognition site. This ARE is 89% AU-rich and 
contains seven AUUUA pentanucleotide motifs, which can be divided into two separate 
AU domains: 1) a 5’ domain consisting of three overlapping AUUUA pentameric 
nucleotide motifs, and 2) an adjacent 3’ domain containing four sequential AUUUA 
pentamers. The nanomeric consensus sequence, UUAUUUA(A/U)(A/U), which has 
been suggested to be the key determinant of mRNA stability 86, is embedded within 
each of these domains. Lastly, a sequence of eight U nucleotides is positioned just 3’ of 
the second AUUUA domain. Numerous RNA binding proteins (RBPs) have the capacity 
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to bind this regulatory element, which then affect stability and/or translation of the 
transcript 76. Table 1.1 describes a list of RBPs that have been shown to bind to COX-2 
mRNA. All of these RBPs show evidence of brain expression, implying that they may 
also regulate COX-2 expression in neurons, a hypothesis that needs to be further 
explored. CUG binding protein 2 (CUGBP2) is one such RBP that is known to bind to 
COX-2 3’UTR and suppress its translation. CUGBP2 was induced by radiation in 
epithelial cells and, upon binding to the first 60nt of COX-2 3’UTR stabilized COX-2 
mRNA yet decreased COX-2 protein translation via disrupting polysome distribution, 
leading to increased cell apoptosis 87. T cell intracellular antigen-1 (TIA-1, described in 
detail in section 1.3) is another RBP that has been shown to suppress COX-2 mRNA 
translation by binding to this ARE 88.  
Table 1.1. Expression and function of potential RBPs for COX-2 
 
RBPs Able to bind COX-2 ARE 
Known regulatory functions for 
COX-2 in non-neuronal cells 
Expressed in 
brain 
HuR Yes 89, 90 mRNA stabilization Yes 91, 92, 93 
TIA-1 Yes 89, 90 Translational suppression Yes 93, 94, 95 
TIAR Yes 89, 90 ND Yes 96, 97 
AUF1 Yes 89, 98 ND Yes 91, 92, 99 
AUF2 Yes 89, 98 ND Yes 100 
RBM3 Yes 89 ND Yes 
101, 102, 103, 
104, 105 
TTP Yes 106, 107 mRNA destabilization Yes 91, 93 
CUGBP2 Yes 87, 108 mRNA stabilization, Translational suppression Yes 
109 
hnRNP A3 Yes 89 ND Yes 110 
 
Abbreviation: TIAR, TIA-1 related protein; AUF1/2, ARE/poly(U)-binding/degradation factor 1/2; RBM3, 
RNA binding motif protein 3; TTP, tristetraprolin; CUGBP2, CUG binding protein 2; hnRNP A3, 
heterogeneous nuclear ribonucleoprotein A3; ND, not determined for COX-2; 
 
 Besides RNA binding proteins, COX-2 mRNA can also be targeted by 
microRNAs (miRNAs), which are short (1922 nucleotides) non-coding RNAs that bind 
partially complementary sequences within the 3’UTR of mRNA. Binding to miRNAs 
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normally leads to functional repression of target transcripts. In non-neuronal cells, COX-
2 3’UTR is recognized by a host of miRNAs including miR-289 111, miR-101a112,113, miR-
199a113, miR-143114, miR-137115 and miR-144116. Importantly, miRNAs could also 
compete with RBPs for 3’UTR binding such as in the case of miR-16. RNA binding 
protein hnRNP-K binds COX-2 3’UTR in S-100 calcium-binding protein-stimulated 
monocytes 117, which competes with miR-16 binding to ARE and stabilizes COX-2 
mRNA. 
 COX-2 mRNA translation is also regulated by alternative usage of its 
polyadenylation site 118. COX-2 3’UTR has a proximal and a distal polyadenylation site. 
The proximal site is weaker (less used) than the distal site due to its non-canonical 
polyadenylation signal. Upstream efficiency elements (USEs) are sequence elements 
located upstream of the polyadenylation sites. Synergistic binding of trans-acting 
factors119 to USE is required for proximal site adenylation. The significance of this 
alternative mRNA processing event has been implicated in cancer.  Colorectal cancer 
cells, for example, selectively stabilize the polyadenylation variant of COX-2 mRNA 
which lacks the distal segment of the 3’UTR during confluence 106, suggesting that 
cancer cells may exploit this mechanism to escape rapid COX-2 mRNA decay. 
 Upon translation into protein, COX-2 is under further regulation through 
mechanisms that affect protein half-life and enzymatic activity. COX-2 protein has a 
unique C-terminus 19-amino acid (19-aa) segment that is crucial for its entry into the   
ER-associated degradation (ERAD) system, where COX-2 protein is transported into 
cytoplasm for degradation by the 26S proteasome 78. COX-2 protein degradation has 
also been found to be initiated by suicide inactivation of the enzyme120, leading to COX-
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2 enzymatic inactivation in the presence of substrate 64. This is supported by the fact 
that COX-2 protein degradation is significantly blocked by non-steroidal anti-
inflammatory drugs (NSAIDs) 121. PTGS genes are the best known cellular target for 
NSAIDs. Most of the NSAIDs inhibit both the PTGS genes, although they vary in their 
efficacies against inhibiting catalysis of the two COX isozymes 122. However, evidence 
suggests that NSAIDs can also regulate COX-2 expression. They do so by potentially 
altering upstream signaling pathways of COX-2 transcription, including peroxisome 
proliferator-activated receptor gamma (PPARγ)123, NF-kB 124 and anti-apoptotic kinase 
(Akt)125. Endogenously, COX-2 enzymatic activity can be regulated by nitric oxide (NO), 
a free radical but also a signaling molecule. NO has a dual effect on COX-2 activity126. 
On the one hand, a low amount of NO potentiates COX-2 activity. As a result, nitric 
oxide synthase (NOS) inhibitors block PG synthesis by inhibiting the generation of 
peroxynitrite, which is required to initiate PTGS genes cyclooxgenase activity. On the 
other hand, a large amount of NO blocks COX-2 activity, possibly through reducing the 
heme group of PTGS genes. In macrophages, exogenous NO was sufficient to block 
COX-2 protein induction and activity, whereas inhibition of NO signaling increased 
COX-2 protein induction and activity after LPS stimulation 127. Furthermore, NOS has 
been shown to bind to COX-2 protein directly and mediate its enzyme activity 128,129. 
 Because COX-2 gene and protein expression and enzymatic activity can be 
regulated on numerous levels, it is not surprising that upstream signaling pathways 
could have different impacts on COX-2 expression and activity via distinct mechanisms. 
As an example, COX-2 transcription has been shown to be up-regulated by β-catenin 
130. β-catenin can also stabilize COX-2 mRNA through direct binding to the β-catenin-
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responsive element located on COX-2 3’UTR 131. Glucocorticoids, through activating 
glucocorticoid receptors (GRs), can interact with transcription factors such as NF-κB 
and AP-1 to suppress COX-2 transcription. However, GRs have also been shown to 
block p38 phosphorylation, which in turn bocks its interaction with a p38-responsive 
ARE on COX-2 3’UTR and destabilize COX-2 mRNA 132. Interleukin-1β (IL-1β) signaling 
is also known to induce COX-2 transcription, possibly through the canonical NF-κB 
signaling 133. However, IL-1β has also been shown to enhance COX-2 mRNA stability 
via a p38/MAPK-dependent mechanism 134, possibly through further activation of 
downstream RNA binding proteins such as hnRNP A0 135 or HuR 90. 
1.2.2.3 COX-2 gene expression and N-Methyl-D-Aspartate type glutamate receptor 
activity 
 COX-2 is constitutively expressed in glutamatergic neurons of the CNS 74 and 
neuronal COX-2 expression is coupled to endogenous post-synaptic N-Methyl-D-
Aspartate type glutamate receptor (NMDAR) activity and as such, can be modified by 
changes in excitatory neuronal activity. Thus, COX-2 mRNA and protein expression 
were markedly induced after high frequency stimulation of the perforant pathway in vivo 
and antagonism of the NMDAR suppressed basal COX-2 mRNA levels by cortical 
neurons in culture 83,136. Activation of the NMDAR is known to induce neurotoxicity in 
various in vivo and in vitro models which results from COX-2-mediated excessive 
production of prostaglandins. Brain damage induced by cortical microinjection of NMDA 
was attenuated by COX-2 inhibitors 137-139, suggesting the detrimental role of COX-2 
proteins in these conditions. It is not entirely clear which PG(s) and downstream PG 
receptor(s) are responsible for neuronal excitotoxicity. The PGE2 receptor EP1 has 
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been shown to mediate the neurotoxic effects of NMDA by increasing intracellular Ca2+ 
through impairing Na+/Ca2+ exchange 140. Pharmacologic or genetic inhibition of EP1 
attenuated lesions induced by microinjection of NMDA or PGE2. In addition, COX-2 
inhibition protected from NMDA induced neurotoxicity in mixed cortical neuron 
culture141. This protective effect was overcome by PGE2 administration and EP1/3 
agonist, but not by PGF2a administration 142, further suggesting the contribution of PGE2 
and EP1 signaling. The type of PGE2 receptor activation is crucial in determining the 
downstream effects. Evidence suggests that PGE2 is indeed protective in cerebral 
ischemia via acting on EP2 143. Similarly, injection of selective EP4 agonist reduced 
lesion volume induced by intrastriatal injection of NMDA 144. Interestingly, it has been 
shown that the concentration and subcellular targeting of NMDA make important 
differences in mechanisms through which COX-2 and PGs mediate excitotoxicity. A low 
dose of NMDA can stimulate both synaptic and extrasynaptic NMDAR (referred to as 
bath NMDAR stimulation hereafter) and lead to excitotoxicity. However, synaptic 
NMDAR stimulation before bath NMDAR stimulation made a neuron resistant to 
excitotoxicity 145. This sequential induction of synaptic then extrasynaptic NMDAR is 
crucial in NMDAR-mediated maximal PG production, as synaptic NMDAR stimulation 
increased COX-2 expression in neurons, whereas bath NMDAR stimulation increased 
polyunsaturated fatty acids, the substrate for COX-2 in neurons. Lastly, COX-1 also 
contributes to NMDAR-mediated excitotoxicity. On the one hand, COX-1 inhibition 
blocked NMDA induced PGE2 production and free radical damage in hippocampus 146, 
suggesting that NMDA induced PG production via COX-1 can be detrimental. On the 
other hand, microglia produced COX-1 was protective in the model of cortical NMDA 
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microinjection147, suggesting that COX-1 protein may be protective in excitotoxicity 
depending on its cellular source. In support of this, COX-1 knockout mice exhibited 
increased susceptibility to ischemic brain injury 148. 
1.2.3 Functions of COX-2 enzyme 
 The complex and multi-dimensional regulation of COX-2 level is a reflection of 
the importance of this enzyme. Indeed, COX-2 has been shown to participate in 
numerous physiological activities, and has been implicated in various pathological 
conditions. Other than the well-studied physiological roles of COX-2 in inflammation, 
fever and pain, COX-2-mediated PG production has been implicated in bone formation 
149 and renal function 150. COX-2 is also required in angiogenesis, the development of 
blood vessels, through facilitating the production of vascular endothelial growth factor 
(VEGF) 151. COX-2 derived PGI2 is critical in different aspects of female reproduction, 
including facilitating oviduct dilation and embryo transfer, as well as embryonic 
development 152. Moreover, estradiol induced COX-2 expression and PGE2 production 
in preoptic neurons, which is critical in masculinization 153.  
 In the normal brain, the activity of COX-2 contributes to physiological functions, 
including regulation of neuronal excitability and plasticity 154. COX-2 inhibition 
suppressed LTP and LTD in mossy-fiber pathway via a mechanism that is independent 
of NMDAR activation 155. Under pathophysiological conditions in the CNS, COX-2 
function has been identified in ischemia, neurodegeneration, schizophrenia, 
hyperalgesia and, epilepsy and epileptogenesis. COX-2 expression was induced by 
various models of ischemia and COX-2 inhibition before and soon after ischemic insult 
reduced the extent of cerebral damage 148. COX-2 protein was induced after retinal 
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ischemia whereas COX-2 inhibitors prevented neuronal death and hematogenous cell 
infiltration 156. In animal models, neuronal COX-2 overexpression led to an age-
dependent increase of neuronal apoptosis and gliosis, as well as an age-dependent 
deficit in spatial memory 157. In humans, COX-2 has been implicated in progression of 
Alzheimer’s disease (AD). AD brains had increased COX-2 expression whereas 
NSAIDs retarded the course of dementia in AD patients 158, although in another study159 
NSAID was found to have no effect on memory in healthy young adults. COX-2 has also 
been shown to be responsible for increased PGE2 production and in turn, increased 
Kynurenic acid (KYNA) production, which mediates NMDAR antagonism in 
schizophrenia 160. In spinal cord, NMDARs were involved in mediating acute mechanical 
nociceptive processing through activation of NOS and COX-2 enzymes 161. COX-2 was 
found to constitutively express in spinal dorsal and ventral horns and in the dorsal root 
ganglia whereas it played an important role in injury induced thermal and mechanical 
hyperalgesia 162. COX-2 can also be induced in spinal cord after mechanical stimulation 
and intrathecal injection of NMDA and by spinal cord injury 163.  
 In epileptogenesis and acute seizure generation, COX-2 may be detrimental or 
beneficial depending on the cellular source and environmental context. In the former 
case, COX-2 promotes neurodegeneration caused by excitotoxicity 141,164. In the latter 
case, the COX-2 pathway of AA metabolism contributes to the maintenance of an 
elevated seizure threshold in the normal brain. As mentioned above, COX-dependent 
PG production increases rapidly and transiently in the brain following acute convulsive 
seizures65,66. The earliest and highest wave of PG production is found in hippocampus 
165,166, the brain region associated with seizure onset 167. Several PGs may have 
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anticonvulsive properties 168-172. Specifically, results from several studies employing 
various animal models showed that inhibitors of COX-2 activity enhanced the 
susceptibility for convulsions 67-69,173-176. This is consistent with observations in human 
cases as well175. In addition, seizure threshold is elevated in mice overexpressing COX-
2 in neurons177. Together, these results provide compelling support for the notion that 
this pathway of PG synthesis functions as a homeostatic control mechanism to maintain 
the innate seizure threshold in the normal brain. On the other hand, results from other 
pharmacological studies argue against this conclusion and even suggest a 
proconvulsant action of the COX-2 pathway 178-183. The observations that some COX 
inhibitors potentiated the action of certain antiepileptic drugs are consistent with this 
possibility 184. The reason for these disparate results remains to be resolved. However, 
several factors may influence the outcome with COX inhibitors 185. For example, unique 
properties of individual inhibitors or differences in their treatment paradigms may have 
contributed to the inconsistencies in some cases. In this regard, only a subset of COX 
inhibitors affected seizure threshold in some studies 186, perhaps owing 
to pharmacokinetic differences or off-target effects 123. Additionally, whereas the COX-2 
selective inhibitor, rofecoxib, lowered the seizure threshold of PTZ when administered 
orally in a bolus dose of 30 mg/kg 3 h prior to PTZ 68, subacute delivery of 30 mg/kg/day 
rofecoxib in the diet for 5 days had no effect 181. It is possible that persistent inhibition in 
the latter study elicited compensatory gene expression changes that masked the role of 
COX-2 123,181. It is more difficult to reconcile results from another study showing that 
acute rofecoxib treatment raised PTZ seizure threshold 180. However, the PTZ treatment 
paradigms (bolus i.p. vs. i.v. infusion, respectively) and mouse strains used (C57BL/6 
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vs. “Laka”, respectively) were key differences between the Akula et al. 
(2008) and Claycomb et al. (2012) studies. 
 Studies using gene deletion approaches to assess the role of COX-2 in seizure 
threshold similarly yield conflicting results. Thus, whereas global deletion of the Ptgs2 
gene in all cell populations of the mouse brain lowered the seizure threshold relative to 
wild-type littermates 187, no effect was observed using a conditional cre-lox approach to 
target Ptgs2 deletion in forebrain neurons exclusively183. This difference might suggest 
that neurons other than those in the forebrain account for the function of COX-2 in 
maintenance of seizure threshold. However, both studies assess the role of COX-2 in 
models of temporal lobe seizures, and as such, both genetic approaches deleted COX-
2 expression in key populations of glutamatergic neurons relevant to this model 
(e.g., hippocampus, cerebral cortex, and thalamus). Alternatively, the results from the 
global deletion approach might be related to loss of COX-2 function in non-neuronal cell 
types, which would not be targeted in the conditional approach. Notably, COX-2 is 
expressed constitutively under normal conditions in endothelial cells of the brain 
microvascular endothelium, where it may modulate blood flow to the brain in response 
to neuronal activity188. Alternatively, the different outcomes could be related to genetic 
background differences between the global and forebrain-specific Ptgs2 gene-deficient 
mouse lines (C57BL/6-129/Ola and C57BL/6, respectively) or to differential alterations 
in early development. In the latter case, whereas the Ptgs2 gene was deleted 
throughout all phases of development in the globally deficient mice, it was deleted 
postnatally in the conditional knockout mice due to the characteristics of the promoter 
used to target cre expression. It is relevant to note, however, that the native Ptgs2 gene 
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reportedly becomes transcriptionally active in neurons in the second week postnatally 
74,136, suggesting that similar developmental concerns might apply to both genetic 
approaches. Again, rofecoxib pretreatment enhanced PTZ induced acute seizure 
incidence and severity 68, whereas neuronal COX-2 overexpression suppressed acute 
seizure activity 177. Future studies are required to confirm the seizure modifying property 
of the COX-2 pathway, and eventually, to determine the contributing PGs and their 
receptors as well as the underlying molecular mechanisms. 
 The transient up-regulation of COX-2 expression observed after seizure was 
accompanied by a less dramatic but prolonged PG production which can last hours to 
days in epileptogenesis models 165,189. This biphasic PG production also leads to 
controversial results when COX-2 expression or activity is blocked in seizure and 
epileptogenesis models (Table 1.2 and summarized in detail in Appendix Table 1). 
Clusters of studies seem to support the idea that prolonged or post-convulsion 
administration of COX-2 inhibitors, which blocks the chronic phase of PG production, 
delays epileptogenesis and attenuates associated neurodegeneration (Table 1.2, 
column 2 & 3). On the other hand, acute pretreatment of COX-2 inhibitors, leads to 
largely controversial results (Table 1.2, column 1) as described above. Distinct roles of 
the various PGs and their receptors in different contexts likely determines the functional 
outcome of PG signals. Therefore, it is possible that PG production during the 
prolonged phase is involved in inflammation or brain blood barrier permeability through 
non-neuronal PG receptors thus negatively affecting disease progression, whereas the 
acute phase of PG production is anticonvulsive and helps prevent repetitive seizure 
activity. 
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Table 1.2. Effects of COX-2 selective inhibition on acute seizure behavior, epileptogenesis and 
associated neurodegeneration. 
 
 Acute Seizure Epileptogenesis
# Neurodegeneration 
+ - + - + - 
Pretreatment 
190, 191, 179, 192, 
182, 180 
174, 193, 68, 168 194, 195 N/A N/A 174, 168 
Post/Chronic 
treatment N/A N/A 
196, 197, 198, 
199, 200 N/A 
137, 201, 199, 
176, 200, 164, 
202 
N/A 
 
+: Positive effects, i.e. anti-convulsive/ antiepileptic/ neuroprotective; -: Negative effects, i.e. increase 
seizure severity and incidence/ facilitate epileptogenesis/ increase neurodegeneration; Pretreatment: 
COX-2 inhibitors were given prior to convulsant administration; Post/Chronic treatment: COX-2 inhibitors 
were given once after convulsant administration or throughout epileptogenesis process; Note that only 
studies that applied selective pharmacological COX-2 inhibition are cited in this table, for a more 
comprehensive summarization on effects of PTGS genes inhibition, please refer to Appendix Table 1. #, 
antiepileptic effects are measured by attenuated spontaneous recurrent seizure and/or kindling 
development. 
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1.3 The role of RNA binding protein T-cell intracellular antigen-1 in regulating 
gene expression levels 
 Messenger RNA (mRNA) transcripts undergo multiple post-transcription 
modifications that are controlled and regulated by proteins. Regulatory proteins are 
involved in every aspect of mRNA biology, from pre-mRNA processing and transport to 
stability and translation.203,204 Key among these are a broad class of RBPs205 referred to 
as heterogeneous nuclear ribonucleoproteins and mRNA binding proteins. RBPs exhibit 
different patterns of expression (e.g., ubiquitous vs. tissue/cell specific; constitutive vs. 
inducible) and can show different patterns of subcellular distribution (e.g., nuclear vs. 
nuclear and cytoplasmic vs. cytoplasmic). As the name implies, RBPs possess domains 
that recognize specific sequence codes, or docking sites, innate to the target mRNA 
called cis-elements,206 which are commonly contained within RNA secondary structures. 
A myriad of these cis-elements exists in the transcriptome.207-209 This interaction 
between RBPs and RNA together with the ability of RBPs to form complexes with other 
proteins dictates the functional outcome.  
 RBPs form complexes with other RBPs and non-RBP regulatory proteins referred 
to generally as ribonucleoprotein particles (RNPs) or RNA granules. These membrane-
less macromolecular structures are remarkably heterogeneous and dynamic and often 
exhibit overlapping components and functions. Nevertheless, several RNPs can be 
distinguished by identifiable differences in protein composition and unique functional 
characteristics. The major classes of cytoplasmic particles are transport 
ribonucleoprotein particles (tRNPs), processing bodies (P-bodies), and stress granules 
(SGs).210 Detailed descriptions of the composition, assembly, and function of these RNA 
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structures can be found elsewhere.210-215 The following is a brief overview. The tRNPs 
are heterogeneous structures that may represent a continuum between nuclear export, 
cytoplasmic transport, and local translational particles. The specific aspects of the 
mRNA cargo (e.g., cis-elements) together with its binding partners contribute 
substantially to the composition of these particles. In neurons, for example, unique 
proteins of tRNPs determine subcellular localization of the mRNA cargo (e.g., 
cytoplasm, axons, dendrites). Associated molecular motors that travel along 
microfilament or microtubule tracks mediate this transport. Moreover, local demands 
and stimuli within each compartment can influence both mRNA stability and translation. 
P-bodies contain mRNA-degrading proteins, such as decapping enzyme, and are sites 
of mRNA decay as well as translational repression.216,217 While P-bodies and tRNPs are 
distinct particles, they appear to interact with each other at sites of translation. In this 
regard, P-bodies are found docked with a large fraction of tRNPs in dendrites of 
neurons.218 Interestingly, the stability of P-bodies in dendrites is inversely related to 
excitatory synaptic activity, suggesting that P-bodies contribute to the control of local 
activity-dependent translation. Finally, SGs sequester silenced mRNAs selectively and 
reversibly and facilitate the reprogramming of translation in response to cellular stress 
conditions. While these granule types have unique components that serve their 
respective functions, some components overlap. A number of RNA granule components 
are found in neuronal dendrites and spines (Appendix table 2). 
 The focus of my research is on the RBP T-cell intracellular antigen-1 (TIA-1) and 
its role in regulating seizure threshold and epileptogenesis. This section will introduce 
the structure of TIA-1 protein as well as its role as a regulator of mRNA life cycle. 
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1.3.1 Discovery of TIA-1 
 TIA-1 is a multifunctional RNA binding protein that can influence alternative pre-
mRNA splicing in the nucleus and control post-transcriptional regulation of gene 
expression in the cytosol 219. Discovery of TIA-1 was facilitated by the generation of TIA-
1 antibody through immunizing BALB/c mice with digitonin permeabilized T lymphocytes 
220. TIA-1 antibody reacted strongly with NK cells and CD8+ cytotoxic T cells (CTLs), 
less strongly with CD4+ activated T cells, suggesting a preferential expression in cell 
clones that express cytotoxic characteristics. The major protein isoform present in 
cytolytic granules is a 15kDa TIA-1 protein isoform that appears to be derived from the 
40 kDa isoform through proteolytic processing 221. Yet both isoforms are able to induce 
DNA fragmentation in permeabilized thymocytes, suggesting that TIA-1 may form the 
granule component responsible for inducing apoptosis in CTL targets. In addition, TIA-1 
protein has been found to actively participate in immune defense against virus. TIA-1 
knockdown or knockout led to susceptibility to TBEV (tick-borne encephalitis virus) 
infection 222. TIA-1 also inhibited HBV (hepatitis B virus) surface antigen expression 223. 
In both cases, TIA-1 functions as an RBP through interacting with virus RNA. 
1.3.2 TIA-1 protein structure 
 TIA-1 is a member of the RNA-recognition motif (RRM) family of RBPs. RRM is 
one of the most abundant protein domains in eukaryotes and is necessary and sufficient 
for binding RNA molecules with a wide range of specificities and affinities 224. TIA-1 
protein has three RRMs (RRM1, 2 and 3) that are functionally independent 225. RRM2 is 
a canonical RNA recognition motif that can bind RNA by itself. Yet it shows a better 
affinity when working with RRM1 and 3 together; RRM3 cannot bind RNA by itself, but it 
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is a bona-fide RNA binding domain that has an auxiliary role in RNA binding, as 
protonation/deprotonation of exposed histidine residues on RRM3 affects RNA binding 
affinity of TIA-1 226; RRM1 has little RNA binding affinity 227, however it enhances 
binding affinity in a sequence-dependent way, where RRM1 is required for high affinity 
binding of poly-U RNA 228. Together, these three RRMs mediate the binding of TIA-1 to 
its targets, which are often U-rich sequences located in either 5’ or 3’ end of mRNA. 
Microarray analysis following TIA-1 immunoprecipitation identified a TIA-1 motif in 
mRNAs that is capable of binding TIA-1 in Human colorectal RKO carcinoma cells 229. 
Although this TIA-1 motif only presented in ~23% of these putative TIA-1 targets, it is 
representative. COX-2 and tumor necrosis factor alpha mRNAs, which are known 
targets of TIA-1, both possessed this motif. This motif also had a higher frequency in 
3’UTRs 229. TIA-1 also possesses a glutamine (Q)-rich domain at its carboxyl (C) 
terminus, which is structurally related to prion protein 221. This domain is capable of self-
oligomerization in vivo and is required for TIA-1 aggregation under stress responses 
(see below). 
1.3.3 TIA-1 regulates pre-mRNA splicing 
 As a splicing regulator, TIA-1 associates selectively with pre-mRNAs that contain 
a 5’ splice site followed by U-rich sequences, promoting U1 snRNP recognition 230. TIA-
1 has also been shown to directly bind to U1 snRNP 231. TIA-1 acts as splicing regulator 
of the Fas receptor gene transcript. It facilitated Fas mRNA exon 6 inclusion and led to 
increased production of the active form of Fas receptor, which promoted apoptosis 232. 
Other targets of TIA-1-mediated regulation of alternative splicing include Msl-2 (male-
specific-lethal 2) 230, lysyl hydroxylase 2 233, CFTR (cystic fibrosis transmembrane 
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conductance regulator) 234, COL2A1 (type II procollagen gene)235 and FGFR-2 
(fibroblast growth factor receptor-2) 236. Interestingly, splicing of TIA-1 mRNA is tightly 
regulated by TIA-1 protein itself, as well as by another RBP, TIAR (TIA1 Cytotoxic 
Granule Associated RNA Binding Protein Like 1), which has high homology with and 
similar binding properties and functions as TIA-1 237. Overexpression of TIA-1 and TIAR 
induced splicing of TIA-1 mRNA using novel alternative 5’ splice sites 238. These are 
weak splice sites followed by U-rich stretches, the use of which possibly results in frame 
shift or nonsense-mediated decay 238. Cells can express two TIA-1 mRNA transcripts, 
TIA-1a and TIA-1b, which result from alternative splicing of exon 5 of the pre-mRNA 
239,240. TIA-1b encodes the active form of TIA-1 protein that has better splicing 
stimulatory activity. TIAR depletion resulted in an increased ratio of TIA-1b over TIA-1a 
240. These results suggest the functional similarity between the two proteins and the 
existence of an auto-regulatory mechanism that controls their expression levels. Both 
TIA-1 and TIAR have indispensable physiological functions during development, as 
double knockout or double knockdown of TIA-1/TIAR led to lethality in animals241 and 
impaired viability in cells242. However, it has also been shown that TIA-1 and TIAR are 
functionally distinct in that they may interact with different RBP partners 243. 
1.3.4 TIA-1 regulates mRNA translation 
 As a post-transcriptional regulator, TIA-1 is known primarily as a negative 
regulator of protein translation, binding to U-rich sequences in 3’UTR of mRNAs. TIA1-
knockdown in HeLa cells showed an increase in ribosomes and translational machinery 
components.244 Specifically, TIA-1 suppressed cytochrome c translation in Hela cells in 
response to ER stress through binding to its 3’UTR 245. In human hepatocellular 
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carcinoma cells, TIA-1 binds to the 3’UTR of IGFBP-3 (Insulin-like growth factor binding 
protein-3) mRNA. TIA-1 knock down led to increased IGFBP-3 protein level 246. TIA-1 
binded to TNFα mRNA 3’UTR and acted as a translational suppressor. LPS induces 
significantly more TNFα production in TIA-1 knockout macrophages 247, whereas TIA-1 
knockout mice were more susceptible to endotoxic shock 241. Other targets of TIA-1-
mediated translational repression include ATP synthase β subunit gene 248, HIF-1α 249, 
and β-actin 250. I became interested in this RBP because of its interaction with COX-2 
mRNA. In non-neuronal cells, TIA-1 directly binded to adenosine/uridine (AU)-rich 
elements (AREs) in the COX-2 mRNA 3’UTR to silence its translation 88. Dysregulated 
RNA-binding of TIA-1 promoted COX-2 expression in neoplasia.88 
 The translational suppressor role of TIA-1 has been largely linked to its 
involvement in the stress responses. TIA-1 is a key component of the protein complexes 
that assemble translationally inactive mRNAs under stress conditions, namely, stress 
granules (SGs) 251. After their recovery from stress, cells release these mRNAs from 
SGs for translation. Thus SG-mediated translation suppression serves as a protective 
mechanism against acute stress. Assembly of SGs is highly regulated and requires 
functional TIA-1 protein.  Under cellular stress, TIA-1 shuttles from the nucleus into 
cytoplasm 252, facilitates the recruitment of stalled preinitiation complexes into SGs 253, 
and self-aggregates via its prion-related C-terminus domain 254. RRM2 and the first half 
of the C-terminal region are necessary for nuclear accumulation, whereas RRM3 is 
required for its nuclear export 255. TIA-1-mediated SG aggregation is resistant to 
protease treatment but can be inhibited by overexpression of heat shock proteins, such 
as HSP70 254. This process resembles prion aggregation, which is further supported by 
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the fact that substitution of the Q-rich domain with the aggregation domain of a yeast 
prion, SUP35-NM, reconstitutes SG assembly 254. TIA-1 regulates SG formation 
downstream of eIF-2α 254. TIA-1 self-aggregation and recruitment into SG has also been 
shown to be Zn2+-dependent 256. SG formation is considered as a dynamic and 
reversible process that coordinates mRNA triage and has been extensively studied in 
mammalian peripheral tissues and cell lines.  
 It is worth mentioning that TIA-1 also suppresses mRNA translation through 
binding to 5’-terminal oligopyrimidine tracts (TOP) sequences located in a class of 
mRNAs that encoding ribosomal protein or translation factors which are more efficiently 
repressed during amino acid starvation 257. Binding of TIA-1 to 5’ TOP is mediated by 
RRM3 258. TIA-1 has also been shown to promote the decay of RNA in certain instances 
241,259. TIA-1-mediated mRNA decay requires polysome disassembly and utilizes both 
5’-3’ and 3’-5’ decay pathway 259. 
1.3.5 TIA-1 functions in central nervous system 
 Both TIA-1 transcripts and protein are detected in the CNS 177,239,260,261. TIA-1-
positive SGs appear acutely in hippocampal neurons following brain ischemia 93,94,262. In 
addition, TIA-1 associates with pathological lesions in several neurodegenerative 
diseases, including amyotrophic lateral sclerosis 263,264, Huntington’s disease 265 and 
tauopathies 266. Overexpression of TIA-1 facilitates tau misfolding 267 whereas reduction 
of TIA-1, in turn, rescues tau-mediated degeneration 268. These findings suggest that in 
neurons, TIA-1 mediates SG formation, serving as a protective mechanism against 
acute stress, but may also lead to deposition of pathological protein aggregations in 
diseases associated with prolonged stress. On the other hand, due to its large number 
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of mRNA targets and protein partners 229,267, TIA-1 may serve biological functions that 
are independent of SG formation in brain. TIA-1 deficiency leads to changes in mRNA 
levels of cell cycle and apoptosis regulators, as well as fat storage and membrane 
trafficking factors in brain 269. TIA-1 is also recently implicated in physiological neuronal 
function 261. 
1.3.6 Interaction between TIA-1 and COX-2 mRNA 
 PGs are potent local mediators that control a wide range of functions under both 
physiological and pathological conditions. COX-2, the key enzyme in the production of 
prostaglandins within the CNS, may serve a neuromodulatory function in epilepsy. 
Evidence from numerous studies have suggested that COX-2 expression is under tight 
regulation of neuronal activity. Thus, constitutive COX-2 expression was found in 
glutamatergic neurons of CNS 74, whereas convulsive seizure activity induced 
upregulation of COX-2 expression in these cells 67,165. In the present study, it is 
hypothesized that activity-dependent expression of COX-2 in neurons is regulated by 
RNA binding proteins. In particular, TIA-1 has been shown to suppress COX-2 mRNA 
translation by binding to its 3’UTR 88.  Deletion of TIA-1 was associated with an increase 
in COX-2 protein expression in non-neuronal cell types 88,270. Thus, it is posited that loss 
of TIA-1 will lead to enhancement of COX-2 expression in neurons. It is further 
hypothesized that this activity-dependent mechanism regulates seizure threshold in the 
brain. This central hypothesis forms the basis for the proposed studies (Specific Aims) 
of my thesis. 
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1.4 Specific Aims 
 Studies in the Aims of this study may suggest novel genetic mechanisms by 
which seizure threshold and epileptogenesis may be regulated. Studies in Aim 1 will 
identify the ionotropic glutamate receptor that is responsible for controlling the activity-
dependent expression of COX-2 in neurons, and identify RNA binding proteins of COX-
2. Studies in Aims 2 will explore the possibility of TIA-1 in regulating the level of 
neuronal COX-2 protein expression from its native gene. Studies in Aim 3 will further 
confirm that whether the loss of TIA-1 will alter seizure threshold in brain or regulate the 
progression of epilepsy, whereas studies in Aim 4 will explore the downstream effectors 
of TIA-1 deletion-mediated plasticity changes in the brain.  
1.4.1 Specific Aim 1: Regulation of neuronal COX-2 expression through NMDAR 
activity-dependent mechanisms (Chapter 2) 
 Since COX-2 is constitutively expressed in glutamatergic neurons of the CNS 
and neuronal COX-2 expression is coupled to changes in excitatory neuronal activity, it 
is hypothesized that neuronal COX-2 expression is regulated via the excitatory NMDAR 
activity. NMDAR inhibitor will be used to test whether constitutive or induced COX-2 
mRNA levels are dependent on NMDAR activity. The mRNA levels of cPLA2α and 
PGESs will be examined to test whether AA pathway genes are co-regulated with COX-
2 by NMDAR activity. COX-2 mRNA half-life will be measured to test whether NMDAR 
activity regulates COX-2 expression through post-transcriptional mechanisms. It is 
hypothesized that NMDAR activity regulates COX-2 expression in part through RNA 
binding proteins. To test this, RBPs will be eluted from cultured neuron lysates using 
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COX-2 3’UTR harboring probes and subjected to peptide mass finger printing to identify 
potential candidates of COX-2 binding RBPs. 
1.4.2 Specific Aim 2: Role of TIA-1 in neuronal COX-2 expression (Chapter 3) 
 TIA-1, which is expressed in excitatory neurons of the CNS, functions as a 
translational silencer of COX-2 expression via binding to 3’UTR of COX-2 mRNA in non-
neuronal cells. It is posited that TIA-1 inhibits neuronal COX-2 protein translation in 
neurons as well. Because TIA-1 is known to suppress COX-2 translation in non-
neuronal cells, it is hypothesized that TIA-1 deletion will result in increased COX-2 
protein expression in brain. To test this, COX-2 protein levels will be measured in brains 
of TIA-1 knockout mice.  
1.4.3 Specific Aim 3: Effects of TIA-1 deletion on acute seizure generation and 
epileptogenesis (Chapter 3 and 4) 
 If acute PGs production by COX-2 is anticonvulsive, enhanced COX-2 
expression in TIA-1 null animals will antagonize acute seizure induction and may affect 
epileptogenesis. To test this hypothesis, TIA-1 KO and their littermate controls will be 
subjected to acute seizure and epileptogenesis models. Selective COX-2 inhibitor will 
be applied during these assays to test if effects of TIA-1 deletion are due to increased 
COX-2. 
1.4.4 Specific Aim 4: Identification of molecular targets of TIA-1 in the 
hippocampus (Chapter 5) 
 Since TIA-1 is also a regulator of mRNA transcription, it is hypothesized that 
disruption of TIA-1 gene (Tia1) may alter mRNA transcriptome in the brain. It is also 
hypothesized that if TIA-1 deletion altered epileptogenesis, it may contribute to disease 
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progression by altering plasticity changes that promote or suppress this process. To test 
this, brains from both wild-type and TIA-1 knockout animals that are subjected to 
epileptogenesis paradigm will be analyzed by next generation sequencing analysis to 
identify candidate molecular targets of TIA-1. 
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CHAPTER 2 Regulation of COX-2 mRNA expression in neurons via NMDARa 
2.1 Synopsis  
 The mechanisms through which constitutive or induced COX-2 expression in 
neurons is regulated are not fully understood. Studies included in this chapter 
investigated the mRNA expression of PTGS genes as well as PLA2 and PGS genes in 
cultured cortical neurons. The NMDAR-dependent expression of COX-2, the activity-
dependent isoform of COX, has been thoroughly examined under basal and induced 
neuronal activity.  
  
                                            
a Much of the work described in this chapter was originally published in the Journal of Biological 
Chemistry. Hewett, S.J. et al. Spontaneous Glutamatergic Synaptic Activity Regulates Constitutive COX-2 
Expression in Neurons: OPPOSING ROLES FOR THE TRANSCRIPTION FACTORS CREB (cAMP 
RESPONSE ELEMENT BINDING) PROTEIN AND Sp1 (STIMULATORY PROTEIN-1). J. Biol. Chem. 
2016; 291: 27279-27288. © the American Society for Biochemistry and Molecular Biology.  
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2.2 Introduction 
 In neurons, excitatory synaptic activity triggers release of arachidonic acid (AA) 
from membrane phospholipid stores via activation of phospholipase A2 (PLA2). Free AA 
can then be rapidly metabolized by several different pathways. Among these pathways, 
prostaglandin (PG) synthesis is catalyzed via concerted activation of cyclooxygenases 
(COX) and prostaglandin synthases (PGS).  
 COX1 and COX-2 are homologous ER-resident N-glycoprotein isozymes that 
catalyze the first committed reaction in metabolism of AA to PGs and thromboxanes 
(section 1.2.2.1). Although they both metabolize AA to PGH2, the intermediate product 
that serves as the substrate for various synthases, the transcriptional regulation of the 
two isozyme genes differs. The promoter region of PTGS1 gene contains three Sp1 
sites and lacks a TATA or CAAT box 75, which results in constitutive expression of COX-
1 protein in many cell types. In contrast, the PTGS2 gene promoter contains a TATA 
box motif and a number of cis-acting elements that are recognized by various 
transcription factors (section 1.2.2.2). This results in a typically transient expression 
pattern of COX-2 protein in many tissue types, which is not expressed constitutively but 
can be induced by a variety of other stimuli. However, an exception to this is the CNS, 
where COX-2 expression is constitutively detected in glutamatergic neurons74, 
mediating rapid, almost simultaneous PG production in response to convulsive stimuli 
67,165. In addition, COX-2 expression is coupled to N-Methyl-D-Aspartate (NMDA) 
receptor activity. Hence, stimuli that enhance excitatory neurotransmission, such as 
NMDA, coordinately up-regulate neuronal COX-2 expression. Conversely, induced 
COX-2 expression is down-regulated by NMDAR antagonists. This is consistent with the 
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notion that COX-2 catalyzes the activity-dependent production of PGE2. The molecular 
and cellular mechanisms that contribute to the constitutive and induced expression of 
COX -2 in these neurons are not fully understood. Therefore, the goal of the work 
described in this chapter is to determine the transcriptional mechanisms regulating 
basal COX-2 expression in cortical neurons and to examine the relationship between 
transcriptional regulation and neuronal activity. 
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2.3 Materials and methods 
2.3.1 Measurement of COX-2 mRNA tissue expression 
 COX-2 mRNA was measured in kidney, lung, heart, cerebellum, hippocampus, 
olfactory bulb, cerebral cortex and spinal cord from 8 weeks old male CD1 mice (Harlan; 
Indianapolis, IN, U.S.A). Total RNA was extracted from homogenized tissue using 
TRIZOL reagent (Invitrogen, Carlsbad, CA). First-strand cDNA synthesis and real-time 
quantitative PCR were performed as described previously271 and in the quantitative real-
time PCR section (2.3.4) below.  
2.3.2 Generation of purified cortical neuronal culture 
 To generate purified cortical neuron cultures (PNCs), brains from day 15 CD-1 
mouse embryos were placed into ice cold dissecting medium (Ca2+/Mg2+-free HBSS 
containing 25mM glucose, 20mM sucrose, and 20mM HEPES), meninges removed, 
and cortices dissected free from the rest of brain. Harvested tissue was minced and 
incubated at 37oC for 15 min in dissecting medium containing 0.025% trypsin. Tissue 
was then pelleted at 700xg for 3 min and re-suspended in modified Eagle’s medium 
(MEM) supplemented with 5% (v/v) heat-inactivated bovine growth serum (BGS) and 
5% (v/v) iron-supplemented calf serum (CS), 2mM L-glutamine, 25mM glucose, 28mM 
sodium bicarbonate, and penicillin/streptomycin (50 IU/ml and 50 µg/ml, respectively). 
Tissue was immediately dissociated by gentle trituration using fire-polished Pasteur 
pipettes and single cell suspensions were plated at a density of 1.5 x 106/mL (measured 
by Muse count & viability assay kit, Millipore) on polyethyleneimine-coated 4 or 24 well 
tissue culture plates (400µL/well). Medium was replaced 4 hours later with neuron 
growth medium (Neurobasal medium containing B27 supplement, 2mM glutamine, 
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penicillin and streptomycin). Cytosine arabinoside (Ara-C; 1µM) was added after plating 
(DIV2) to inhibit growth of contaminating glial cells. Cells were fed on DIV4 and 7 by 
removing 250µL medium from each well and adding 250µL of fresh neuron growth 
medium. All cultures were kept at 37oC in a humidified 5.5% CO2-containing 
atmosphere. 
2.3.3 Drug Exposure  
 To block NMDAR alone (Fig. 2.3 and 2.14), PNCs were treated with NMDAR 
antagonist 5-amino-phosphonovaleric acid (APV; TOCRIS) for two days (DIV 5-7). Ten 
µL stock solution of APV (1.2mM, dissolved in dH2O) was added in each well 
(containing 400µL/well medium) for final concentration of 30µM. In a different 
experiment (Fig. 2.4), to block either NMDAR or AMPAR, PNCs were exposed to APV 
or AMPAR antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX; Research 
Biochemicals Inc.) for two days (DIV 5-7). Four hundred µL stock solution of APV or 
CNQX (60μM, both dissolved in 0.6% DMSO) was added to each well (containing 
400µL/well medium) to make a final concentration of 30µM. After gently swirling, 400µL 
medium was removed from each well. DMSO was used as vehicle and all experimental 
conditions contained 0.3% DMSO. 
 To block evoked synaptic exocytosis, PNCs were exposed to Tetanus Toxin 
(TeNT; Calbiochem) for two days (DIV 5-7). Ten µL stock solutions of Tetanus Toxin 
(12μg/ml, dissolved in dH2O) was added in each well (containing 400µL/well medium) to 
make a final concentration of 300ng/ml. 
 To enhance excitatory neuronal activity (Fig. 2.6), 10µL stock solution of the 
GABAA receptor antagonist bicuculline (Cayman Chemical, CAS 485-49-4) (4mM, 
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dissolved in 0.6% DMSO) was added in each well (containing 400µL/well medium) to 
make a final concentration of 100µM. DIV7 PNCs were either pre-treated with 300ng/ml 
Tetanus Toxin for two days (DIV5-7) before being exposed to bicuculline at DIV7 for 4 
hours at 37oC, or co-incubated with both bicuculline and 10µM NMDAR antagonist MK-
801 (dizocilpine maleate, Research Biochemicals Inc.) at DIV7 for 4 hours at 37oC. 
DMSO was used as vehicle and all experimental conditions contained 0.3% DMSO.  
 To activate NMDAR directly, PNCs were exposed to NMDA (Sigma-Aldrich) and 
glycine (Fisher Scientific) for 1 hour at DIV7. Ten µL 40x stock solution of NMDA and 
glycine dissolved in 1x Hank's Balanced Salt Solution (HBSS) was added in each well 
(containing 400µL/well medium) to make a final concentration of 50µM and 0.05µM for 
NMDA and glycine respectively. HBSS (1x) was used as vehicle. 
2.3.4 Quantitative Real-Time PCR 
 Gene expression was measured using real-time quantitative reverse 
transcriptase-polymerase chain reaction (qRT-PCR). Cells from 3 to 4 wells of tissue 
culture plates were harvested, combined and total RNA was extracted using TRIZOL 
reagent (Invitrogen, Carlsbad, CA), suspended in RNase-free water, and quantified 
using a NanoDrop UV-Vis Spectrophotometer (Thermo Sci). First-strand cDNA 
synthesis was performed in a 20µL reaction mix containing 1µg total RNA, reverse 
transcriptase (200U M-MLV, Life Tech.), 1x reaction buffer (Life Tech.), DTT (10mM, 
Life Tech.), dNTPs (0.2mM each, Promega), and oligo (dT) primers (10µg/mL, 
Promega). Reactions were performed at 42°C for 1 hour. qRT-PCR was performed 
using Taqman® gene expression master mix and the following gene expression assays 
(Applied Biosystems) for Actb (Mm01205647_m1), Grin1 (Mm00433790_m1), Fos 
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(Mm00487425_m1), Ptgs1 (Mm00477214_m1), Ptges1 (Mm00452105_m1), Ptgs2 
(Mm00478374_m1), Ptges2 (Mm00460181_m1), Pla2g4a (Mm00447040_m1) and 
Ptgds (Mm01330613_m1) according to manufacturer’s instruction. Reactions were 
performed using Mastercycler ep RealPlex2 Real-Time PCR System (Eppendorf North 
America) under the following conditions: 50°C for 2 minutes and 95°C for 10 minutes, 
followed by 40 amplification cycles (95°C for 15 s and 60°C for 1 minutes). Expression 
was assessed using the comparative cycle threshold method (ΔΔCT), where CT values 
of the transcript of interest were normalized to β-actin CT values from the same sample 
to derive ΔCT. These values were compared to a calibrator ΔCT value to determine the 
relative fold increase in mRNA. To assess primer efficiency for each analysis, reactions 
were performed on a dilution series of known template concentrations (12.5, 25, 50, 100 
and 200 ng/reaction, cDNA generated from DIV 7 PNC of CD-1 mice). Similar efficiency 
across all input concentrations was confirmed (slope of relative efficiency plot <0.1) 
between all primer pairs and housekeeping gene primer pair. 
2.3.5 Western blotting  
 Purified neuron cultures were washed once with ice-cold PBS and harvested by 
gentle scraping. Cells were spun (700 g; 5 minutes; 4◦C) and the resulting pellet was 
suspended in lysis buffer containing: 20 mM HEPES (pH 7.4), 2 mM EGTA (pH 8.0), 50 
mM β-glycerol phosphate (pH7.2), 1 mM DTT, 1 mM Na3VO4, 5 mM NaF, 1% Triton X-
100, 0.2 mM PMSF and 1 X Complete Protease Inhibitor (Roche). Lysates were then 
incubated on ice (30 minutes), cellular debris was removed by centrifugation (12,000 g; 
20 minutes; 4˚C), protein concentration was determined by BCA assay(Pierce; 
Rockford, IL), protein (40µg) was separated by 15% SDS-PAGE under reducing 
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conditions and electrophoretically transferred to a PVDF membrane (Bio-Rad; Hercules, 
CA). Membranes were blocked (Odyssey® blocking buffer; at 25◦C for 1 hour) and then 
probed (4◦C overnight) with an anti-synaptobrevin-2 rabbit polyclonal antibody (1:1000 
dilution; Synaptic System) and a mouse monoclonal antibody directed against β-actin 
(1:4000 dilution; Sigma). Species-specific secondary antibodies labeled with spectrally 
distinct IRDye® fluorescent dyes (LI-COR Biosciences; Lincoln, NE) were used to 
detect primary antibodies (1 hour at 25◦C).  Results were recorded on LI-COR 
ODYSSEY® Fc Imaging system (LI-COR Biosciences). 
2.3.6 Measurement of COX-2 mRNA half-life 
 To determine if NMDAR activity mediates post-transcriptional regulation of COX-
2 by changing mRNA stability, the COX-2 mRNA half-life was measured in NMDA-
stimulated cortical neuron cultures that were incubated with or without the NMDAR 
antagonist APV. DIV7 cortical neurons were treated with NMDA (50µM, Sigma-Aldrich) 
and glycine (0.05µM, Fisher Scientific) for 1 hour, after which actinomycin D (ActD, 
1µg/mL, Sigma-Aldrich) with or without APV (30µM) was added for various times and 
COX-2 mRNA level was measured using real-time quantitative reverse transcriptase-
polymerase chain reaction (qRT-PCR) as described in section 2.3.4. Non-linear 
regression (one phase exponential decay) was then performed using GraphPad Prism, 
Version 6.0.1 (GraphPad Software, Inc., La Jolla, CA, U.S.A.) on the time course 
expression levels of COX-2 mRNA. The half-life of COX-2 mRNA was calculated from 
the equation, t1/2= 0.693/k, where k= the rate constant for mRNA decay (i.e., percent 
change over time). 
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2.3.7 Identification of NMDAR-responsive COX-2 RNA binding proteins 
 A 3’ biotinylated RNA probe representing the first 60nt of COX-2 mRNA 3’UTR 
(UAUUUAUUUAUUUAUGUGAAGAAUUUAAUUUAAUUAUUUAAUAUUUAU) was 
obtained from Integrated DNA Technologies (Newark, NY). RNA probe (0.17mg) was 
diluted in 170µL TE buffer containing 10 mM Tris-HCl (pH 8.0) and 0.1 mM EDTA, 
supplemented with 20U/mL RNase Inhibitor (Human Placenta, NEB) and 400µM vanadyl 
ribonuclease inhibitor (NEB), and stored at -80°C before use. To restore secondary 
structure, RNA probe was heated at 90°C for 2 minutes and immediately transferred to 
ice for 2 minutes. Probe was then incubated at room temperature with RNA structure 
buffer containing 10mM Tris (pH 7.0), 0.1M KCl and 10mM MgCl2 supplemented with 
Rnase inhibitor and vanadyl ribonuclease inhibitor. Cells were washed gently with cold 
PBS, harvested and lysed in CE buffer containing 10mM HEPES (pH 7.4), 60mM KCl, 
1mM EDTA, 0.075%(v/v) NP40 and 1mM DTT supplemented with 1mM PMSF, 1x 
Proteinase inhibitor (Complete, Roche), 1x Rnase inhibitor, and 400µM vanadyl 
ribonuclease inhibitor. Cellular debris was removed by centrifugation (12,000 g; 20 
minutes; 4˚C). Lysates (1mg protein, determined via BCA assay) were precleared with 
streptavidin agarose beads (Sigma-Aldrich), incubated with 12µg RNA probe at 4°C for 1 
hour and then with streptavidin beads for an additional 45 minutes. Beads were washed 
5 times at 4°C with CE buffer and loaded on a 4-15% Mini-PROTEAN TGX precast 
polyacrylamide gel (Bio-Rad). Protein bands were electrophoretically separated via SDS-
PAGE and stained with a Pierce Silver Stain Kit (Thermo Fisher). Precision Plus Protein 
Dual Color Standards (Bio-Rad) was used to indicate molecular weight of protein bands. 
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2.3.8 Statistical analysis 
 All statistical analyses were performed using GraphPad Prism, Version 6.0.1 
(GraphPad Software, Inc., La Jolla, CA, U.S.A.). For qRT-PCR, statistics were 
performed on the logarithmic transformation of 2−ΔΔCT values. COX-2 mRNA tissue 
expression was analyzed by a one-way ANOVA followed by Bonferroni’s multiple 
comparisons test. Time course expression of AA pathway mRNA, effect of AMPA and 
Kainate receptor antagonism on COX-2 mRNA levels and neuronal cell death measured 
by lactate dehydrogenase release were analyzed by a one-way ANOVA followed by 
Dunn’s multiple comparisons test. Effect of NMDAR antagonism on AA pathway mRNA 
levels and effect of NMDAR activation on COX-2 mRNA levels were analyzed by an 
unpaired Student’s t-test. Effect of NMDAR antagonism on bicuculline-induced COX-2 
mRNA levels was analyzed by a two-way ANOVA followed by Tukey’s multiple 
comparison test. The COX-2 mRNA half-life was calculated using one phase 
exponential decay nonlinear regression analysis. Differences between remaining mRNA 
levels were analyzed by a two-way ANOVA test. Significance was set at p < 0.05. In 
figure legends, p values were reported as their exact values whenever available. For all 
multiple comparison analysis, exact p values were not provided by Prism and were 
reported as “p < 0.05”. Exact p values that are less than 0.0001 were not provided by 
Prism and were reported as “p < 0.0001”.  
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2.4 Results 
2.4.1 COX-2 mRNA is constitutively expressed in brain 
 Quantitation of COX-2 mRNA levels in different tissues revealed that the brain 
possesses the highest levels of constitutive mRNA levels (Figure 2.1), with lung and 
heart also expressing a considerable amount of the transcript. Analysis of isolated brain 
areas demonstrated high levels in regions including cerebral cortex, hippocampus, and 
olfactory bulb, but not in spinal cord and cerebellum. This endogenous expression 
pattern of COX-2 mRNA correlates well with that of mouse COX-2 promoter activity 83, 
with the exception of cerebellum and spinal cord where high COX-2 promoter activity 
was detected.  
Fig. 2.1 COX-2 mRNA levels in tissues. Three adult male CD-1 mice were anesthetized and 
transcardially perfused with ice-cold saline. Organs were rapidly dissected and frozen, and mRNA levels 
were measured via quantitative PCR as described in section 2.3.1. COX-2 mRNA levels in kidneys were 
used as the comparator (set to 1). Significant difference between treatments was identified via one-way 
ANOVA (p < 0.0001). *, p <0.05, Bonferroni’s multiple comparison test (vs Kidney) following one-way 
ANOVA. 
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2.4.2 Expression of COX-2 mRNA in cultures of cortical neurons is coupled with 
NMDAR expression and neuronal activity 
 Neuronal COX-2 level (Fig. 2.2A) near perfectly paralleled the temporal 
expression of the obligate NMDAR (NR) subunit, NR1 (Fig. 2.2B), as well as c-Fos (Fig. 
2.2C), which is used herein as marker of excitatory neuronal activity272. All three 
mRNAs increased steadily from DIV1 through DIV5 and dramatically increased on 
DIV7, suggesting transcription of COX-2 mRNA is correlating with the expression and 
activity of NMDAR. On the other hand, COX-1 mRNA level remained stable from DIV1 
through DIV5 but increased modestly at DIV7 (Fig. 2.2D). These findings are consistent 
with the notion that Ptgs1 gene is constitutively active in cells due to lack of a TATA box 
motif in its 5′ promoter region273,274, whereas COX-2 is inducible due to the presence of 
various transcription factor binding sites in its 5’ promoter region75. 
Fig. 2.2 Correlation between increased excitatory activity and PTGS genes mRNA expression in 
cultures of cortical neurons. Shown is a comparison of the temporal pattern of COX-2 (A), NR1 (B), c-
Fos (C) and COX-1 (D) mRNA levels in pure wild-type neurons at 1, 3, 5, and 7 days in vitro as quantified 
by real-time qRT-PCR. Relative mRNA levels on DIV 1 were set to 1 and used as the comparator (N = 3-
5 from three independent experiments). Significant differences between treatments were identified via 
one-way ANOVA (p = 0.0002 for COX-2, p < 0.0001 for NR1, p = 0.0002 for c-Fos, p = 0.0032 for COX-
1). *, p < 0.05, Dunn’s test (vs DIV1) for multiple comparison following one-way ANOVA. 
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2.4.3 Constitutive COX-2 expression in neurons is regulated by NMDAR activity 
 Constitutive COX-2 mRNA levels measured in NR1−/− cultures at DIV7 were 
dramatically reduced when compared with that found in NR1+/+ cultures 83, suggesting 
that indeed NMDAR activity was necessary for constitutive expression of neuronal 
COX-2 mRNA. In support of this, the addition of 30μM NMDAR antagonist APV, a 
concentration that reduced NMDAR activity in pure neuronal cultures as evidenced by 
block of c-Fos mRNA production (Fig. 2.3A), also significantly decreased the levels of 
COX-2 mRNA (Fig. 2.3B). This effect was specific to NMDAR inhibition as functional 
block of AMPARs or Kainate receptors by CNQX did not inhibit the constitutive neuronal 
expression of COX-2 or c-Fos (Fig. 2.4A and B). Interestingly, neither c-Fos nor COX-2 
mRNA levels in cultured neurons were affected by pretreatment with tetanus toxin 
(300ng/ml), a Clostridium toxin that prevents evoked but not spontaneous, synaptic 
vesicle exocytosis by cleaving the SNARE protein, synaptobrevin-2 273 (Fig. 2.5). 
Together, these results indicate that constitutive COX-2 mRNA levels are strongly 
correlated with basal neuronal activity. 
Fig. 2.3 Effect of NMDAR antagonism on c-Fos and COX-2 mRNA levels. DIV 5 pure neuronal 
cultures were treated with 30μM APV (+ APV) or its vehicle (−APV) and c-Fos (A) and COX-2 (B) mRNA 
were quantified via qRT-PCR 2 days later. Relative mRNA levels on DIV 1 (dashed lines) were set to 1 
and used as comparator (N = 4 from two independent experiments). *, p < 0.0001, unpaired 
Student’s t test of the geometric means.  
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Fig. 2.4 Effect of AMPA and Kainate receptor antagonism on COX-2 mRNA levels. DIV5 pure 
neuronal cultures were treated with 30μM APV (in 0.3% DMSO), 30μM CNQX (in 0.3% DMSO) or their 
vehicle control (0.3% DMSO) and COX-2 (A) and c-Fos (B) mRNA levels were quantified via qRT-PCR 2 
days later. Relative mRNA levels in Control were set to 1 and used as comparator (N = 3-5 from two 
independent experiments). Significant differences between treatments were identified via one-way 
ANOVA (p = 0.0156 for COX-2 and p < 0.0001 for c-Fos). *, p < 0.05, Dunn’s test (vs Control) for multiple 
comparison following one-way ANOVA.  
 
 
 
 
 
 
 
 
Fig. 2.5 Lack of effect of tetanus toxin on c-Fos and COX-2 mRNA levels. Pure neurons were treated 
with 300ng/ml tetanus toxin (+TeNT) or its vehicle (−TeNT) on DIV5 and c-Fos (A) and COX-2 (B) mRNA 
levels quantified via qRT-PCR on DIV7. Results are expressed as fold change relative to vehicle (−TeNT, 
set to 1). There was no significant difference (p = 0.1286 and 0.4421 for c-Fos and COX-2 respectively) 
as determined via unpaired Student’s t test of the geometric means (N = 3 from three independent 
experiments). Top blot in A: Western blot demonstrating Efficacy of TeNT-induced synaptobrevin-2 (SB2) 
cleavage (representative of three blots) assessed at DIV7. 
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2.4.4 Increased neuronal activity induces COX-2 mRNA levels via NMDAR activity 
 I next tested whether increasing neuronal activity via network disinhibition by 
GABAA receptor antagonism145 is sufficient to enhance COX-2 mRNA level. Increased 
neuronal activity was significantly induced by GABAA receptor antagonist bicuculline, as 
measured via c-Fos mRNA (Fig. 2.6A). Indeed, COX-2 mRNA levels were also 
significantly induced by bicuculline (p = 0.0077, two-way ANOVA, Fig. 2.6B), indicating 
that enhanced neuronal activity resulted from disinhibition is sufficient to induce COX-2 
mRNA levels. As would be expected if this was mediated by NMDAR activity, addition of 
the NMDAR open channel blocker MK801 prevented the increase in c-Fos and COX-2 
mRNA levels seen after the addition of bicuculline (Tukey’s multiple comparison test). In 
addition, NMDAR antagonism completely blocked (Tukey’s multiple comparison test) 
constitutive c-Fos and COX-2 mRNA levels. In contrast, block of evoked synaptic 
vesicle exocytosis using TeNT did not reduce either basal or induced COX-2 mRNA 
levels (Tukey’s multiple comparison test), suggesting that bicuculline-induced network 
disinhibition must facilitate spontaneous, rather than evoked synaptic vesicle release 
which then activate NMDAR. Together, these results suggest that COX-2 mRNA levels 
induced by enhanced neuronal activity requires NMDAR activity. This conclusion is 
further supported by direct induction of COX-2 mRNA via stimulation of NMDAR through 
adding its co-agonists NMDA and glycine. One hour NMDA and glycine treatment 
enhanced COX-2 mRNA levels nearly 4 folds (p = 0.0139, unpaired Student’s t-test, Fig. 
2.7A) without inducing neuronal cell death as measured by lactate dehydrogenase 
(LDH) release (Fig. 2.7B). 
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Fig. 2.6 Effect of NMDAR antagonism on bicuculline-induced COX-2 mRNA levels. DIV7 pure 
neuronal cultures were treated with 100μM bicuculline (+Bic) or its vehicle (-Bic). Cells were either pre-
treated with Tetanus toxin (+TeNT) for two days (DIV 5-7), or co-incubated with NMDAR antagonist MK-
801 (+MK801). c-Fos (A) and COX-2 (B) mRNA was quantified via qRT-PCR 4 hours later. Relative 
mRNA levels in Control in absence of bicuculline were set to 1 and used as comparator (N = 3 from three 
independent experiments). *, p < 0.05, two-way ANOVA followed by Tukey’s test (vs Control -Bic) for 
multiple comparison. #, p < 0.05, two-way ANOVA followed by Tukey’s test (vs -Bic) for multiple 
comparison. For two-way ANOVA, p < 0.001 for treatment (Control vs +TeNT vs +MK801) comparison, p 
= 0.0077 for bicuculline (-Bic vs +Bic) comparison, p = 0.7019 for interaction. 
 
Fig. 2.7 Effect of NMDAR activation on COX-2 mRNA expression. (A) DIV 7 pure neuronal cultures 
were treated with 50μM NMDA and 0.05μM glycine (50μM NMDA) or its vehicle (Control) and COX-2 
mRNA was quantified via qRT-PCR one hour later. Relative mRNA levels in Control were set to 1 and 
used as comparator (N = 4 from four independent experiments). *, p = 0.0139, unpaired Student’s t-test. 
(B) DIV7 pure neuronal cultures were treated with 25μM NMDA and 0.025μM glycine (25μM NMDA), 
50μM NMDA and 0.05μM glycine (50μM NMDA), 100μM NMDA and 0.1μM glycine (100μM NMDA) or 
vehicle (Control) for one hour. No neuronal cell death (p = 0.3971, one-way ANOVA) was found via 
measurement of lactate dehydrogenase (LDH) release. 
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2.4.5 COX-2 mRNA half-life in neurons is regulated by NMDAR activity 
 While both steady-state and induced COX-2 mRNA levels were strongly 
correlated with neuronal activity (Fig. 2.2 to 2.7), it is not known that whether this is due 
to transcription or post-transcriptional regulation of COX-2 mRNA. Post-transcriptional 
control of COX-2 expression by elements in the mRNA 3’UTR has been well 
established in non-neuronal cell types. However, in neurons, the importance of NMDAR 
activity in post-transcriptional regulation of COX-2 expression has yet to be 
demonstrated. To test this, COX-2 mRNA half-life was measured in control or NMDA-
stimulated cortical neuron cultures that were incubated with or without the NMDAR 
antagonist APV. Results show that both constitutive COX-2 mRNA half-life (Fig. 2.8A, 
from 1.9 ± 0.7 to 0.63 ± 0.17 hours) and NMDA-induced COX-2 mRNA half-life (Fig. 
2.8B, from 0.78 ± 0.52 to 0.28 ± 0.18 hours) was reduced by APV treatment, suggesting 
that NMDAR activity maintains the half-life of COX-2 mRNA in both conditions. 
Interestingly, one hour NMDA and glycine stimulation reduced COX-2 mRNA half-life by 
60% (from 1.9 ± 0.7 to 0.78 ± 0.52 hours). Thus, it appears that an NMDAR-dependent 
mechanism controls the tradeoff between increase COX-2 mRNA level and decreased 
mRNA half-life. Together these results support the conclusion that the 3’UTR is a key 
site of post-transcriptional regulation by NMDAR activity.  
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Fig. 2.8 Regulation of COX-2 mRNA half-life by NMDAR activity in neurons.  DIV7 neurons were 
treated with dH2O (A, labeled as –NMDA) or with NMDA (50µM) and glycine (0.05µM) (B, labeled as 
+NMDA) for one hour. Cells were then treated with ActD (1µg/mL) for 0.5, 1, 2, 4 and 8 hours, with or 
without APV (30µM). Remaining COX-2 mRNA levels at various time points after ActD treatments were 
measured via quantitative PCR. The COX-2 mRNA half-life was calculated using nonlinear regression 
analysis, specifically one phase exponential decay as described in section 2.3.6 (N = 3 from three 
independent experiments). Significant differences were identified via two-way ANOVA for comparisons 
between different time points after ActD treatments (p < 0.0001 for –NMDA and p = 0.0126 for +NMDA), 
no significant difference was found between –APV and +APV comparisons (p = 0.5901 for –NMDA and p 
= 0.3910 for +NMDA). 
 
2.4.6 Identification of NMDAR activity-responsive COX-2 mRNA binding proteins 
 Post-transcriptional regulation of mRNA expression could be mediated by 
interaction between RBPs and mRNA 3’UTR. COX-2 mRNA 3’UTR has been shown to 
bind a number of RBPs as described above (Chapter 1). Therefore, it is hypothesized 
that NMDAR activity maintains COX-2 mRNA levels through regulating neuronal RBPs 
that recognize COX-2 mRNA 3’UTR.  
 To identify neuronal RBPs for COX-2, an RNA probe containing the first 60nt of 
COX-2 mRNA 3’UTR was generated. This segment has been shown to bind numerous 
RBPs in a macrophage cell line 89. Indeed, this probe was able to pull down several 
possible RBPs for COX-2 in cultured cortical neurons harvested at DIV7, visualized as 
protein bands on silver stained gels (Fig. 2.9, one band of size 15kD~20kD, bands 
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between 25kD~37kD and bands between 75kD~100kD). To confirm the strong protein 
bands observed near 10kDa were not coming from protein degradation during sample 
preparation or during immunoprecipitation, neuron lysates were incubated with lysis 
buffer on ice for different times. No protein degradation was detected (Fig. 2.10). 
Rather, the 10kDa band appeared to be fragmented streptavidin beads, as it became 
more prominent when a higher concentration of beads was applied (Fig. 2.11). To test 
the possible NMDAR-mediated alteration of binding affinity between RBPs and the 
probe, neurons were treated with 50µM NMDA and 0.05µM glycine or their vehicle for 1 
hour at DIV7. The profile of protein bands that were visualized on gels did not differ 
drastically between control and NMDA treated samples (Fig. 2.12), with the intensity of 
protein bands slightly reduced after NMDA/glycine treatment. This result may imply that 
the binding of most RBPs with COX-2 mRNA may be negatively affected by acutely 
altered NMDAR activity. Thus, NMDAR activation during excitatory transmission 
stimulates disassembly of RBPs from COX-2 mRNAs, which may further lead to altered 
half-life of COX-2 mRNAs (as seen in Fig. 2.8). Indeed, evidence has suggested that 
such RBPs (e.g. Smaug1) are presented in neurons (section 6.4.5.3). Lastly, the 
proteins on gel were subjected to peptide mass finger printing in order to identify 
neuron-specific RNA binding protein of COX-2. Unfortunately, although protein bands 
were visible through silver staining, mass spectrometry failed to detect any specific 
protein (data not shown), possibly due to insufficient protein concentration. Thus, these 
experiments will need to be repeated with an improved design in the future (discussed 
in section 6.4.2). 
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Fig. 2.9 Pull down of neuronal RNA binding proteins of COX-2 mRNA. Lysates harvested from DIV 7 
cortical neurons were incubated with an RNA probe representing the first 60nt of COX-2 mRNA 3’UTR. 
RNA and their putative RNA binding proteins were pulled down with Streptavidin beads, loaded on a 4–
15% polyacrylamide gel, electrophoretically separated via SDS-PAGE, and visualized by silver staining. 
Left, molecular size of the standards (Marker). IP input, 5µg protein obtained before immunoprecipitation. 
Pull-down, 10%(v/v) protein on Streptavidin beads obtained after immunoprecipitation. No Probe Control, 
10%(v/v) protein lysate harvested after mock immunoprecipitation with Streptavidin beads only. 
 
Fig. 2.10 Validation of protein lysis procedure. Lysates harvested from DIV 7 cortical neurons were 
incubated with lysis buffer containing Proteinase inhibitors and RNase Inhibitors for 0, 1, 2, and 3 hours. 
5µg lysates were then loaded on a 4–15% polyacrylamide gel, electrophoretically separated via SDS-
PAGE, and visualized by silver staining. Right, molecular size of the standards (Marker).  
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Fig. 2.11 Validation of pull down procedure. Lysates harvested from DIV 7 cortical neurons were 
incubated with Streptavidin beads of different concentrations. Supernatant containing protein lysate was 
separated from beads via centrifugation. Both supernatant (5µL) and beads (5µL) were loaded on a 4–
15% polyacrylamide gel, electrophoretically separated via SDS-PAGE, and visualized by silver staining. 
Right, molecular size of the standards (Marker). Arrows indicate the concentration-dependent increase in 
staining intensity of the 10kDa bands. 
 
Fig. 2.12 Pull down of RNA binding proteins of COX-2 mRNA from NMDA stimulated neurons. DIV 
7 cortical neurons were treated with 50µM NMDA and 0.05µM glycine or their vehicle for 1 hour. Lysates 
were harvested and incubated with an RNA probe representing the first 60nt of COX-2 mRNA 3’UTR. 
RNA and their putative RNA binding proteins were pulled down with Streptavidin beads, loaded on a 4–
15% polyacrylamide gel, electrophoretically separated via SDS-PAGE, and visualized by silver staining. 
Input, 20µg protein obtained before immunoprecipitation. Pull down, 1mg protein on Streptavidin beads 
obtained after immunoprecipitation. 
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2.4.7 Expression of components of the arachidonic acid metabolism pathway 
 While previous sections (2.4.2 to 2.4.5) have demonstrated a clear association 
between neuronal COX-2 expression and excitatory neuronal activity, it is not known 
that whether this association remains true for the putative enzyme partners of COX-2. It 
appears that the mRNA levels of two downstream prostaglandin synthases, mPGES-1 
and PGDS, changed in a manner that only weakly coupled to synaptic activity. mPGES-
1 mRNA level dropped dramatically at DIV5 and remained low at DIV7 (Fig. 2.13A), 
whereas PGDS mRNA level decreased dramatically from DIV3 through DIV7 (Fig. 
2.13B), with the decrease starting well before the onset of increased neuronal activity at 
DIV5 (Fig. 2.2C). On the other hand, the mRNA levels of mPGES-2, another 
downstream prostaglandin synthase, steadily increased from DIV1 through DIV7 (Fig. 
2.13C), an effect that parallel to change in COX-2 mRNA level. Interestingly, a modest 
increase in upstream phospholipase cPLA2 mRNA level was observed at DIV7 (Fig. 
2.13D), also paralleled to the drastic increased neuronal activity at DIV7.   
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Fig. 2.13 Time course mRNA levels of arachidonic acid pathway in cultures of cortical neurons. 
Shown is a comparison of the temporal pattern of mPGES-1 (A), PGDS (B), mPGES-2 (C) and cPLA2 
(D) mRNA levels in pure wild-type neurons at 1, 3, 5, and 7 days in vitro as quantified by real-time qRT-
PCR. Relative mRNA levels on DIV 1 was set to 1 and used as the comparator (N = 3-5 from three 
independent experiments). Significant differences between treatments were identified via one-way 
ANOVA (p = 0.0002 for mPGES-1, p = 0.0002 for PGDS, p = 0.0032 for mPGES-2, p = 0.0031 for cPLA2
). *, p < 0.05, Dunn’s test for multiple comparison following one-way ANOVA. 
 
 To further test whether the expression of these arachidonic acid pathway enzyme 
genes is directly dependent on NMDAR activity, mRNA expression levels were 
measured in cortical neurons at DIV7 after NMDAR antagonism with APV. No 
significant change was observed in the mRNA expression levels of NR1 after APV 
treatment (Fig. 2.14A), indicating that the reduction in neuronal activity did not result 
from altered expression level of NMDAR. Similarly, APV did not alter the mRNA levels 
of mPGES-1, mPGES-2 and PGDS (Fig. 2.14B, C and D), indicating that the expression 
of prostaglandin synthases is not stringently co-regulated with COX-2 by NMDAR 
activity in cultured cortical neurons. It is worth mentioning that neuronal cPLA2 mRNA 
levels were increased by APV treatment (Fig. 2.14F), but not by CNQX treatment (data 
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not shown), suggesting that reduced NMDAR activity results in enhanced expression of 
this enzyme.  
 
 
Fig. 2.14 Effect of NMDAR antagonism on arachidonic acid pathway mRNA levels. DIV5 pure 
neuronal cultures were treated with 30μM APV (+APV) or its vehicle (−APV) and NR1 (A), mPGES-1 (B), 
mPGES-2 (C), PGDS (D), COX-1 (E) and cPLA2α (F) mRNA were quantified via qRT-PCR two days 
later. Relative mRNA levels on DIV1 were set to 1 and used as comparator (N = 3-9 from five 
independent experiments. For unpaired Student’s t-test, p = 0.1821 (NR1), p = 0.9819 (mPGES-1), p = 
0.7762 (mPGES-2), p = 0.6964 (PGDS), p = 0.1171 (COX-1), p = 0.0244 (*, cPLA2α). 
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2.5 Discussion 
 In many peripheral tissues, COX-2 expression has been shown to be primarily 
inducible by various stimuli75. In contrast, constitutive expression of COX-2 in 
physiologically significant levels has been found in tissues such as kidney150 and in 
neurons from spinal cord162 and brain136. Despite knowing that the COX-2 gene 
expression is under transcriptional and post-transcriptional regulation by various cis-
acting elements, the molecular mechanisms underlying constitutive neuronal COX-2 
expression remain largely unknown. With respect to this, I investigated the expression 
of COX-2 mRNA in cultured cortical neurons and presented several original findings. 
First, COX-2 mRNA is expressed constitutively in brain and is especially high in cerebral 
cortex. Second, constitutive expression in cortical neurons depends largely on the 
presence of functional NMDARs as functional block of NMDARs prevents the 
constitutive neuronal expression of COX-2. Third, increased neuronal activity is 
sufficient to induce COX-2 mRNA via activation of NMDARs. Fourth, spontaneous 
glutamatergic synaptic activity may be involved in both constitutive and induced 
expression as shown by the lack of effect of tetanus toxin in both conditions. 
 Consistent with the mRNA expression profile from the Allen Brain Atlas (© 2004, 
Allen Institute for Brain Science. Allen Mouse Brain Atlas. Available from: 
http://mouse.brain-map.org/),  high level endogenous COX-2 mRNA is found in 
hippocampus, olfactory bulbs and cortex (Fig. 2.1). A low-level expression of COX-2 
mRNA was also found in cerebellum and in spinal cord, consistent with previous 
observation that COX-2 protein and mRNA are expressed constitutively in cerebellum 
astrocytes 275 and in both neurons and astrocytes from spinal cord 162. Interestingly, 
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mice harboring a transgenic construct consisting of −371/+70 bp of the 
proximal Ptgs2 gene promoter fused 5′ of a luciferase transgene exhibited high 
luciferase expression in both cerebellum and spinal cord83. These results suggest that 
native expression of COX-2 mRNA in these two CNS structures may be regulated by 
elements located outside the proximal region of COX-2 promoter, such as those located 
in the COX-2 3′-UTR. It is also possible that other elements in COX-2 promoter confer 
the brain region-specific suppression of COX-2 mRNA, as the full-length Ptgs2 gene 
promoter drives high level of luciferase expression in cortex and hippocampus, with little 
expression in cerebellum in a knock-in mouse line73,276.  
 The high-level expression of endogenous COX-2 mRNA in cerebral cortex was 
faithfully reflected in cultured cortical neurons. COX-2 mRNA was constitutively 
expressed in cultures in a temporal pattern which coincided with the developmental 
expression of NMDAR proteins confirmed via measurement of NR1 mRNA level (Fig. 
2.2). Constitutive COX-2 expression also correlated with the temporal pattern of 
NMDAR activity reported previously 277, suggesting that it is NMDAR-dependent. 
Indeed, pharmacological block of NMDAR effectively suppressed neuronal COX-2 
mRNA expression (Fig. 2.3 and 2.4), consistent with previous results that genetic 
inhibition of NMDAR reduced constitutive neuronal expression of COX-2 mRNA 83. Bath 
NMDA and bath glutamate treatments have been reported to induce neuronal COX-2 
activity and expression in dissociated cultures141,143. This was confirmed in my cultures, 
where acute (1 hour) bath NMDA and glycine-induced COX-2 mRNA expression (Fig. 
2.7A). In this case, excitotoxicity did not seem to contribute to the induced COX-2 
expression as shown by others143, as no obvious cell death was observed during the 
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treatment paradigm (Fig. 2.7B). Increased neuronal activity facilitated by blocking 
inhibitory neurotransmission also induced COX-2 mRNA levels, an effect that was 
blocked by NMDAR inhibition (Fig. 2.6). Together these results indicate that NMDAR 
activity is both sufficient and required for up-regulation of COX-2 mRNA levels. In 
addition, the ineffectiveness of tetanus toxin in reducing both constitutive and induced 
COX-2 mRNA levels (Fig. 2.5) suggests that spontaneous synaptic activity regulates 
both basal and induced neuronal COX-2 expression in this in vitro model. Tetanus toxin 
is a Clostridium toxin that prevents evoked, but not spontaneous, synaptic vesicle 
exocytosis in neurons 278. It has been shown that in immature hippocampal neurons 
(DIV 4-5 cultured hippocampal neurons), spontaneous vesicular release level was high 
279. In addition, young neurons are known to respond to low concentration of glutamate 
via NR2B containing NMDAR280, and that spontaneous glutamate release may signal 
distant NMDAR to provide dendritic guidance or branching cues281. It is possible that 
spontaneous glutamate release is high and can be further elevated via inhibition of 
inhibitory neurotransmission at DIV 7 cultured cortical neurons, which activates 
NMDAR-dependent downstream signaling cascades through a mechanism that does 
not involve ion-influx282.   
 Although compelling evidence indicates that neuronal COX-2 expression is 
regulated by NMDAR-dependent excitatory synaptic activity, the molecular mechanisms 
by which glutamate (or NMDA) regulates COX-2 expression are poorly understood. 
Interestingly, the NMDAR-dependent factor(s) that regulate constitutive neuronal COX-2 
expression seem to be intrinsic to neurons, as COX-2 mRNA level in neurons was not 
altered by co-culture with astrocytes or treatment with astrocyte-conditioned media83. 
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These factor(s) could be acting transcriptionally, as Ptgs2 gene promoter is known to 
contain a TATA box motif and a number of cis-acting elements, including CREB, 
C/EBP, NF-IL6, AP-1, Sp1, and NF-κB consensus sequences 283. Among these 
transcription factors, constitutive neuronal COX-2 transcription seems to be 
independent of NF-κB, as a COX-2 promoter segment that lacks the NF-κB site was still 
able to drive constitutive expression of luciferase in neurons 83. Rather, constitutive 
expression of COX-2 appears to be negatively regulated by Sp1 and is positively 
regulated by CREB, as shown by promoter mutation studies 83. On the other hand, post-
transcriptional regulation of COX-2 expression may also exist. The COX-2 mRNA 
3’UTR, which in the mouse is >2kb in length, has been shown to possess cis-acting 
elements that regulated RNA stability and translation efficiency 76,84,85 76,84,85. My results 
indicate, for the first time, that NMDAR-dependent COX-2 expression in neurons 
involves posttranscriptional regulation. The half-life of COX-2 mRNA was reduced by an 
antagonist of basal NMDAR activity suggesting that the half-life of the COX-2 transcript 
is maintained by glutamate signaling through the NMDAR (Fig. 2.8). This notion is 
further supported by unpublished observations (J.A.Hewett) from cultures of cortical 
neurons showing that the COX-2 mRNA 3’UTR enhanced expression of a luciferase 
reporter gene in a manner that was dependent on functional NMDARs in cultures of 
cortical neurons. Additionally, NMDAR inhibition attenuated the effect of the COX-2 
mRNA 3’UTR on reporter gene upregulation. These results support the conclusion that 
the 3’UTR is a key site of post-transcriptional regulation by NMDAR activity. 
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CHAPTER 3 Maintenance of the innate seizure threshold by COX-2 is not influenced by 
the translational silencer TIA-1b 
3.1 Synopsis  
 COX-dependent PG production has been shown to possess anti-convulsive 
properties. COX-2 gene expression levels are subjected to post-transcriptional 
regulation by RBPs. In non-neuronal cells, it is known that the RBP TIA-1 enhances 
COX-2 protein translation via direct binding to COX-2 3’UTR. Therefore, studies 
included in this chapter tested the hypothesis that in neurons, TIA-1 regulates COX-2 
expression and by doing so influences the innate seizure threshold.   
                                            
b This chapter is a near duplicate of the previously published work in Neuroscience. Gong, Y. & Hewett, 
J.A. Maintenance of the Innate Seizure Threshold by Cyclooxygenase-2 is Not Influenced by the 
Translational Silencer, T-cell Intracellular Antigen-1. Neuroscience. 2018; 373: 37-51. © IBRO. Published 
by Elsevier Ltd. 
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3.2 Introduction 
 Activity of neuronal COX-2 is enhanced by excitatory neurotransmission and this 
is thought to be involved in seizure suppression. COX-dependent PG production 
increases rapidly and transiently in the brain following acute convulsive seizures. 
Pharmacological inhibitors of COX-2 activity or inactivation of the Ptgs2 gene reduced 
the innate seizure threshold 68,69,174,176,187, an effect that is thought to be due to the loss 
of anticonvulsant PGs 67,170. On the other hand, genetic overexpression of COX-2 
suppressed the incidence of pentylenetetrazole (PTZ)-induced convulsions 177. These 
results suggest that COX-2 contributes to the maintenance of an elevated seizure 
threshold in the normal brain. 
 Control of COX-2 expression is complex, involving transcriptional, 
posttranscriptional, and posttranslational mechanisms 75,81. While the regulation of 
COX-2 expression has been studied extensively in non-neuronal cell types, much less 
is known about its regulation in neurons. The 3′UTR of COX-2 mRNA is a regulatory 
region that has the capacity to bind numerous RBPs, which can affect stability and/or 
translation of the transcript 76. T-cell intracellular antigen-1 (TIA-1) is one such RBP. In 
non-neuronal cell types, inactivation of the TIA-1 gene (Tia1) was associated with an 
increase in COX-2 protein expression indicating that TIA-1 functions to repress COX-2 
mRNA translation 88. Whether TIA-1 performs a similar function in the regulation of 
COX-2 expression in neurons has yet to be explored. 
 The goal of the work described in this chapter is to test the possibility that TIA-1 
regulates COX-2 expression in neurons and by doing so influences the innate seizure 
threshold. Specifically, because inhibitors of COX-2 activity lower the acute seizure 
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threshold and TIA-1 deletion enhances COX-2 expression, it is reasoned that 
inactivation of the Tia1 will increase neuronal COX-2 expression in the brain and 
consequently will increase resistance to acute seizures.  
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3.3 Materials and methods 
3.3.1 Animal housing  
 Mice were housed on a 12 h light/dark schedule in the vivarium at Syracuse 
University, which is accredited by the Association for Assessment and Accreditation of 
Laboratory Animal Care International. Standard mouse chow and water were 
provided ad libitum. Except for breeding units, mice were housed three to five per cage. 
All animal procedures conformed to the National Academy of Sciences Guide for the 
Care and Use of Laboratory Animals (NRC, 2011) and were approved by the Syracuse 
University Institutional Animal Care and Use Committee (IACUC). 
3.3.2 Animal breeding 
 The TIA-1 gene mutant mouse line (Tia1−/−) was obtained from cryostorage at 
The Jackson Laboratory (stock # 009248) and a colony established by crossing 
heterozygous founder mice (Tia1+/−) with their wild-type (Tia1+/+) C57BL/6J counterparts 
(stock #000664). Tia1+/+ and Tia1−/− littermates were generated for studies by crossing 
Tia1+/− breeding pairs from this colony. Genotyping of both mouse lines was performed 
at weaning by PCR analysis of genomic DNA isolated from tail biopsies. To ensure the 
integrity of the C57BL/6J genetic background, the line was backcrossed with wild-type 
female C57BL/6J mice from The Jackson Laboratory every 3–5 generations.  
3.3.3 Dosing paradigms 
 The acute PTZ-induced seizure model was used to examine changes in the 
innate seizure threshold. All mice were acclimated to handling for 5–7 days prior to each 
experiment. Injection solutions were prepared freshly by dissolving PTZ (Sigma 
Chemical Co., St. Louis, MO) in 0.9% saline, which was sterilized by filtration and 
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administered in a volume of 10 ml/kg body weight, i.p. Male littermates were randomly 
segregated at weaning without knowledge of genotype and treated with a single dose of 
PTZ or saline vehicle between 8 and 12 weeks of age. Seizure activity was monitored 
for 25 min after PTZ administration and graded by an observer blinded to genotype 
using a previously established scoring system181: stage 0, normal behavioral 
activities; stage 1, hypoactivity; stage 2, ≥two isolated myoclonic jerks; stage 3, 
generalized clonic convulsions with preservation of righting; stage 4, generalized clonic 
or tonic–clonic convulsions with loss of righting. Maximal seizure score and latency to 
seizure onset were recorded for individual mice and the incidence of convulsions (stage 
3 or 4) in a given cohort was determined by the ratio of # of mice convulsed per total # 
treated. 
3.3.4 Immunofluorescence staining 
 Mice were deeply anesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine 
administered i.p. in saline and exsanguinated by transcardial perfusion with 
0.05 M phosphate-buffered saline (PBS) followed by 4% paraformaldehyde fixative 
(PFA) in PBS. After post-fixing at 4 °C for 8–16 h in PFA solution, brains were saturated 
with 20% sucrose in PBS, embedded in O.C.T. compound (Tissue Tek), and rapidly 
frozen on dry ice prior to storage (−80 °C). Serial 12-µm-thick coronal sections were cut 
within 1.34–2.06 mm posterior to bregma using a cryostat (Microm HM550, Thermo 
Scientific) and mounted on microscope slides prior to storage at −20 °C. Sections were 
washed in PBS and incubated in PBS containing 0.25% Triton-X100 (PBT). 
Permeabilized sections were incubated overnight at 4 °C in blocking solution containing 
PBT with 5% normal donkey serum (Jackson ImmunoResearch Inc.) and 1% 
		77	
bovine serum albumin (BSA; Sigma, A2153) then incubated overnight at 4 °C with 
antigen-specific primary antibody diluted in PBT containing 1% normal donkey serum 
and 1% BSA. After washing 5 times with PBT, sections were incubated at 20 °C with 
secondary antibody for 4 h, washed again, then incubated for 5 minutes with PBS 
containing 1 µg/ml DAPI (Life Technology) to label cell nuclei. Images were captured 
with ZEN 2 software (Version 2.0.0.0) using an Axio Imager.A2 microscope fitted with 
an AxioCam MRc digital camera (Zeiss United States). Images from individual studies 
were processed identically using Adobe Photoshop (Adobe Systems, Inc., San Jose, 
CA, USA). 
 Primary and secondary antibodies for immunostaining were goat anti-TIA-1 
(1 µg/ml, Santa Cruz Biotechnology Cat# sc-1751, RRID: AB_2201433), rabbit anti-
COX-2 (1:200, Cayman Chemical Cat# 160126-1, RRID: AB_327872), mouse anti-
GFAP (1:50, Genetex, GeneTex Cat# GTX73615, RRID: AB_378828), Alexa Fluor 594 
donkey anti-Goat IgG (7.5 µg/ml, Jackson ImmunoResearch Labs Cat# 705-585-147, 
RRID: AB_2340433), Alexa Fluor 488 AffiniPure Donkey anti-rabbit IgG (7.5 µg/ml, 
Jackson ImmunoResearch Labs Cat# 711-545-152, RRID: AB_2313584), and Alexa 
Fluor 488 AffiniPure Donkey anti-mouse IgG (7.5 µg/ml, Jackson ImmunoResearch 
Labs Cat# 715-545-150, RRID: AB_2340846). Specificity of the anti-TIA-1 antibody was 
confirmed using comparable sections from Tia1+/+and Tia1−/− mice processed in parallel. 
For GFAP/TIA-1 double staining, sections were processed for antigen-retrieval as 
described (Abcam, http://www.abcam.com/protocols/ihc-antigen-retrieval-protocol). 
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3.3.5 Quantification of fluorescent intensity 
 Images were converted to 8-bit grayscale and fluorescent intensity quantified 
using NIH Image J, version 1.50i284. For each brain, two images were taken from 
coronal sections at −1.7 ± 0.12 relative to bregma. Maximal threshold was set to 255 
and minimal threshold was set to 55 (TIA-1) or 40 (COX-2), using the default auto 
thresholding method. The mean integrated density in 8 non-overlapping regions of 
interest (ROIs) with fixed size (100 × 100 pixel2) was calculated for CA1 and CA3 
pyramidal and DG granule cell layers of the hippocampal formation. Results were 
averaged across duplicate sections from each brain. 
3.3.6 Generation of purified cortical neuron and astrocyte cultures 
 Pure cultures of cortical neurons were prepared from gestational day 15 
C57BL/6J fetuses as detailed in section 2.3.2. To generate purified cortical astrocyte 
cultures, brains from postnatal day 1–3 pups were placed into ice cold dissecting 
medium (Ca2+/Mg2+-free HBSS containing 25mM glucose, 20mM sucrose, and 20mM 
HEPES), meninges removed, and cortices dissected free from the rest of brain. 
Harvested tissue was minced and incubated at 37oC for 15 min in dissecting medium 
containing 0.025% trypsin. Single cell suspensions were plated at a density of two 
hemispheres/plate on Falcon Primaria 24-well culture plates (BD Biosciences, Lincoln 
Park, NJ) in media stock (MS) supplemented with 10% FBS (Hyclone, Logan, UT), 10% 
calf serum (CS; Hyclone), 10 ng/ml epidermal growth factor (Life Technologies, 
Grand Island, NY), and penicillin/streptomycin (50 IU/ml and 50 µg/ml, respectively). MS 
is composed of modified Eagle’s medium (MEM, Earle’s salts; Mediatech, Herndon, VA) 
supplemented with 2 mM glutamine and 20 mM glucose. Upon reaching confluence, the 
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cultures were treated once for 2 days with cytosine arabinoside (8 µM) and were 
maintained thereafter in maintenance media (MS plus 10% CS and antibiotics). One 
day before experimentation, cells were treated with l-leucine methyl ester (75 mM, 
30 min) to remove microglia285. Astrocyte cultures were used on DIV 30. 
3.3.7 Measurement of TIA-1 mRNA expression 
 TIA-1 mRNA was measured in lung, spleen, liver, kidney, heart, and brain from 
8-week-old male C57BL/6J mice, as well as from cultures of cortical neurons and 
astrocytes. Real-time quantitative PCR was performed as described previously 271 and 
in quantitative real-time PCR section (2.3.4). Mouse TIA-1 (Mm00441742_m1) or β-
actin (Mm01205647_m1) TaqMan gene expression assay probes were used in 
singleplex reactions. The TIA-1 assay detects mRNA splice variants 1a and 1b that 
contain or lack exon 5, respectively.  
 TIA-1 isoform expression was measured by reverse transcriptase-polymerase 
chain reaction. cDNA was subjected to RT-PCR in a 25µl reaction containing either the 
amplimer pairs for TIA-1 (5’-AAGTGAATTGGGCAACAACC-3’, sense; 5’- 
TGAATGGCATTTTCTGCATC-3’, anti-sense) or β-actin (5’- 
GTGGGCCGCTCTAGGCACCAA-3’, sense; 5’-CTCTTTGATGTCACGCACGAT-3’, 
anti-sense), along with Taq DNA polymerase (Promega). Reactions were run in a MJ 
Mini (Bio-Rad) personal thermal cycler. Each cycle consisted of a denaturation step 
(94°C for 30s), an annealing step (45s), and a primer extension step (72°C, 1 minute). 
Annealing temperatures and cycle number were as follows: TIA-1 (48°C, 28 cycles); β-
actin (63°C, 25 cycles). 
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3.3.8 Measurement of arachidonic acid pathway mRNA expression 
 Total RNA was extracted from hippocampus of Tia1+/+ and Tia1−/− animals 3 
hours after acute PTZ-induced convulsion. Control group received Saline injection. 
Real-time quantitative PCR was performed as described in quantitative real-time PCR 
section (2.3.4). The following mouse-specific primer pairs (Applied Biosystems) were 
used: Actb (Mm01205647_m1); Fos (Mm00487425_m1); Ptgs2 (Mm00478374_m1); 
Ptges1 (Mm00452105_m1); Ptges2 (Mm00460181_m1); Pla2g4a (Mm00447040_m1) 
according to manufacturer’s instruction. Efficiency of all primers were analyzed as 
described in section 2.3.4. 
3.3.9 Statistical analysis 
 All statistical analyses were performed using GraphPad Prism, Version 6.0.1 
(GraphPad Software, Inc., La Jolla, CA, U.S.A.). For qRT-PCR, statistics were 
performed on the logarithmic transformation of 2−ΔΔCT values. TIA-1 mRNA tissue 
expression was analyzed by a one-way ANOVA followed by Dunnett’s multiple 
comparisons test. TIA-1 mRNA expression between astrocytes and neurons was 
analyzed by unpaired t-test. AA pathway mRNA expression was analyzed by a two-way 
ANOVA followed by Sidak’s multiple comparison test. Quantitative protein expression of 
TIA-1 or COX-2 immunoreactivity was analyzed by a two-way ANOVA on the 
logarithmic transformation of gray values. Latency to convulsion after acute PTZ 
injection between genotypes was assessed using two-tailed Mann–Whitney test. 
Datasets representing proportions (percentage mortality or incidence of convulsions) 
were analyzed using a two-tailed Fisher’s exact test. Significance was set at p < 0.05. In 
figure legends, p values were reported as their exact values whenever available. For all 
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multiple comparison analysis, exact p values were not provided by Prism and were 
reported as “p < 0.05”. Exact p values that are less than 0.0001 were not provided by 
Prism and were reported as “p < 0.0001”.  
3.4 Results 
3.4.1 TIA-1 mRNA expression profile in the brain 
 Prior to assessing the role of TIA-1 in the regulation of neuronal COX-2 
expression and seizure threshold maintenance, a comprehensive analysis of its 
expression profile in the brain was performed. High levels of TIA-1 mRNA were found in 
the normal brain. Indeed, a quantitative analysis of its tissue distribution demonstrated 
that the relative expression in various tissues was 
brain > heart > kidney > liver ≈ spleen ≈ lung (Fig. 3.1A). Within the brain, high levels of 
TIA-1 mRNA were detected in the cerebral cortex and hippocampus. A comparison 
between cultures of cortical neurons and astrocytes shows that neurons expressed 4-
fold higher TIA-1 than astrocytes (Fig. 3.1B), suggesting that neurons are a primary 
contributor to TIA-1 mRNA expression in this brain region. 
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Fig. 3.1. TIA-1 mRNA is expressed constitutively at high levels in normal mouse brain tissue and 
cells. (A) Tissue expression. Relative TIA-1 mRNA in mouse tissues was assessed by qRT-PCR 
analysis. Results are expressed as Mean ± Standard Error of the Mean relative to lung (N = 3 mice). *, 
significantly higher than lungs (p < 0.0001, Dunnett’s multiple comparisons test following one-way ANOVA 
on log-transformed 2−ΔΔCTvalues). (B) Neural cell expression. TIA-1 mRNA levels were assessed in 
primary cultures of astrocytes and neurons by qRT-PCR. Results are expressed as Mean ± Standard 
Error of the Mean relative to astrocytes (N = 3 independent cultures). #, significantly higher than 
astrocytes (p = 0.002, unpaired Student’s t-test on log-transformed 2−ΔΔCT values). 
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 TIA-1 has two major isoforms (TIA-1a and TIA-1b) generated by alternative 
splicing 239,240. Both isoforms were detected in all tissue types examined (Fig. 3.2). 
Interestingly, astrocytes appear to present a much higher TIA-1a over TIA-1b ratio than 
neurons, shown by RT-PCR, although this requires further confirmation in a quantitative 
assessment.  
 
Fig. 3.2. Expression of TIA-1 isoforms in tissue samples. Top, TIA-1 mRNA isoforms (TIA-1a, 265bp 
and TIA-1b, 232bp) were measured by RT-PCR from primary astrocyte and neuron cultures derived from 
C57BL/6J animals or tissue samples isolated from adult male C57BL/6J mice. Bottom, β-actin (500bp) 
mRNA expression was shown as loading control for each sample. Lanes from left to right: M, marker 
(100bp DNA Ladder, New England BioLabs Inc.); N1, DIV1 cultured cortical neurons; N7, DIV7 cultured 
cortical neurons; A, DIV30 astrocytes; C, cortex; Hi, hippocampus; Li, liver; K, kidney; He, heart; Lu, lung; 
S, spleen; Ng, negative control. Image represents N = 3 cultures or mice.  
 
3.4.2 TIA-1 protein expression profile in the brain 
 To examine in detail the distribution of constitutive TIA-1 expression in the brain, 
a comprehensive analysis of protein expression was performed. Prior to performing this 
analysis, the specificity of the TIA-1 antibody was assessed in the mouse brain (Fig. 
3.3). Strong TIA-1 protein expression was detected in the DG of wild-type mice 
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possessing two functional Tia1 alleles (Tia1+/+). This was reduced in brains from mice 
containing only one functional allele (Tia1+/−) and no staining was detected in brains 
from mice in which both alleles were inactivated (Tia1−/−). This gene dosage effect 
confirms the specificity of the TIA-1 antibody and verifies the genotype of Tia1 mutant 
mice at the protein level. 
 
Fig. 3.3. Verification of TIA-1 protein deletion and validation of anti-TIA-1 antibody. Brains of adult 
Tia1+/+ (A), Tia1+/− (B), and Tia1−/− (C) animals were fixed, sectioned (12 µm) and stained with anti-TIA-1 
antibody (red). White scale bar = 100 µm. Images are representative of brains from two mice per 
genotype.  
 
 TIA-1 protein was expressed broadly in the brain under basal conditions (Figs. 
3.4 and 3.5). Particularly high constitutive levels were detected in the hippocampal 
formation (Fig. 3.4A), where the primary excitatory neurons of the CA3 and CA1, as well 
as the DG, strongly express TIA-1 protein (Fig. 3.4B–D). Although the protein appeared 
to be concentrated in the nucleus of these cells, TIA-1 was detected in the cytoplasm of 
neurons in the less densely populated CA3 layer (Fig. 3.4D). A small number of cells 
outside of the primary cell layers expressed TIA-1 protein as well, including within the 
hilus of DG (Fig. 3.4C). A subset of TIA-1-positive cells appeared to co-
express GFAP (Fig. 3.5), consistent with mRNA expression in astrocyte cultures (Fig. 
3.1B). TIA-1 expression was detected in layers 2–6 of the somatosensory cerebral 
cortex (Fig. 3.6A) and particularly prominent expression was observed in layer 2 of the 
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retrosplenial and piriform cortical regions (Fig. 3.6B and C, respectively). Scattered TIA-
1-positive cells, possibly oligodendrocytes and/or white matter astrocytes, were 
detected in the myelinated fiber tracts of the fimbria and corpus callosum (Fig. 3.6E, F, 
respectively). Expression was also detected in numerous other brain regions, 
including choroid epithelium, caudoputamen, hypothalamus, and amygdala (Fig. 3.6G–
J, respectively). It is also noteworthy that whereas many cells of the 
medial habenula express TIA-1, many fewer cells express the protein in the lateral 
habenula. These observations are in agreement with the TIA-1 mRNA profile in the 
normal mouse brain (Tia1 – RP_041122_01_B01 – sagittal, © 2004, Allen Institute for 
Brain Science. Allen Mouse Brain Atlas. Available from: http://mouse.brain-map.org/). 
Finally, the level of TIA-1 protein expression was not altered by a convulsive stimulus, 
suggesting that its expression is not linked to excitatory neuronal activity (Figs. 
3.7 and 3.9A). 
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Fig. 3.4. TIA-1 protein is expressed in the primary neuronal layers of the hippocampal formation. 
Coronal sections (12 µm, bregma −1.70 ± 0.12 mm) were obtained from normal C57BL/6J mouse brains 
and stained for TIA-1 (red), GFAP (green) and DAPI (blue). Magenta indicates co-localization of TIA-1 
and DAPI. (A) Brain hemisphere along the dorsal–ventral axis between the cerebral cortex (CTX) 
and thalamus (TH) and laterally between the third (V3) and lateral ventricles (VL); RSPv, 
ventral retrosplenial cortex; DG, dentate gyrus; CA1/CA3, hippocampal layers; CP, caudoputamen; 
MH/LH, medial/lateral habenula; cc, corpus callosum; fi, fimbria. White scale bar = 200 µm. (B) CA1; (C) 
DG and hilus; and (D), CA3. White bar represents 50 µm. Image panels B–D were taken from a different 
section than panel A. Images are representative of brains from two Tia1+/+ mice. 
 
 
Fig. 3.5. Hippocampal astrocytes express TIA-1 protein. Images were acquired from the molecular 
layer of the dentate gyrus in the adult Tia1+/+ mouse brain (12 µm). (A, E) TIA-1 (red); 
(C, G) GFAP (green); (B, F) nuclei (blue). (D, H) overlay of A–C and E–G, respectively. Arrows, 
astrocytes expressing TIA-1 protein (magenta/green). White scale bar = 10 µm. A–D and E–H are 
representative images from two mice.  
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Fig. 3.6. TIA-1 protein expression profile in the brain of wild-type (Tia1+/+) mice. TIA-1 protein 
(red), GFAP protein (green), and cell nuclei (DAPI, blue) were visualized by epifluorescence microscopy 
in 12 µm thick coronal sections obtained at bregma −1.70 ± 0.12 mm. Magenta indicates co-localization of 
TIA-1 and DAPI. TIA-1 expression in: (A) somatosensory cortical layers 1–6; (B) ventral retrosplenial 
cortical layers 1–6 (RSPv); (C) piriform cortical layers 1–3 (Pir); (D) medial (MH) and 
lateral habenula (LH); (E) thalamus (TH) and fimbria (fi); (F) corpus callosum (cc); (G) choroid 
plexus (ChP), lateral ventricle (LV); (H) caudoputamen (CP); (I) hypothalamus, 3rd ventricle (V3); (J) 
medial amygdalar nuclei, anterodorsal (MEApd) and anteroventral (MEApv) parts. CTX, cerebral cortex; 
DG, dentate gyrus; CA1, cornu ammonis area 1. White scale bar = 100 µm. Images are representative of 
two mouse brains. 
		88	
 
Fig. 3.7. Effect of acute convulsive seizures on TIA-1 protein expression in the hippocampal 
formation. Cohorts of Tia1+/+ mice were treated with saline or 54 mg/kg PTZ (N = 4). Brains from PTZ-
treated animals were harvested 3 h following convulsions, fixed, sectioned (12 µm) and stained with TIA-
1 antibody (red) and DAPI (blue). Brains from saline-treated mice were processed in parallel. 
(A, E, I, C, G, K) Representative images from a saline-treated mouse. (B, F, J, D, H, L) Representative 
images from PTZ-treated mouse. (A–D) CA1; (E–H) CA3; (I–L) dentate gyrus. High/low magnification 
images showing the same brain structure were taken from different sections. White scale bar = 100 µm (J) 
and 10 µm (L). Images are representative of four mice from each treatment group.  
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3.4.3 Effect of TIA-1 gene deletion on neuronal COX-2 protein expression in the 
brain  
 Next, the expression profile of COX-2 protein in the hippocampus of Tia1+/+ mice 
was compared to Tia1−/− littermates. In Tia1+/+ mice under basal conditions, constitutive 
expression of COX-2 protein was detected in only a few granule neurons of the DG, 
whereas it was broadly expressed by pyramidal neurons of the CA3 region (Fig. 3.8A, E, 
respectively). This expression pattern was modified following a PTZ-induced convulsion. 
Specifically, expression was induced strongly in neurons of the DG and enhanced in 
CA3 neurons (Fig. 3.8C, G, respectively). Importantly, this expression profile was not 
altered in mutant mice lacking TIA-1 as hypothesized. Thus, the COX-2 expression 
patterns in the DG and CA3 regions of Tia1+/+ and Tia1−/− mice were comparable under 
both basal conditions and after the PTZ-induced convulsion (Fig. 3.8B/F and D/H, 
respectively). Note that COX-2 protein expression was undetectable in the pyramidal 
neurons of the CA1 in both genotypes and this was not changed following an acute 
PTZ-induced convulsion (data not shown). It is noteworthy that under either basal or 
induced conditions, COX-2 protein was detected only in the outer layer of DG, 
consistent with previous results that COX-2 protein is absent from neural progenitor 
cells in subgranular zone286. Together, these results indicate that TIA-1 does not control 
COX-2 expression in neurons under normal conditions or in response to a marked 
increase in excitation induced by inhibition of endogenous GABA neurotransmission by 
PTZ. Quantitative analysis of the expression changes further supports this contention 
(Fig. 3.9B). 
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Fig. 3.8. Basal and convulsion-induced COX-2 expression in the hippocampal formation. 
Tia1+/+ and Tia1−/− littermate mice were treated with saline or 54 mg/kg PTZ. Brains from saline- and PTZ-
treated animals that had convulsive seizures were harvested 3 h later, fixed, sectioned (12 µm) and 
stained with COX-2 antibody (green) and DAPI (blue). (A, B, E, F) COX-2 expression in a saline-treated 
mouse brain. (C, D, G, H) COX-2 expression in a PTZ-treated mouse brain. (A–D) Dentate gyrus; (E–
H) CA3. White scale bar = 100 µm. Images are representative of three mice per genotype.  
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Fig. 3.9. Quantification of basal and convulsion-induced TIA-1 and COX-2 expression in 
the hippocampal formation of Tia1+/+ mice. Fluorescent intensity in brain images was quantified using 
NIH Image J (version 1.50i). (A) TIA-1 protein expression in CA1, CA3 and DG. Results were analyzed by 
a two-way ANOVA on log-transformed gray values. Results are the average of duplicate sections from 
four mice. A significant difference was detected between brain regions (p < 0.0001) but not between 
treatment (p = 0.6181). (B) COX-2 protein expression in CA1, CA3 and DG. Results are the average of 
duplicate sections from three mice. CA3, significant difference between treatments (p = 0.0017) but not 
genotypes (p = 0.3185). DG, significant difference between treatments (p = 0.0001) but not genotypes 
(p = 0.8467). Minimal COX-2 protein expression was detected in CA1. 
 
3.4.4 Effect of TIA-1 gene inactivation on the arachidonic acid pathway gene 
expression 
 Besides translational suppression, TIA-1 has been shown to participate in pre-
mRNA splicing, through interacting with 5’ splice sites and U1 snRNP 230,231. TIA-1 also 
mediates mRNA decay through polysome disassembly 259. To test whether deletion of 
TIA-1 results in alteration of COX-2 mRNA levels, real-time qPCR was performed on 
hippocampal tissue harvested from Tia1+/+ and Tia1−/− mice, 3 hours after acute PTZ-
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induced convulsions. As expected, PTZ significantly increased COX-2 (Fig. 3.10A) and 
c-Fos (Fig. 3.10B) mRNA levels in hippocampus in both genotypes, however, knockout 
animals showed a slightly higher induction of COX-2 mRNA but a slightly lower 
induction of c-Fos. Although PTZ-induced convulsion did not change the mRNA levels 
of mPGES-1 (Fig. 3.10C) or mPGES-2 (Fig. 3.10D) dramatically, a significant genotypic 
difference (p = 0.0210, two-way ANOVA) was observed for mPGES-1 where knockout 
showed slightly reduced expression. A significant treatment difference (p = 0.0268, two-
way ANOVA) was observed for mPGES-2 where PTZ-induced convulsion slightly 
decreased its mRNA levels in both genotypes. Interestingly, cPLA2α mRNA was 
significantly reduced by convulsive seizures in both genotypes (Fig. 3.10E, p = 0.0045, 
two-way ANOVA), consistent with the results that its expression is inversely correlated 
with excitatory neuronal activity (Fig. 2.13D). TIAR is an RBP that has high homology 
with and similar binding properties and functions as TIA-1 89,227. TIAR is constitutively 
expressed in the brain and its mRNA expression profile is remarkably similar to TIA-1 
287. Since COX-2 3’UTR ARE also serves as a docking site for TIAR, to test the 
possibility that TIAR may compensate for the absence of TIA-1 in neurons, TIAR mRNA 
levels were measured. Interestingly, TIAR mRNA was slightly elevated in TIA-1 
knockout hippocampus, but only after PTZ-induced convulsion (no statistical 
significance by Sidak’s multiple comparison test following two-way ANOVA), suggesting 
that TIAR may indeed be up-regulated by excessive neuronal activity. 
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Fig. 3.10. Effect of acute convulsive seizures on AA pathway mRNA levels. Tia1+/+ and 
Tia1−/− littermate mice were treated with saline or 42 mg/kg PTZ. Brains from saline- and PTZ-treated 
animals that had convulsive seizures were harvested 3 h later. Relative mRNA levels for COX-2 (A), c-
Fos (B), mPGES-1 (C), mPGES-2 (D), cPLA2α (E) and TIAR (F) in mouse hippocampal tissues were 
assessed by qRT-PCR analysis. Results are expressed as Mean ± Standard Error of the Mean relative to 
saline treated Tia1+/+ (N = 3 mice). *, p < 0.05, significant between genotype difference identified via two-
way ANOVA. #, p < 0.05, significant between treatment difference identified via two-way ANOVA. 
 
Table 3.1. Effect of acute convulsive seizures on AA pathway mRNA levels (p values) 
 
Between group differences were analyzed using two-way ANOVA and p values for between treatment 
comparison, between genotype comparison and interaction are presented in Table 3.1. 
Gene Saline vs PTZ convulsion Tia1-/- vs +/+ Interaction 
COX-2 < 0.0001 0.6974 0.0052 
c-Fos 0.0003 0.4654 0.3321 
mPGES-1 0.1866 0.0210 0.6874 
mPGES-2 0.0268 0.7432 0.9310 
cPLA2a 0.0045 0.5975 0.3732 
TIAR 0.4196 0.2420 0.0351 
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3.4.5 Effect of Tia1 gene inactivation on the innate seizure threshold 
 To test the possibility that TIA-1 influences the innate seizure threshold 
independent of regulating COX-2 expression, the PTZ-induced seizure threshold was 
assessed in mice lacking TIA-1 protein (Fig. 3.11). The results indicate that seizure 
severity and incidence of or latency to convulsions was not altered in Tia1−/− mice 
relative to Tia1+/+. These results were the same regardless of whether mice were 
treated with 42 or 54 mg/kg PTZ. Within this dose range, convulsion-induced mortality 
was low regardless of genotype. Thus, TIA-1 does not appear to influence the sensitivity 
of mice to acute PTZ-induced seizures. 
Fig. 3.11. TIA-1 does not influence the innate seizure threshold. Seizure severity is shown for 
Tia1+/+ (●) and Tia1−/− (○) littermates that were treated with PTZ i.p. (A–C) 54 mg/kg; N = 11 per 
genotype). (D–F) 42 mg/kg; N = 20 and 18 for Tia1+/+ and −/−, respectively. Symbols indicate maximum 
seizure scores for individual mice. Horizontal lines indicate median seizure score. Ratio in parentheses 
indicates incidence of convulsions. Genotype responses are not significantly different (p = 1.0, two tailed 
Fisher’s exact test). (B, E) Latency to convulsive seizures. Symbols indicate latencies for mice in A and D. 
Horizontal lines indicate mean values. No significant difference was detected between genotypes 
(p = 0.5714 and p = 0.474, for B and E respectively, two-tailed Mann Whitney test). (C, F) Mortality. No 
significant difference was detected between genotypes (p = 1.0, two-tailed Fisher’s exact test). 
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3.5 Discussion 
 In glutamatergic neurons of the cerebral cortex, activation of post-synaptic 
NMDARs triggers the release of AA from membrane stores, which is rapidly 
metabolized to biologically active prostaglandins via the COX pathway 71. The capacity 
for basal prostaglandin production by neurons is increased more than 10-fold by COX-2 
overexpression 157. The observation that these COX-2 overexpressor mice exhibited 
reduced sensitivity to a convulsive stimulus177 is consistent with an increasing body of 
evidence suggesting that this pathway may serve as a homeostatic control mechanism 
to maintain an elevated seizure threshold in the normal brain, antagonizing abnormal 
excitation and epileptiform activation of circuits 67-69,174,288. The fact that COX-2 
expression is coupled positively to NMDAR activity is consistent with this notion 74,136,141. 
A better understanding of the molecular mechanisms that link NMDAR activity to 
changes in COX-2 expression could facilitate development of novel approaches for 
antiepileptic therapies. In this regard, I investigated COX-2 expression in brain after 
acute seizure generation and whether it is regulated by the RNA binding protein TIA-1. 
TIA-1 mRNA and protein expression was found in both neuron and astrocyte. However, 
knockout of TIA-1 did not alter COX-2 protein expression under basal conditions or after 
acute PTZ-induced convulsion. In addition, TIA-1 deletion did not alter acute seizure 
threshold. 
 TIA-1 mRNA distribution in mouse tissues has been shown previously using 
Northern blot 239. The highest level of TIA-1 mRNA was observed in brain, consistent 
with our result (Fig. 3.1A). Perplexingly, TIA-1 mRNA levels were suggested to be low in 
human brain 240,260. This disparity suggests species difference in TIA-1 mRNA in the 
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brain. For example, TIA-1 mRNA was highly expressed in mouse cortex (Fig. 3.1A), but 
was surprisingly low in human cortex 260. In addition, TIA-1 mRNA appeared to be more 
restrained to certain brain areas (Fig. 3.6). Results from Allen Human Brain Atlas 289 
also suggest low to absent level of TIA-1 mRNA in cerebral cortex, in contrast to the 
enriched mRNA levels in cerebellum. Notably, hippocampi from all human donors 
showed high TIA-1 mRNA levels, matching the high mRNA and protein level we showed 
in mouse hippocampus (Fig. 3.1 and 3.2). This may suggest a conserved physiological 
role of TIA-1 in this structure. Although TIA-1-positive SGs have been previously found 
in astrocytes in mouse brains with tauopathies 266, we are the first to show endogenous 
TIA-1 mRNA and protein expression in astrocytes. TIA-1 mRNA was found in untreated 
primary astrocyte culture (Fig. 3.1B) and co-localization of TIA-1 protein and astrocyte 
marker GFAP was found in wild-type mouse brain (Fig. 3.5). Compared to neurons, 
astrocytes showed less mRNA and protein expression, along with a higher ratio of TIA-
1a over TIA-1b mRNA isoform (Fig. 3.2). TIA-1b isoform was suggested to have 
increased alternative splicing activity, as compared to the TIA-1a isoform in mammalian 
cell lines 240. However, it is not clear whether this remains true in neurons and 
astrocytes.  
 While the posttranscriptional regulation of COX-2 expression has been studied 
extensively in other cell types, the extent to which these mechanisms control expression 
of COX-2 in glutamatergic neurons is not known. TIA-1 has been shown to suppress 
basal expression of COX-2 in embryonic fibroblasts 88 as well as induction of COX-2 
expression by proinflammatory mediators in macrophages 270 and this is likely by virtue 
of its ability to bind to the COX-2 mRNA 3′UTR and repress translation. It does not 
		97	
appear, however, to perform a similar function in neurons. Despite the fact that COX-2 
and TIA-1 proteins are constitutively expressed by CA3 pyramidal neurons, basal COX-
2 protein expression was not altered in brains of mutant mice lacking TIA-1 (Fig. 3.9). 
Furthermore, in granule cells of the DG, which are largely devoid of COX-2 expression 
under basal conditions, induction of COX-2 expression by an acute convulsive seizure 
was not affected by deletion of TIA-1. Thus, TIA-1 regulates neither constitutive nor 
activity-dependent neuronal COX-2 expression. It is worth to note, however, that COX-2 
mRNA induction by acute convulsive seizure was slightly enhanced in TIA-1 knockout 
hippocampus (Fig. 3.10), raising the possibility that TIA-1 may still regulate COX-2 
mRNA turnover, independent of its translation.  
 In addition to its broad mRNA binding specificity 229, TIA-1 protein interacts 
extensively with other proteins in the brain 267. However, the lack of an effect of TIA-1 
gene deletion on PTZ-induced acute seizures (Fig. 3.11) suggests that TIA-1 does not 
function in the maintenance of the innate seizure threshold of the brain either by 
affecting COX-2 expression or by mechanisms other than via COX-2 regulation. 
Nevertheless, the prominent and widespread expression of TIA-1 in neurons, 
particularly in excitatory neurons of the cerebral cortex and the hippocampal formation, 
suggests that this protein may modulate physiological activities, either through its role 
as a pre-RNA splice regulator or silencer of mRNA translation, or via its ability to 
interact with other neuronal proteins. Although the TIA-1-deficient mice appear to 
behave normally, a more careful analysis of the role of this protein in normal brain 
function warrants further investigation. The significance of the comparative difference in 
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mRNA levels between neurons and astrocytes reported herein is not clear, particularly 
since this cell-type difference was not observed by others 290. 
 It could be argued that compensatory mechanisms in the Tia1 mutant mice may 
have masked its role in the regulation of COX-2 expression in neurons. For example, 
the COX-2 mRNA ARE also serves as a docking site for TIAR, an RBP that has high 
homology with TIA-1 89,227. TIAR is constitutively expressed in the brain and its mRNA 
expression profile is remarkably similar to TIA-1 239. It was also observed that TIAR 
mRNA was elevated only in TIA-1 knockout hippocampus after acute convulsive seizure 
(Fig. 3.10). Thus, the possibility that TIAR may compensate for the absence of TIA-1 in 
neurons cannot be excluded. However, the observation that COX-2 expression was 
enhanced in embryonic fibroblasts derived from the same TIA-1 mutant mouse line 
employed herein argues against this possibility 88. On the other hand, it is possible that 
TIA-1 indeed has no role and that another RBP regulates COX-2 expression post-
transcriptionally in neurons (see below). In this case, TIA-1 would not be expected to 
bind to the ARE of the COX-2 mRNA in neurons, a possibility that requires verification. 
This could be achieved by RNA immunoprecipitation.  
 In addition to TIA-1 and TIAR, a number of mRNA stability factors and 
translational regulators bind to this region of the COX-2 mRNA, including CELF2 
(CUGBP2), HNRNPD (AUF1), hnRNPK and the ELAVL proteins, HuR and HuD 87,89,117. 
Like TIA-1, each of these RBPs is broadly expressed throughout the brain (Allen Brain 
Atlas). Whether these or other novel RBPs bind to and regulate COX-2 expression in 
neurons has to be investigated in future. It is hoped that a better understanding of the 
molecular mechanisms that link NMDAR activity to changes in COX-2 expression could 
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identify approaches for the development of novel antiepileptic therapies that target 
enhancement of the level of COX-2 expression in neurons. 
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CHAPTER 4 Deletion of TIA-1 increases incidence of PTZ-induced kindling and 
increases risk of death during epileptogenesis 
4.1 Synopsis  
 TIA-1 has recently been implicated in several acute and chronic 
neurodegenerative conditions, including cerebral ischemia and Alzheimer’s disease. 
Because brain damage is an important risk factor for development of epilepsy, a chronic 
disorder that is characterized by spontaneous seizures, the purpose of the studies 
included in this chapter was to examine the possibility that TIA-1 functions in 
epileptogenesis, the process by which normal brain becomes prone to spontaneous 
seizures.  
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4.2 Introduction 
 Through the course of studying whether TIA-1 regulates COX-2 expression and 
in turn modulates seizure threshold in brain (Chapter 3), I did not observe any change in 
COX-2 protein level in TIA-1 deficient brain under basal levels, nor did I see an altered 
acute seizure response in TIA-1 knockout animals 177. However, it is known that TIA-1 is 
a key component of the protein complexes that assemble translationally inactive 
mRNAs under stress conditions, namely, stress granules (SGs) 251. Assembly of SGs is 
highly regulated and requires functional TIA-1 protein.  Under cellular stress, TIA-1 
shuttles from nucleus into cytoplasm 252, facilitates the recruitment of stalled preinitiation 
complexes into SGs 253, and forms aggregation with its prion-related C-terminus domain 
254. TIA-1-mediated SGs formation is considered as a dynamic and reversible process 
that coordinate mRNA triage and has been extensively studied in mammalian peripheral 
tissue and cell lines.  
 In the CNS, TIA-1 transcripts and proteins are also detected 239,260,261. A growing 
interest has developed only recently to uncover the largely unknown role of TIA-1 in 
brain. TIA-1 positive SGs appear acutely in hippocampal neurons following brain 
ischemia 93,94,262. In addition, TIA-1 has been found to associate with pathological 
lesions in several neurodegenerative diseases, including amyotrophic lateral sclerosis 
263, Huntington’s disease 265 and tauopathies 266. TIA-1 facilitated tau misfolding and 
tau-mediated neurodegeneration whereas tau, in turn, promotes SGs formation 267. 
Evidence suggests that depletion of tau ameliorated the epileptic phenotype in a model 
of Dravet Syndrome 267,291 . These findings suggest that in neurons, TIA-1-mediated 
SGs formation serves as a protective mechanism against acute stress, but may lead to 
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deposition of pathological protein aggregations in diseases associating with prolonged 
stress. On the other hand, due to its large number of mRNA targets and protein partners 
229,267, TIA-1 may serve biological functions that are independent of SGs formation in 
brain. TIA-1 deficiency led to changes in mRNA expression of cell cycle and apoptosis 
regulators, as well as fat storage and membrane trafficking factors in brain 269. TIA-1 
was also recently implicated in physiological neuronal function 261. 
 Since TIA-1 and SG have been shown to contribute to chronic pathologies, 
including taupathies, it is possible that loss of TIA-1 in brain could lead to alterations in 
neuroplasticity. Therefore, the goal of the work described in this chapter is to investigate 
the role of TIA-1 in PTZ-induced kindling model of epileptogenesis. 
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4.3 Materials and methods 
4.3.1 Animal housing and breeding  
 The housing and breeding of the TIA-1 gene mutant mouse line (Tia1−/−) has 
been described in section 3.2.1. All animal procedures conformed to the National 
Academy of Sciences Guide for the Care and Use of Laboratory Animals (NRC, 2011) 
and were approved by the Syracuse University Institutional Animal Care and Use 
Committee (IACUC). 
4.3.2 Dosing paradigms for kindling 
 Male mice of different genotypes (Tia1-/-, Tia1+/- and Tia1+/+) were randomly 
segregated without knowledge of genotype. All mice were acclimated to handling by 
performing mock daily intraperitoneally (i.p.) injections 5-7 days prior to each study. 
During kindling paradigm, mice were treated daily with PTZ (freshly diluted in 0.9% 
saline, filter sterilized and administered i.p. in a volume of 10ml per kg body weight) for 
up to 21 days. Seizure activity was monitored daily immediately after PTZ injection for 
25 minutes and graded by an observer blinded to genotype using a previously 
established scoring system 181 as described in section 3.2.3. Doses of PTZ used in 
kindling studies were determined by a dose-ranging study (data not shown) where 
Tia1+/+ mice were treated acutely with a single dose of PTZ (36-54 mg/kg). Doses were 
chosen to ensure that no convulsive seizure (score 3 or 4) activity was recorded during 
acute PTZ injection.  
 Two kindling studies (study 1 and 2) applying slightly different experimental 
settings were conducted in chronological order. In study 1, 36 mg/kg PTZ was given to 
the animals daily. Successive exposure of mice to PTZ resulted in a progressive 
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reduction in PTZ seizure threshold. Mice were considered kindled after exhibiting three 
consecutive convulsive seizures, after which daily PTZ injections were stopped. In study 
2, a slightly higher daily injection dose of PTZ (39 mg/kg) was applied in order to 
achieve an increased kindling incidence. Due to high mortality found in Tia1-/- mice 
during kindling paradigm of study 1, I also used a less stringent rule in study 2 to 
determine kindling establishment in order to minimize mortality. Specifically, mice were 
considered kindled in study 2 when three total convulsive seizures (they may not be 
consecutive) were recorded, after which PTZ injections were stopped. In both studies, 
the permanence of the kindled state was assessed by re-challenging mice with 36mg/kg 
(study 1) or 39mg/kg (study 2) PTZ one week after cessation of the PTZ injection. A 
permanent reduction of seizure threshold is confirmed by the presence of a stage 3 or 4 
convulsive seizure. Kindling latency was defined as the number of days of PTZ 
injections required to establish kindling status. For study 2, brain tissues were harvested 
72 hours after the re-challenge injection. 
4.3.3 Immunofluorescence staining 
 Immunofluorescence staining was performed as described previously in section 
3.2.4. Primary and secondary antibodies for immunostaining were goat anti-TIA-1 
(1 µg/ml, Santa Cruz Biotechnology Cat# sc-1751, RRID: AB_2201433) and Alexa Fluor 
594 donkey anti-Goat IgG (7.5 µg/ml, Jackson ImmunoResearch Labs Cat# 705-585-
147, RRID: AB_2340433). Specificity of the anti-TIA-1 antibody was confirmed using 
comparable sections from Tia1+/+and Tia1−/− mice processed in parallel.  
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4.3.4 Quantification of fluorescent intensity 
 Fluorescent intensity was quantified using NIH image J (version 1.50i) 284. Raw 
images in .czi format were exported to .jpg files and converted into 8bit grey scale. 
Maximal threshold and minimal threshold was set to 35 and 255 respectively using the 
Default auto thresholding method. For each animal, mean intensity of TIA-1 fluorescent 
within an ROI (region of interest) of 100 *100 pixel2 in dentate gyrus granule cell layer 
was measured from coronal sections obtained near Bregma -1.70. Results were 
averaged across duplicate sections. 
4.3.5 Statistical analysis 
 All statistical analyses were performed using GraphPad Prism, Version 6.0.1 
(GraphPad Software, Inc., La Jolla, CA, U.S.A.). Survival curves and curves depicting 
the percentage of mice kindled as a function of time were compared using a log-rank 
test. Unpaired Student’s t-test was used to compare latency to kindling between 
knockout and wild-type groups. Acute convulsive seizure latency during the kindling 
treatment was analyzed by two-way ANOVA followed by Bonferroni's multiple 
comparisons test. Datasets representing proportions (percentage mortality and 
percentage kindled) were analyzed using a two-tailed Fisher’s exact test. TIA-1 protein 
expression in kindled brain was analyzed by Kruskal-Wallis test. Significance was set at 
p < 0.05. In figure legends, p values were reported as their exact values whenever 
available. For all multiple comparison analysis, exact p values were not provided by 
Prism and were reported as “p < 0.05”. Exact p values that are less than 0.0001 were 
not provided by Prism and were reported as “p < 0.0001”. 
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4.4 Results 
4.4.1 Effect of TIA-1 gene inactivation on PTZ-induced kindling progression and 
acquisition 
 Kindling is frequently used to model the plasticity changes that occur during 
epileptogenesis, the process by which the normal brain becomes epileptic 292. In the 
PTZ model of kindling, daily injection of a dose initially elicits mild seizure responses 
(seizure severity scores ≤ 2) that progress to convulsive seizures (seizure severity score 
≥3) over the 2-3 weeks period of dosing, indicating a reduction in seizure threshold. This 
reduction in seizure threshold persists once established 181. This model was used to test 
the role of TIA-1 in epileptogenesis. In the present study, two kindling studies were 
conducted as described in section 4.3.2. Whereas study 2 applied a higher dose of PTZ 
and a less stringent definition of kindling establishment compared to study 1, both 
studies produced persistently kindled animals. Incidence of convulsive seizure during 
re-challenge was 93.3% and 93.8% for study 1 and 2 respectively. The time course of 
kindling acquisition (Fig. 4.1) and the latencies to acute PTZ-induced convulsive 
responses during the kindling paradigm (Fig. 4.2) in Tia1+/+ and Tia1-/- littermates are 
shown for both studies.  
 In study 1, kindling acquisition in the two genotype groups occurred over a similar 
time course (p = 0.8157, log-rank test, Fig. 4.1A). The mean latency period to kindling 
acquisition did not differ significantly between Tia1+/+ and Tia1-/- for study 1 (p = 0.3993, 
unpaired Student’s t-test; 16.4 ± 1.6 days and 14.0 ± 2.5 days, Mean ± SEM, 
respectively, Fig. 4.1B). Similarly, no change was observed between the two genotype 
groups in their average latency time to first acute convulsion following PTZ 
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administration, which was 436s for Tia1+/+ mice and 456s for Tia1-/- mice respectively 
(Fig. 4.2A). Successive daily exposures of mice to PTZ resulted in a progressive 
reduction in their latencies to convulsive seizures. At the time of the 3rd convulsive 
response, the latency to convulsion was shortened in both groups to 245 and 309s, 
respectively. 
 Although no genotypic difference was observed during kindling paradigm in study 
1, it is possible that the dose applied (36 mg/kg) is not sufficient to induce kindling within 
21 days in both genotypes. Therefore, a higher daily PTZ dose (39 mg/kg) was applied 
in study 2. As expected, the mean latency to kindling was reduced as as a result of 
higher daily PTZ dose, yet did not differ between genotypes (p = 0.2786, unpaired 
Student’s t-test; 8.3 ± 2.3 days and 11.8 ± 1.7 days for Tia1+/+ and Tia1-/-, respectively, 
Fig.4.1D). However, whereas the percentage of kindled animals in wild-type group 
plateaued at day 14 within the paradigm, knockout group exhibited a steep and steadily 
increasing kindling progression curve (p = 0.017, log-rank test) and achieved a 
significantly higher kindling incidence by the end of the protocol (p = 0.0176, fisher’s 
exact test; 69.7% and 23.5% for Tia1-/- and Tia1+/+, respectively). A similar reduction in 
latency to convulsion was observed from first to 3rd convulsive response (597 to 485s 
for Tia1+/+ and 598 to 458s for Tia1-/- mice, Fig. 4.2B).  
 Interestingly, in both studies, latencies to convulsions after kindling was 
established (Fig.4.2, “Re-challenge”) remained low for Tia1+/+ mice (280 vs 274s for 
study 1 and 2 respectively), but seemed to rebound in Tia1-/- mice (504s and 428s for 
study 1 and 2 respectively). However, this difference was not statistically different 
(Bonferroni's multiple comparisons test following two-way ANOVA). 
		108	
 
 
Fig 4.1. Analysis of TIA-1 function in PTZ-induced kindling acquisition. Tia1+/+ and Tia1-/- littermates 
were treated daily with 36 mg/kg (Study 1; A, B) or 39 mg/kg (Study 2; C, D) PTZ i.p. and seizure severity 
was scored. Mice were considered kindled after having either 3 consecutive convulsive seizures in Study 
1, or 3 total convulsive seizures in Study 2. (A) Time course of kindling acquisition for Study 1 (N=24 and 
20 for Tia1+/+ and Tia1-/- genotypes, respectively). Neither the rate nor incidence of kindling acquisition 
differed significantly between groups (p = 0.8157, log-rank test). (B) Latency to kindling acquisition for 
Study 1. Scatter plot represents latency times for individual mice. Horizontal lines indicate median values. 
No significant difference was detected between genotypes (p=0.3696, Mann Whitney test). (C) Time 
course of kindling acquisition for Study 2 (N=17 and 18 for Tia1+/+ and Tia1-/- genotypes, respectively). 
Progression of kindling acquisition differed significantly between groups (p = 0.017, log-rank test). (D) 
Latency to kindling acquisition for Study 2. No significant difference was detected between genotypes (p = 
0.2736, Mann Whitney test). 
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Fig. 4.2. Acute convulsive seizure latencies during the kindling treatment paradigm. For Study 1 (A, 
36mg/kg PTZ) and Study 2 (B, 39mg/kg PTZ), latencies between PTZ dosing and onset of convulsive 
seizures for each individual animal are shown for the 1st, 2nd and 3rd convulsive responses in the kindling 
paradigm. The latencies to convulsion is also shown for re-challenge convulsion in kindled brain. 
Horizontal lines indicate median values, error bars represent standard errors. No significant difference 
was detected between Tia1+/+ and Tia1-/- mice (p = 0.6035 and p = 0.8515 for study 1 and 2 respectively, 
two-way ANOVA). 
 
4.4.2 Role of TIA-1 in mortality associated with PTZ-induced kindling  
 Although the dose of PTZ was chosen to maximize kindling acquisition while 
minimized mortality, lethality occurred in each genotype group. Incidences of mortality 
were observed either during the PTZ dosing paradigm or after the kindling phenotype 
was established (at re-challenge injections). All mortality, regardless of genotype, 
resulted acutely from PTZ-induced convulsions. No spontaneous mortality was 
observed at any time during the kindling paradigm.  
 Incidence of mortality associated with the kindling paradigm was shown for both 
studies (Fig. 4.3). In study 1, the total mortality was 12.5, 17.8, and 26%, for Tia1+/+, 
Tia1+/-, and Tia1-/- genotypes, respectively (Fig. 4.3A). All wild-type lethality occurred 
during re-challenge. Hence, no mortality occurred in the Tia+/+ genotype group during 
the PTZ dosing paradigm (Fig.4.3B). Of the mice possessing one functional Tia1 allele 
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(Tia1+/-), ~7% succumbed during the treatment paradigm. This increased to 17% in mice 
lacking both alleles (Tia1-/-). Thus, the increased mortality during kindling acquisition 
was proportional to the number of inactivated TIA-1 alleles. Additionally, the lethality in 
these mice occurred late in the kindling paradigm (second and third weeks, Fig. 4.3B). 
In study 2, a similar total mortality was observed (11.8 and 33.3% for Tia1+/+ and Tia1-/- 
genotypes, Fig. 4.3C). In Tia1+/+, ~6% succumbed during the treatment paradigm 
whereas in Tia1-/- this ratio is 16.7% (Fig. 4.3D). In both studies, the total incidence of 
lethality in -/- mice was higher than that of their +/+ littermates, yet not significant (p = 
0.6686 and 0.2285, for study 1 and 2 respectively, two tailed Fisher’s exact test).  
 
Fig. 4.3. Mortality associated with the PTZ-induced kindling paradigm. In Study 1 (A, B), Tia1+/-, 
Tia1-/- mice and their wild-type littermates (Tia1+/+) were treated with PTZ (36 mg/kg, i.p.) to induced 
kindling and then re-challenged after kindling was established. In Study 2 (C, D), Tia1-/- and Tia1+/+ mice 
were treated with PTZ (39 mg/kg, i.p.) to induced kindling. (A, C) Each bar shows the total % mortality for 
each genotype group. No significant differences were found between Tia1-/- and Tia1+/+ genotypes (For 
Study 1 and 2, p = 0.6686 and 0.2285, respectively, two tailed Fisher’s exact test). (B, D) Each line 
shows % survival for each genotype group during kindling paradigm. For Study 1, significant difference in 
trend was observed (p = 0.0369, log-rank test).  
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4.4.3 Expression of TIA-1 in kindled brain 
 Kindling is known to induce oxidative stress in the hippocampus, resulting in 
excessive lipid peroxidation and altered anti-oxidant enzymatic activities 293,294. Since 
oxidative stress is a known inducer of SGs, I measured TIA-1 expression and TIA-1-
positive SG formation in kindled wild-type hippocampus (Fig.4.4). In kindled animals or 
animals that received PTZ injections for 3 weeks but shows no convulsion (non-
kindled), TIA-1 protein expression remained unchanged in dentate gyrus (Fig.4.4A, p = 
0.1964, Kruskal-Wallis test), compared with saline treated animals. In granule cells of 
control hippocampus, TIA-1 protein exhibited a pattern of strong nuclear expression and 
weak cytosol expression (Fig.4.4B). This pattern remained the same in kindled brain, 
with no SG detected in cytoplasm (Fig.4.4C). SG formation was not found in CA1 and 
CA3 pyramidal cells in kindled hippocampus either (Fig. 4.5).  
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Fig. 4.4. TIA-1 protein expression in DG of kindled brains. Wild-type (Tia1+/+) mice were treated with 
PTZ (39 mg/kg, i.p.) to induced kindling and then re-challenged one week after kindling was established. 
Controls were treated with saline for 3 weeks and received an additional injection of saline one week 
after. Brains of saline controls, kindled mice and non-kindled mice (animals that showed no convulsive 
seizure throughout the protocol) were harvested 72 hours after their last injection, fixed, sectioned (12 
µm) and stained with TIA-1 (red; B, C) antibody. The nucleus were outlined by DAPI (blue; B, C) staining. 
Mean intensity on a grey scale of TIA-1 staining was quantified by image J. (A) Each bar (N = 3 animals) 
shows the relative mean intensity of TIA-1 protein over saline controls. No significant differences were 
found between groups (p = 0.1964, Kruskal-Wallis test). TIA-1 staining was observed in the nucleus and 
cytoplasm of dentate gyrus granule cells in saline treated brains (B). No stress granule (visualized as TIA-
1-positive cytoplasmic aggregates) formation was observed in kindled brains (C). White scale bar 
represents 20 µm.   
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Fig. 4.5. TIA-1 protein expression in CA1 and CA3 of kindled brains. Wild-type (Tia1+/+) mice were 
treated with PTZ (39 mg/kg, i.p.) to induced kindling and then re-challenged one week after kindling was 
established. Controls were treated with saline for 3 weeks and received an additional injection of saline 
one week after. Brains of saline controls, kindled mice and non-kindled mice (animals that showed no 
convulsive seizure throughout the protocol) were harvested 72 hours after their last injection, fixed, 
sectioned (12 µm) and stained with TIA-1 (red; B, C) antibody. The nucleus were outlined by DAPI (blue; 
A-D) staining. TIA-1 staining was observed in the nucleus and cytoplasm of CA1 (A) and CA3 (C) 
pyramidal neurons in saline treated brains. No stress granule (visualized as TIA-1-positive cytoplasmic 
aggregates) formation was observed in kindled brains (B, D). White scale bar represents 20 µm.   
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4.5 Discussion 
 Little is known about TIA-1 function in brain. In the present study, we investigated 
the effect of TIA-1 deletion on epileptogenesis. Knockout of TIA-1 led to enhanced 
kindling acquisition and increased mortality during kindling paradigm. In addition, no 
neuronal TIA-1 aggregation was found in kindled brain of wild-type animals (Fig. 4.5). 
Thus, it is possible that the Tia1-/- phenotypes observed during kindling progression may 
not result from altered formation or degradation of stress granules. However, the 
assembly of SGs has never been evaluated during kindling progression. It is known that 
oxidative stressors such as arsenite is sufficient to induce SG formation in neurons261, 
whereas this type of stress has been identified in brains that had acute seizures and in 
kindled brains293,295,296. Thus, to confirm the absence of SG formation in kindling model, 
future studies are required to thoroughly investigate the presence of SG during kindling 
paradigm and at various time points after kindling is established (section 6.3.1).  
 It is also possible that SG formation should be examined in other cell types of the 
brain, rather than in the neurons. Astrocytes are important cells that support neuron 
development and functionality in many different ways297,298. They are capable of 
releasing and responding to various neurotransmitters and are able to maintain 
homeostasis of reactive oxygen species, neurotransmitters and ions in the extracellular 
space. Under pathological stress such as brain trauma, astrocytes go through a 
transformation named reactive astrogliosis, which is a defensive reaction against acute 
stress that restores CNS homeostasis and limits tissue damage299. Reactive gliosis 
marked by increased GFAP immunereactivity in astrocytes has been observed in 
epileptic patients and animal models for epileptogenesis including kindling19, suggesting 
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a functional role of astrocytes during epileptogenesis. While TIA-1 and SG formation 
have been previously examined in other cell types, their function or even presence in 
astrocytes has never been thoroughly investigated thus far. Evidence exists that brain 
microglia and astrocyte were capable of forming SG in Alzheimer brain and in P301L 
Tau transgenic mice266. In the present study, I showed TIA-1 mRNA expression in 
primary cultures of astrocytes (Fig. 3.1) and TIA-1 protein expression in hippocampal 
astrocytes (Fig. 3.5). In addition, astrocytes in the brain of Tia1-/- mice showed 
decreased level of GFAP protein expression (Yifan Gong and James Hewett, 
unpublished observations), suggesting an altered astrocyte reactivity in knockout brain. 
In future studies, it will be necessary to determine if astrocytic TIA-1 plays a role in 
epileptogenesis progression (section 6.4.3). 
 It is worth noting that TIA-1 function in epileptogenesis may be independent of its 
role in forming SGs, but may rather dependent on its direct or indirect roles as an RNA 
binding protein in alternative splicing, translational repression and message stability. 
TIA-1 recognizes a large number of mRNA transcripts via binding to AREs located 
within their 3’UTR 229, among them are COX-2 and Tumor necrosis factor alpha (TNFα).  
 TIA-1 directly binds to an ARE in the COX-2 mRNA to silence its translation 88. 
Thus, basal COX-2 protein expression and activity were elevated in embryonic 
fibroblasts from mice lacking TIA-1. In the CNS, COX-2 is constitutively expressed in 
discrete subpopulations of glutamatergic neurons 66,74. Yet we did not find elevated 
COX-2 in naïve Tia1-/- brains nor after acute convulsive seizure, suggesting TIA-1 may 
not regulate COX-2 expression in brain. However, it is known that COX-2 mRNA and 
protein expression are markedly induced in the dentate gyrus neurons by high 
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frequency stimulation of the perforant pathway or by acute convulsive seizures 66,136,181, 
and are induced in non-neuronal cell types including endothelial cells, microglia and 
astrocytes in epileptogenesis models that involve inflammation 202,300. Future studies will 
be looking at COX-2 expression in Tia1-/- neurons and astrocytes during 
epileptogenesis, in order to confirm whether TIA-1 interact with COX-2 in the CNS and 
whether such interaction, if any, contributes to acute seizure generation and 
epileptogenesis.  
 The role of TIA-1 in post-transcriptional control of TNFα expression has been well 
characterized in macrophage in the context of inflammation 241, as well as in 
cardiomyocytes 301. TIA-1 deletion promotes TNFα translation and leads to increased 
TNFα protein production. This pro-inflammatory cytokine is a putative neuromodulator 
that regulates synaptic transmission through scaling of the receptors and mediating 
glutamate release from microglia and astrocytes 302,303. Kindling induced by PTZ and 
electrical stimulation of amygdala result in increased TNFα production 304,305, whereas 
administration of TNFα leads to prolonged epileptiformic discharges in amygdala 
kindling model 306. It is possible that TIA-1 deletion lead to overexpression of TNFα in 
hippocampus, which contributes to the accelerated reduction of seizure threshold during 
kindling development. Therefore, in future studies, as an established target of TIA-1, 
TNFα production in kindled brain need to be further characterized. 
 It is intriguing that not only kindling acquisition was enhanced in mice lacking 
TIA-1, these mice showed an increase in incidence of mortality (Fig. 4.3). Typically, 
mortality is not associated with the progression of epileptogenesis in this model as 
demonstrated by wild-type mice herein. Thus, the increase in lethality in TIA-1 deficient 
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mice during this phase of epileptogenesis is unusual and an unanticipated outcome. 
The incidence of lethality was low but exhibited a gene dosage effect (study 1, Fig. 4.3A 
and B), increasing in proportion to the number of functional TIA-1 alleles from 0% in 
mice with two functional alleles to 7% and 17% with loss of one or both alleles, 
respectively. This is compelling evidence to support the notion that this effect was 
indeed due to loss of TIA-1 function. It is interesting that TIA-1 deficiency did not 
enhanced lethality associated with acute convulsive seizures in naïve mice 177 or in 
kindled mice after kindling acquisition was complete and a sustained reduction in 
seizure threshold was established (i.e., re-challenge with PTZ kindling dose). This 
indicates that TIA-1 suppresses lethality specifically during the process of 
epileptogenesis (i.e., during the process of kindling acquisition). The reason for this will 
require further investigation. 
 Together, the results described in this chapter suggest that TIA-1 functions to 
antagonize the progressive changes in neuroplasticity associated with kindling 
development. The observations suggesting that TIA-1 suppresses lethality associated 
with epileptogenesis could lead to a better understanding of the molecular mechanisms 
in unexpected death in epileptic individuals (section 6.3.2).  
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CHAPTER 5 Transcriptome analysis in kindled brain of TIA-1 knockout animals 
5.1 Synopsis  
 Since TIA-1 deletion results in enhanced kindling acquisition (Chapter 4), it is 
hypothesized that kindling progression leads to gene expression changes in 
hippocampus that may differ between TIA-1 knockout and wild-type. The work 
described in this chapter identified differentially expressed transcripts in hippocampi of 
TIA-1 knockout mice that received repeat convulsant stimuli using next generation 
sequencing approach.  
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5.2 Introduction 
 In the kindling model of epileptogenesis, repeated application of electrical 
stimulation or chemical agents (including but not limited to PTZ) leads to a reduction in 
seizure threshold and enhanced behavioral seizure responses. This is associated with a 
variety of neurobiological changes in neuroanatomy and channel electrophysiology 307. 
Importantly, the increased susceptibility to seizure can last nearly indefinitely 308,309. This 
suggests that the underlying mechanism of kindling is due to a long-lasting and 
profound perturbation of neuronal function, which could result from altered expression of 
mRNAs or proteins, as well as post-translational changes in key protein products. 
Indeed, some of the very early studies demonstrated that protein synthesis inhibitors, 
such as cycloheximide and anisomycin significantly delay kindling development 310.  
 Enhanced kindling acquisition was found in TIA-1 deleted mice (Chapter 4), 
suggesting that TIA-1 may function to antagonize the progressive neuroplastic changes 
associated with kindling development. TIA-1 is a multifunctional RBP that can influence 
alternative pre-mRNA splicing in the nucleus and control post-transcriptional regulation 
of gene expression in the cytosol 219. In the latter case, it is known primarily as a 
negative regulator of protein translation, although it has also been shown to promote 
decay RNA transcripts in certain instances 241,259. Due to the large number of targets of 
TIA-1 protein, as well as its multi-dimensional regulation of mRNA life cycle, it is 
hypothesized that deletion of TIA-1 will result in a genome wide alteration of the 
expression levels of genes. In fact, deletion of TIA-1 has a major effect on mRNAs 
encoding cell cycle and apoptosis regulator genes, as well as lipid homeostasis factor 
genes in the brain, as identified by microarray technique 269. Therefore, the work 
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described in this chapter takes advantage of the next-generation sequencing technique 
to study potential transcriptome alterations in hippocampus of mice that received 
repeated convulsant stimuli and attempts to unravel the molecular mechanism by which 
TIA-1 deletion facilitates kindling progression. 
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5.3 Materials and methods 
5.3.1 Animal housing and breeding  
 The housing and breeding of the TIA-1 gene mutant mouse line (Tia1−/−) has 
been described in section 3.2.1. A total number of 18 adult male mice were used in this 
study. 
5.3.2 Dosing paradigms 
 A modified PTZ-induced kindling model of epileptogenesis was used to examine 
genetic changes during epileptogenesis. The purpose of this study is to identify 
plasticity changes that occur during kindling progression, rather than changes in the 
expression levels of immediate early genes or metabolism genes induced by acute 
convulsive seizures. Therefore, among all animals that received daily PTZ injections, 
only those that did not have convulsive responses were used. In addition, due to the 
high incidence of lethality found in Tia1-/- mice during kindling paradigm (Chapter 4), a 
shortened (10-day) injection paradigm was applied compared to the original 21-day 
paradigm to minimize the number of convulsive seizures induced by PTZ injections. 
Thus, male Tia1+/+ and Tia1-/- littermates were randomly segregated at weaning without 
knowledge of genotype and were used between 8-12 weeks of age. All mice were 
acclimated to handling for 5-7 days prior to studies. PTZ (39mg/kg, dissolved in 0.9% 
saline) was delivered daily for 10 days, whereas six mice served as control group were 
administrated with 0.9% saline delivered daily for 10 days. Seizure activity was 
monitored for 25 minutes after PTZ administration and graded by an observer blinded to 
genotype using a previously established scoring system 181. Animals that showed any 
seizure activity of stage 3 or above were removed from the study.  
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Table 5.1. Groups of mice used in the study. 
Genotype\Treatment Tia1-/- Tia1+/+ Total 
PTZ 5 5 10 
saline 3 3 6 
Total 8 8 16 
 
5.3.3 Sample Preparation 
 Mice were deeply anesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine 
administered i.p. in saline and perfused transcardially with 0.05 M phosphate-buffered 
saline (PBS). Left and right dorsal hippocampi were dissected, combined, snap-frozen 
using a dry ice/ethanol slurry, and stored at -80 ˚C before use.  
5.3.4 RNA-Seq 
 RNA-Seq was performed in the SUNY Molecular Analysis Core (SUNYMAC) at 
Upstate Medical University. Briefly, total RNA was purified using the RNeasy kit 
(Qiagen), followed by quantification and assessment of RNA quality (Fig. 5.1A) on an 
Agilent Technologies 2100 Bioanalyzer (Agilent Technologies) using the Agilent RNA 
6000 Nano kit (Agilent Technologies). The RNA integrity number (RIN) algorithm311 was 
used to assess integrity of RNA by utilizing the ratio between the 28S and 18S rRNA. 
cDNA libraries were prepared following TruSeq® Stranded mRNA Sample Preparation 
Guide (Illumina). cDNAs quantity and integrity were assessed (Figure 1B) on an Agilent 
Technologies 2100 Bioanalyzer using the Agilent DNA 1000 Kit (Agilent Technologies) 
by looking for a peak between 200bp to 500bp. Samples were sequenced with an 
Illumina NextSeq 500 instrument using 2 x 75 bp paired end reads, with a targeted 
depth of coverage of 25 million reads per sample (NextSeq 500/550 High Output Kit v2 
(150 cycles), Cat# FC-404-2002, Illumina). 
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Fig. 5.1 Bioanalyzer electropherograms of samples. (A) Representative electropherogram pattern of 
extracted mRNA from hippocampal tissue, noting the peaks at ~1,900nt and ~ 4,000nt for 18S and 28S 
rRNA respectively. All mRNA samples have RNA integrity number (RIN) > 9 (RIN assigns an 
electropherogram a value of 1 to 10, with 10 being the least degraded). (B) Representative 
electropherogram pattern of synthesized cDNAs, noting the highest abundancy of cDNAs between 200-
400 bp, with the peak lies at ~ 260bp, indicating successful cDNA library preparation. nt, nucleotide. bp, 
base pair. FU, fluorescence units. 
 
5.3.5 Alignment, quantification and normalization of raw sequence reads 
 After obtaining the raw sequence reads (Appendix Table 3), FASTQ files were 
generated on the SUNYMAC iCompute server and initial read quality metrics generated. 
Adapter were trimmed via Partek Flow Trim Adapters v1.12 using the following adapter 
sequences: AGATCGGAAGAGCACACGTCTGAACTCCAGTCA (first mate adapter 
sequences); AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT (second mate 
adapter sequences). Alignment was performed on trimmed reads (Appendix Table 4) to 
version Mm10 of the mouse genome using the Bowtie2 algorithm within the TopHat2 
application deployed in Partek Flow. Aligned BAM file reads were subjected to QC 
analysis (Fig. 5.2) and quantification of RNA alignments was performed using the 
Partek E/M algorithm based on the May 2017 RefSeq annotation. Quantified reads 
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(Appendix Table 5) were subjected to QC analysis (Fig.5.3 and Fig.5.4). Normalization 
of reads to the length of genes and the depth of sequencing was performed using either 
the TPM (Transcripts Per Million) method (Fig. 5.5A) or FPKM (Fragments Per Kilobase 
Million) method (Fig. 5.5B) as described previously 312.  
5.3.6 Generation of correlation matrix 
 Correlation matrix was generated from normalized raw gene counts (TPM) using 
the gplot package 313 in R (version 3.3.2) 314. Samples were clustered via a complete 
linkage method with Euclidean distance measure. 
5.3.7 PCA analysis 
 PCA analysis was performed using TPM values on a subset of genes first. 
Genes that show a TPM value < 1,350 in >= 50% of the tissue samples (8 out of 16 
mice) were filtered out from the analysis. In total, 4,965 out of 24,543 genes remained in 
the dataset after the filtering step. Further analysis was performed online via 
MetaboAnalyst 315. TPM values were uploaded in comma separated values (.csv) 
format, with 16 samples in rows and 4,965 genes in columns. No data filtering was 
performed. Data were normalized row-wise by the sum, followed by a generalized log 
transformation. The PCA analysis is performed using the prcomp R package. The 
calculation is based on singular value decomposition. The gene expression data were 
summarized into PCs, which were weighted average of the original variables (genes). 
PCA analysis was then performed on the entire dataset (24,543 genes) using the 
FactoMine R package. 
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Fig. 5.2 Post-Alignment QA/QC. Left, green bars represent the average read depth (average number of 
reads representing a given nucleotide in the reconstructed sequence) for each sample. Average 
alignment per read is 1 for all samples (data not shown). Right, hollowed dots connected by the black line 
represent the percentage of the genome covered by aligned reads. Genotype and treatment of each 
animals is labeled as horizontal text in the center of each bar. 
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Fig. 5.3 Post-Quantification Analysis. Top left, box-whisker plot displays expression signal distribution 
for each sample. Top right, histogram of genes of different expression levels for each sample. Bottom, bar 
chart on distribution of raw read counts in each sample. Note that a high frequency of genes has raw 
gene counts that are between 100-10,000.  
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Fig.5.4 Coverage of reads. Coverage breakdown bar chart summarizes the mapping of raw reads to 
transcription based on the annotation file provided. The distribution of aligned reads within exons, introns, 
intergenic regions was noted. Genotype and treatment of each animals is labeled as horizontal text in the 
center of each bar. 
 
Fig. 5.5 Post-Normalization Analysis. (A) Box-whisker plot displays expression signal distribution after 
TPM normalization for each sample. Error bar represent standard deviation of TPM values. (B) Bar plot 
displays mean and standard deviation of FPKM values of each sample. 
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5.4 Results 
5.4.1 Samples show overall similarity in their gene expression profiles 
 By day 10 of the paradigm, two Tia1-/- mice were removed from the study after 
showing stage 4 convulsive seizures, whereas the remaining 16 mice (Table 5.1) were 
used in tissue preparation, with 12 mice received daily PTZ injection and 6 mice 
received daily saline injection. A high correlation in general was observed between 
samples (Fig. 5.6). Although all samples show an overall similarity in their gene 
expression profiles, three knockout animals that received PTZ showed lower correlation 
when compared with the rest of the animals. 
 
Fig. 5.6 Sample correlation on TPM of 24,543 genes. A heat map of the average Pearson correlation 
coefficients of normalized raw gene counts (TPM) of 24,543 genes from 16 samples. The legend on the 
top left depicts the correlation color scale from low (blue) to high (red). Samples are categorized into two 
groups (WT or KO, black or gray bars on the left side of the matrix table). The two axes of the 
dendrogram represents the distance or dissimilarity between clusters and the samples and clusters.  
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5.4.2 Choroid plexus genes account for major variation between samples 
 Principal component analysis (PCA) is an unsupervised statistical approach to 
reduce the dimensions of a data set. PCA uses linear combinations of the original data 
to define a new set of variables called principal components (PCs). These PCs are 
orthogonal to each other, thus each contributing to the total variation independently. 
Here, PCA was used to find the directions that best explain the between-sample-
variance in normalized raw gene counts (TPM). PCA analysis was performed on filtered 
TPM values (Materials and methods). The variances explained by each PC was 
depicted in the scree plot (Fig. 5.7). PC1 alone was responsible for 64.9% of the total 
variation while PC1 and 2 together accounted for 74.4% of the total variance. The score 
plot (Fig. 5.8) displays the PCA score of each sample with respect to the first two PCs. 
The same three knockout animals that received PTZ (TB3, TC3 and TA2) were 
clustered on PC1 axis.  
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Fig. 5.7 Variance explained by each PC in PCA of top 5000 highly expressed genes. The scree plot 
visualizes which principal components (PCs) account for which fraction of total variance in the data. The 
PCs are listed by decreasing order of contribution to the total variance. The green line on top shows the 
cumulative variance explained; the blue line underneath shows the variance explained by each individual 
PC. 
 
  
Fig. 5.8 Scores plot of PC1 and 2 in PCA of top 5000 highly expressed genes. Two principal 
components (PCs) responsible for 74.4% of the total variance of the original 4,965 variables (The 
explained variances are shown in brackets), PC1 alone accounts for 64.9% of the total variance. Shading 
eclipse represent the 95% confidence interval showing the estimated population mean.  
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 The loadings plot shows the relationship between original variables (genes) and 
subspace dimensions (PCs). It allows the identification of genes that are most strongly 
correlated or anti-correlated with the selected PCs. The contributions of each gene to 
the first two PCs are shown in Fig. 5.9. While most genes had almost zero weight in 
PC1 loading, a few genes showed a significant contribution towards PC1. Surprisingly, 
all of these genes (Ttr, Kcnj13, F5, Clic6, 1500015O10Rik, Sulf1, Prlr, Enpp2, Ace, Kl, 
Igf2, Igfbp2, Vat1l, Col9a3) are highly expressed in mouse choroid plexus (ChP), 
according to Allen Brain Atlas (© 2004, Allen Institute for Brain Science. Allen Mouse 
Brain Atlas. Available from: http://mouse.brain-map.org/). Among them, Ttr gene, which 
encodes transthyretin, a transport protein for thyroxine and retinol, has long been 
considered as a unique marker for ChP 316.  
Fig. 5.9 Loadings plot of PC1 and 2 in PCA of top 5000 highly expressed genes. Loading plot 
reveals the contribution of each feature in creating the first two principal axes.  
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 Similar results were obtained when the analysis was performed on the entire 
dataset (24,543 genes). Principal Component Analysis was used to compare the 
normalized raw gene counts (TPM) profiles across all samples (i.e. samples were 
plotted as variables). PC1 alone consist of 95.74% of total between-sample variation 
whereas PC2 and PC3 account for 3.32% and 0.64%, respectively. Whereas all 
samples have strong positive loadings on PC1, the same three animals (TB3, TC3 and 
TA2, circled in Fig. 5.10A) showed strong positive loadings on PC2, which, was 
contributed almost exclusively by two ChP genes, Ttr and Enpp2 (Fig. 5.10B). 
Fig. 5.10 Variable and individual factor map of PC1 and 2 in PCA of 24,543 genes. (A) Principal 
Component Analysis variables factor map. The direction of the arrows represents the relative loadings of 
all 16 samples on the first (Dim1) and second (Dim2) dimension. All samples had strong positive loadings 
on dimension 1; Red circle, three KO-PTZ samples (TB3, TC3 and TA2) had significant positive loadings 
on dimension 2. (B) Individual factor map. Ttr and Enpp2 had strong positive loadings on the second 
(Dim2) dimension. 
  ChP is a small cauliflower-like tissue located inside the ventricles that produces 
cerebral spinal fluid (CSF) and maintains blood-brain homeostasis. ChP is presented in 
lateral ventricle, which is anatomically adjacent to hippocampus, and both ChP and 
hippocampus can be closely associated with meninges. This raises the possibility that 
contamination from ChP tissues occurred during tissue preparation and thus may be a 
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confounding factor in the RNA-seq analysis. Indeed, a previous study has suggested 
that detection of ChP genes in other brain structures is contributed by ChP 
contamination during dissections317. 
 To account for variances in gene expression profiles between samples caused 
by differentially expressed ChP tissues, a factor analysis via PCA was performed using 
StatView (Version 5.0.1, SAS Institute Inc.). A total number of 15 genes that are 
specifically expressed in either ChP or in three different CNS cell types (i.e. neuron, 
astrocyte and oligodendrocyte) were selected. The panel of ChP specific genes (Table 
5.2) was selected based on mouse expression profile data from a previous study 318 and 
further verification via Allen Brain Atlas. Panels of genes (Table 5.2) that are specifically 
expressed in oligodendrocytes, neurons or astrocytes were selected based on mouse 
expression profile data from another study 319. Factor analysis via PCA was performed 
on normalized raw gene counts (FPKM) of these 15 genes in all 16 samples. Results 
(Table 5.3) indicated that the first four PCs accounted for ~90% of the total variance 
whereas PC1 alone accounted for 67% of the total variance. Specifically, all 6 ChP 
specific genes had large positive contributions to PC1 (Table 5.4) as expected, whereas 
all 3 oligodendrocytic genes had mild positive contributions to PC1 as well. Interestingly, 
all 3 neuronal genes had negative contributions to PC1, further supporting the notion 
that the variance captured by PC1 were indeed due to increased proportion of ChP 
versus neuronal tissues. 
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Table 5.2 Cell/Tissue specific marker genes used for PCA 
 
Gene Category Gene symbol 
ChP genes 
Ttr 
Otx2 
Emb 
Col8a1 
Arsg 
Kcnj13 
Oligodendrocytic genes 
Mag 
Myrf 
Tmem125 
Neuronal genes 
Calb1 
Camkv 
Nefl 
Astrocytic genes 
Aqp4 
Slc1a3 
Slc25a18 
 
 
Table 5.3 Variances explained by PCs 
 
  Eigenvalue (nonzero) 
Proportion 
(%) 
Cumulative 
(%) 
PC1 42.88 66.99 66.99 
PC2 9.63 15.05 82.04 
PC3 2.83 4.42 86.47 
PC4 2.03 3.17 89.64 
PC5 1.58 2.48 92.11 
PC6 1.28 1.99 94.11 
PC7 0.93 1.46 95.57 
PC8 0.82 1.28 96.85 
PC9 0.51 0.80 97.65 
PC10 0.41 0.64 98.29 
PC11 0.34 0.52 98.81 
PC12 0.30 0.46 99.27 
PC13 0.22 0.35 99.62 
PC14 0.14 0.22 99.84 
PC15 0.10 0.16 100.00 
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Table 5.4 Loadings of individual genes to PC 1-4 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.5 Unrotated factor scores of individual samples 
 
Sample ID Genotype Treatment PC1 PC2 PC3 PC4 
TA5_S1 WT Saline 0.101 -0.067 -0.660 -0.230 
TB2_S2 WT Saline 1.303 0.501 0.615 -1.909 
TB5_S3 WT Saline 0.494 -0.164 -0.306 0.131 
TA1_S11 KO Saline 0.194 -1.123 -1.307 0.431 
TD3_S9 KO Saline 1.246 3.007 -0.950 0.705 
TD4_S10 KO Saline -0.480 -0.351 -1.940 -1.040 
TC1_S4 WT PTZ 0.499 -0.425 0.293 -1.281 
TC2_S5 WT PTZ 0.674 -0.634 0.644 -0.378 
TE5_S6 WT PTZ -0.557 0.144 0.032 1.553 
TF1_S7 WT PTZ 0.427 -0.408 0.078 -0.390 
TF4_S8 WT PTZ 0.974 -0.158 2.369 1.057 
TE2_S15 KO PTZ 0.213 -1.278 -0.229 1.280 
TE3_S16 KO PTZ -0.059 -0.489 -0.529 1.123 
TA2_S12 KO PTZ -1.044 -0.061 0.843 -0.398 
TB3_S13 KO PTZ -2.023 1.243 0.472 0.300 
TC3_S14 KO PTZ -1.962 0.264 0.574 -0.953 
 
  
Gene Category Gene symbol PC1	 PC2	 PC3	 PC4	
ChP genes 
Ttr 0.937	 -0.264	 -0.19	 0.103	
Otx2 0.941	 -0.225	 -0.124	 0.193	
Emb 0.939	 -0.225	 0.014	 0.083	
Col8a1 0.939	 -0.255	 -0.189	 0.098	
Arsg 0.951	 0.014	 -0.218	 0.084	
Kcnj13 0.935	 -0.252	 -0.204	 0.125	
Oligodendrocytic genes 
Mag 0.714	 0.623	 0.108	 0.039	
Myrf 0.654	 0.573	 0.089	 0.018	
Tmem125 0.439	 0.567	 -0.231	 -0.482	
Neuronal genes 
Calb1 -0.57	 -0.501	 -0.136	 0.364	
Camkv -0.345	 0.469	 -0.631	 0.43	
Nefl -0.376	 0.44	 -0.225	 0.703	
Astrocytic genes 
Aqp4 0.131	 -0.241	 0.79	 0.376	
Slc1a3 -0.566	 -0.059	 -0.44	 -0.107	
Slc25a18 0.168	 0.613	 0.542	 0.226	
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 Next, the unrotated factor scores (Table 5.5) for PC1 of each sample were used 
to normalize raw gene counts (FPKM) for 19,762 genes. Consistent with the correlation 
matrix (Fig. 5.6), the same three animals (KO-PTZ) showed large negative factor scores 
for PC1, indicating their biased ChP genes expression level. These factor scores were 
fed to the batch effect removal algorithm in Partek Genomic Suite (Partek Inc., St. 
Louis, Missouri) as covariates, which calculates the variation attributed to these factor 
scores and adjusts the original FPKM values to remove the variation. 
 To validate whether the batch effect removal process (referred to as “the 
correction” from here on) successfully adjusted the biased expression of ChP genes, a 
correlation matrix was generated from normalized raw gene counts (FPKM) before and 
after the correction. Before the correction, three KO PTZ animals presented a low 
correlation score when compared with the rest of all samples (Fig. 5.11A). The 
correction increased the overall correlation scores between these samples (Fig. 5.11B). 
In addition, samples from wild-type and knockout animals showed a clearer clustering 
according to their genotypes (vertical bars with grey and black shading in Fig. 5.11A 
and B).  
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Fig. 5.11 Sample correlation on FPKM of 19,762 genes before and after correction of ChP bias. A 
heat map of the average Pearson correlation coefficients of normalized raw gene counts (FPKM) of 
19,762 genes from 16 samples computed before (A) and after (B) the batch effect removal correction. 
The legend on the top left depicts the correlation color scale from low (blue) to high (red). Samples are 
categorized into two groups (WT or KO, black or gray bars on the left side of the matrix table). The two 
axes of the dendrogram represents the distance or dissimilarity between clusters and the samples and 
clusters. 
 
 To further confirm that the correction indeed adjusted the biased expression of all 
ChP genes without introducing new bias in reference gene expression, I then computed 
the correlation scores between the PC1 unrotated factor score (Table 5.5) and the 
original (before correction) FPKM values of each gene. I filtered the result list with 1) a 
list of ChP genes; 2) a list of neuronal specific genes and 3) a list of reference genes. 
The list of genes that are highly expressed in ChP of young (two-month-old) CD1 mice 
was obtained from a previous study 320. Briefly, for each microarray Probe Set ID, an 
average expression value (log2-transformed expression levels) was calculated between 
the 3 young CD1 mice. Probe Set IDs were then sorted from high to low based on the 
average expression value. For each gene, only the Probe ID with the highest 
expression level was kept. A list of the top 34 highly expressed genes (column 1, Table 
5.6) in ChP was generated. A list of 35 neuronal specific genes and a list of 100 
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reference genes (column 2 and 3, Table 5.6) were obtained from the Harmonizome 
database321. The ChP specific genes all seemed to have strong negative correlation 
scores with unrotated factor scores of PC1 (Table 5.7), whereas the majority of 
neuronal specific genes had positive correlation scores. This is consistent with the 
pattern observed in the loadings of the 6 ChP specific genes and 3 neuronal genes 
(Table 5.4) where the two groups had an opposite contribution towards PC1. On the 
other hand, both positive and negative correlations scores were observed in reference 
genes. Many reference genes that showed a high negative correlation score are indeed 
genes that are also highly expressed in ChP (Table 5.8). The FPKM values of both CP 
specific genes and reference genes that are highly expressed in ChP were normalized 
after the correction (Fig. 5.12). Finally, to confirm that the correction did not alter the 
within or between group variation across the entire transcriptome, I calculated the mean 
within and between group coefficient of variation (CV) values averaged across all 
genes. The correction process did not alter either within or between group CV across all 
genes significantly (Table 5.9a). In contrast, the CV values of ChP specific gene, such 
as Ttr (Table 5.9b), were significantly improved (tightened) by the correction process. 
On the other hand, between-sample variation of genes that showed a small within or 
between group CV before the correction process remained unchanged (Table 5.9c). In 
sum, the correction process successfully improved the between-sample variation 
caused by biased expression of ChP genes.  
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Table 5.6 List of ChP, neuronal and reference genes 
 
ChP Neuron Reference 
Ttr Afp F5 B2m Ckm 
Rpl41 Apoe Ace Aldh1b1 Vdr 
Enpp2 App Slc22a8 Ccl3 Crybb2 
Pebp1 Arrb1 Aldh2 Tk1 Tpo 
Rps27 Atp1a3 Wfdc2 App Lcn2 
Gm1821 Bdnf Nqo1 Tnfsf11 Gsk3a 
Rpl36 Caly Clu Cckar Mapt 
Hnrnpab Casp3 Ctdspl Rbp4 Adarb1 
Hbb-b1 Clvs1 Emp3 Tnfsf13b Mpo 
Clu Clvs2 Pon1 Pparg Adipoq 
Rps29 Eno2 Gstt1 Thbd Il6 
Rplp2 Fez1 Plxnb1 Cst3 Slpi 
Chchd10 Gfap Cryab Tnnt2 Eno1b 
Rpl38 Grin1 Rpl41 Gstm1 Pik3ca 
Cox7a2 Gsk3b Rpl13a Adora3 Dsg3 
Kxd1 Itsn1 Brca2 Epo Ipo8 
Rps28 Lims1 Erbb2 Slc22a4 P2ry12 
Ptgds Muc1 Gpt Ubb Ptpn22 
Ndufa13 Ngb Igf1r Nup153 Egfr 
Atp6ap2 Ntrk2 Scn5a Afm S100a2 
Sod1 Plch2 Mfap5 Pum1 Tfrc 
Rpl31 Prkca Eno1 Gapdh Shbg 
Cox6a1 Ptprs Brca1 Tshb Nat1 
Rpl35 Rbfox3 Gstp1 Igfbp3 L1cam 
Cox6c Reep1 Cd14 Asxl1 Atxn10 
Cox5b Rest Mlh1 Amh Fmr1 
Ndufb11 Rit2 Itgb3 Pgf Rb1 
Vdac1 S100b Rplp0 Tnf Igf1 
Rpl26 Shc3 Cntf Fanci Kras 
Atp5e Srpk1 Drd4 Rpl4 Htr1a 
Igf2 St8sia5 Park7 Actb  
Rps21 Syp Afp Ercc1  
Ndufb7 Taf1 Spp1 Ifrd1  
Uqcrh Ube3a Tnfrsf11b Gsk3b  
 Vldlr  Snrpa1  
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Table 5.7 Correlation of ChP, neuronal and reference genes with unrotated factor scores 
 
ChP Neuron Reference 
Ttr -0.94 Afp -0.41 F5 -0.95 B2m -0.35 Ckm 0.02 
Rpl41 -0.73 Apoe -0.70 Ace -0.94 Aldh1b1 -0.34 Vdr 0.05 
Enpp2 -0.94 App -0.31 Slc22a8 -0.94 Ccl3 -0.34 Crybb2 0.05 
Pebp1 -0.67 Arrb1 0.15 Aldh2 -0.93 Tk1 -0.32 Tpo 0.07 
Rps27 -0.59 Atp1a3 0.03 Wfdc2 -0.92 App -0.31 Lcn2 0.08 
Gm1821 -0.47 Bdnf 0.72 Nqo1 -0.88 Tnfsf11 -0.29 Gsk3a 0.09 
Rpl36 -0.63 Caly 0.21 Clu -0.87 Cckar -0.27 Mapt 0.11 
Hnrnpab -0.46 Casp3 -0.28 Ctdspl -0.84 Rbp4 -0.25 Adarb1 0.13 
Hbb-b1 0.11 Clvs1 0.78 Emp3 -0.84 Tnfsf13b -0.24 Mpo 0.14 
Clu -0.87 Clvs2 0.59 Pon1 -0.83 Pparg -0.23 Adipoq 0.18 
Rps29 -0.47 Eno2 0.33 Gstt1 -0.81 Thbd -0.22 Il6 0.20 
Rplp2 -0.40 Fez1 0.56 Plxnb1 -0.75 Cst3 -0.21 Slpi 0.21 
Chchd10 -0.92 Gfap -0.17 Cryab -0.74 Tnnt2 -0.19 Eno1b 0.24 
Rpl38 -0.24 Grin1 0.12 Rpl41 -0.73 Gstm1 -0.19 Pik3ca 0.25 
Cox7a2 -0.61 Gsk3b 0.01 Rpl13a -0.73 Adora3 -0.18 Dsg3 0.28 
Kxd1 -0.54 Itsn1 0.09 Brca2 -0.73 Epo -0.18 Ipo8 0.29 
Rps28 -0.26 Lims1 0.00 Erbb2 -0.73 Slc22a4 -0.18 P2ry12 0.30 
Ptgds -0.67 Muc1 0.07 Gpt -0.71 Ubb -0.18 Ptpn22 0.31 
Ndufa13 -0.70 Ngb -0.54 Igf1r -0.69 Nup153 -0.15 Egfr 0.32 
Atp6ap2 -0.73 Ntrk2 -0.73 Scn5a -0.67 Afm -0.13 S100a2 0.33 
Sod1 -0.56 Plch2 0.40 Mfap5 -0.67 Pum1 -0.13 Tfrc 0.37 
Rpl31 -0.20 Prkca 0.58 Eno1 -0.64 Gapdh -0.13 Shbg 0.38 
Cox6a1 -0.64 Ptprs -0.01 Brca1 -0.61 Tshb -0.12 Nat1 0.40 
Rpl35 -0.30 Rbfox3 0.24 Gstp1 -0.60 Igfbp3 -0.12 L1cam 0.47 
Cox6c -0.34 Reep1 0.33 Cd14 -0.57 Asxl1 -0.11 Atxn10 0.49 
Cox5b -0.49 Rest -0.60 Mlh1 -0.53 Amh -0.10 Fmr1 0.60 
Ndufb11 -0.79 Rit2 0.11 Itgb3 -0.52 Pgf -0.08 Rb1 0.60 
Vdac1 -0.26 S100b 0.18 Rplp0 -0.49 Tnf -0.08 Igf1 0.61 
Rpl26 -0.29 Shc3 0.06 Cntf -0.48 Fanci -0.03 Kras 0.66 
Atp5e -0.82 Srpk1 0.31 Drd4 -0.48 Rpl4 -0.03 Htr1a 0.71 
Igf2 -0.95 St8sia5 0.36 Park7 -0.45 Actb 0.00   
Rps21 -0.59 Syp 0.48 Afp -0.41 Ercc1 0.00   
Ndufb7 -0.55 Taf1 0.69 Spp1 -0.41 Ifrd1 0.01   
Uqcrh -0.66 Ube3a -0.18 Tnfrsf11b -0.37 Gsk3b 0.01   
    Vldlr -0.82     Snrpa1 0.02     
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Table 5.8 Reference genes that are highly expressed in ChP 
 
Gene 
Symbol Correlation 
F5 -0.947 
Ace -0.944 
Aldh2 -0.931 
Wfdc2 -0.923 
Clu -0.866 
Cryab -0.738 
Rpl13a -0.732 
Eno1 -0.644 
Gstp1 -0.602 
Rplp0 -0.488 
Park7 -0.445 
B2m -0.351 
App -0.311 
Cst3 -0.212 
 
Fig. 5.12 Normalized gene counts (FPKM) before and after batch effect removal. The FPKM values 
of a choroid plexus specific gene, Ttr (A) and a reference gene that is highly expressed in choroid plexus, 
Ace (B) before (blue bars) and after (orange bars) batch effect removal correction. 
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Table 5.9a Mean within and between group CV 
 
Mean	
Within	Group	CV	
Between	Group	CV	
WT	Saline	 KO	Saline	 WT	PTZ	 KO	PTZ	
Before	Normalization	 0.24	 0.30	 0.31	 0.33	 0.26	
After	Normalization	 0.23	 0.31	 0.31	 0.41	 0.26	
 
Table 5.9b Ttr within and between group CV 
 
 
Ttr	
Within	Group	CV	
Between	Group	CV	
WT	Saline	 KO	Saline	 WT	PTZ	 KO	PTZ	
Before	Normalization	 1.40	 1.66	 1.54	 0.87	 1.00	
After	Normalization	 0.47	 1.13	 0.24	 0.59	 0.20	
 
Table 5.9c Tia1 within and between group CV 
 
 
Tia1	
Within	Group	CV	
Between	Group	CV	
WT	Saline	 KO	Saline	 WT	PTZ	 KO	PTZ	
Before	Normalization	 0.03	 0.07	 0.02	 0.08	 0.18	
After	Normalization	 0.07	 0.04	 0.04	 0.06	 0.20	
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5.4.3 Differential gene expression in TIA-1 knockout brain 
 After batch effect removal correction, genes that showed a normalized raw count 
(FPKM) < 0.05 in >= 50% of the tissue samples (8 out of 16 mice) were further filtered 
out from the analysis. In total, 16,066 out of 19,762 genes remained in the dataset after 
this filtering step. Further analysis was performed online via MetaboAnalyst 315. FPKM 
values were uploaded in comma separated values (.csv) format, with 16 samples in 
rows and 16,066 genes in columns. Data were then normalized row-wise by the sum, 
followed by a generalized log transformation and auto scaling (mean-centered and 
divided by the standard deviation of each variable).  
 Differential gene expression was analyzed via one-way Analysis of Variance 
(ANOVA) followed by Fisher's least significant difference method (Fisher's LSD). 
Multiple testing correction is applied using the Benjamini-Hochberg False Discovery 
Rate (FDR) algorithm. Seventy-four genes (Fig. 5.13) were identified to be differentially 
expressed (FDR < 0.1) among the four experimental groups. Among them, 11 genes 
(Table 5.10) had a FDR < 0.05. Hierarchical clustering was performed on all 16 samples 
across all genes (Fig. 5.14) or across the 74 genes with FDR < 0.1 (Fig. 5.15) identified 
via ANOVA with the hclust function in package stat. Similarities between samples was 
measured via Euclidean distance measure. Samples were clustered using Ward’s 
linkage clustering algorithm. In wild-type animals, PTZ treatment did not seem to induce 
dramatic alteration in gene expression profiles as the heat map patterns between the 
two treatment groups (WT-Saline and WT-PTZ) remained largely unchanged (Fig. 
5.15). However, PTZ treatment induced a shift of gene expression profiles in knockout 
animals (KO-PTZ compared to KO-Saline). This is supported by the clustering of 
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samples in the heat map computed across all genes (Fig. 5.14), where KO-Saline and 
KO-PTZ samples tended to cluster into different groups but WT-Saline and WT-PTZ 
samples were intermingled with each other. Lastly, genotype, rather than PTZ 
treatment, contributed more significantly to the differential expression of genes as 
visualized by Venn diagram (Fig. 5.16). This stays true before and after the adjustment 
of the biased expression of ChP genes (Fig. 5.16 Left vs Right). Although the 
adjustment greatly increased the number of differentially expressed genes between KO 
and WT or between PTZ and Saline groups, it did not alter the number of genes that are 
differentially expressed between WT-Saline and WT-PTZ, which is 0 before adjustment 
and 1 after adjustment, suggesting that the adjustment process did not introduce new 
bias in WT gene expression profiles. Interesting, among the differential expressed 
genes identified via two-way ANOVA between knockout and wild-type groups, 339/413 
genes were down-regulated, indicating a global reduction of mRNA levels in knockout 
tissues. 
		145	
 
Fig. 5.13 Important features selected by ANOVA plot with FDR threshold 0.1. Important features 
identified by ANOVA analysis. Each dot on the 2-D plane represents an individual gene. Y-axis 
represents the –log10 transformation of the ANOVA p value. Red dots represent genes with an adjusted 
p value (FDR) < 0.1.  
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Table 5.10 Important features identified by One-way ANOVA with FDR threshold 0.05 
 
Gene 
Symbol Entrez Gene Name FDR Major Gene Ontology 
Vamp2 vesicle associated membrane protein 2 0.01 calmodulin binding, syntaxin binding 
Aak1 AP2 associated kinase 1 0.01 
transferase activity, transferring 
phosphorus-containing groups and 
protein tyrosine kinase activity 
Tia1 TIA1 cytotoxic granule associated RNA binding protein 0.01 
nucleic acid binding and nucleotide 
binding 
Asprv1 Aspartic Peptidase Retroviral Like 1 0.03 aspartic-type endopeptidase activity 
Napb NSF Attachment Protein Beta 0.03 syntaxin binding, soluble NSF attachment protein activity 
Ldb3 LIM Domain Binding 3 0.03 cytoskeletal protein binding, muscle alpha-actinin binding 
Ift20 intraflagellar transport 20 0.03 opsin binding 
Ppp1r1a Protein Phosphatase 1 Regulatory Inhibitor Subunit 1A 0.03 
protein phosphatase inhibitor activity, 
protein serine/threonine phosphatase 
inhibitor activity 
Smpd5 Sphingomyelin Phosphodiesterase 5 0.03 NA 
Magi1 
membrane associated guanylate 
kinase, WW and PDZ domain 
containing 1 
0.05 protein C-terminus binding and alpha-actinin binding 
Bri3bp BRI3 binding protein 0.05 mitochondrial outer membrane 
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Fig. 5.14 Clustering result for 16,066 genes shown as heat map. Top, the vertical axis of the 
dendrogram represents the distance or dissimilarity between clusters. The horizontal axis represents the 
samples and clusters. Left, the horizontal axis of the dendrogram represents the genes and clusters, the 
vertical axis represents the distance or dissimilarity between clusters. Heat map grids of different colors 
represent the expression level (normalized raw gene counts) of each feature from low (blue) to high (red). 
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Fig. 5.15 Clustering result for 74 genes shown as heat map. Top, the vertical axis of the dendrogram 
represents the distance or dissimilarity between clusters. The horizontal axis represents the samples and 
clusters. Left, the horizontal axis of the dendrogram represents the genes and clusters, the vertical axis 
represents the distance or dissimilarity between clusters. Heat map grids of different colors represent the 
expression level (normalized raw gene counts) of each feature from low (blue) to high (red). 
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Fig. 5.16 Venn diagram of differentially expressed genes. Overlapping of differentially expressed 
genes between PTZ and Saline or between knockout and wild-type groups are shown. Left, before ChP 
gene expression adjustment; Right, after ChP gene expression adjustment. Gene lists were derived from 
two-way ANOVA performed on the corrected FPKM values across 19,762 genes with the cutoff in FDR 
set as 0.1. 
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A 
B 
 
Fig. 5.17 TIA-1 mRNA levels in all samples. (A) Top, the red line indicates the part of the chromosome 
that is currently depicted on the canvas. Middle, alignments of reads to genome are shown as stacked 
histograms. The y-axis shows number of base calls per position. Reads are colored by sample. Bottom, 
structure of TIA-1 transcripts variants are shown. Exons are plotted as boxes and introns as lines 
connecting them. Untranslated regions (UTRs) are seen as narrow boxes. The arrows on the lines 
indicate directionality. Black arrow points to exon 4 of Tia1 gene. (B) Enlarged view of absent peak in TIA-
1 knockout sequences.  
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 A closer examination of the top 11 genes with smallest FDR values in one-way 
ANOVA revealed that 2 out of 11 genes (Vamp2 and Napb) are synaptic vesicle 
associated genes. Both genes were increased in knockout groups, indicating altered 
synaptic plasticity after TIA-1 deletion. In addition, 2 out of 11 gene products (Ldb3 and 
Magi1) are able to bind alpha-actin proteins, which is an isoform of actin found primarily 
in muscle tissues. This suggests a potential alteration in brain blood vessel physiology. 
Interestingly, TIA-1 mRNA itself was elevated in the knockout animals regardless of 
their treatment paradigm (Fig. 5.17). This might be a feedback regulation occurred in 
response to knockout of this important gene product. Importantly, although TIA-1 mRNA 
was increased in knockout animals, it has been shown previously that these animals 
lack TIA-1 protein expression 241. Moreover, the increased TIA-1 mRNA reads in 
knockout animals lacks a peak within its coding region comparing to wild type animals 
(Fig. 5.17A and B). The missing sequence was confirmed to represent exon 4 (Fig. 
5.17B) via BLAST. This is in consistent with the previously reported targeted gene 
knockout schema where parts of intron 3 and exon 4 are replaced by a neomycin 
resistance gene cassette 241. 
5.4.4 Pathway analysis of differentially expressed genes 
 Gene network analysis was performed to test for over-representation in different 
Gene Ontology (GO) categories using Ingenuity Pathway Analysis (IPA) software 
(QIAGEN). A two-way ANOVA analysis was performed in Partek Genomic Suite to 
generates a list of between-genotype (KO vs WT) p-values for each gene in the list of 
19,762 genes. A threshold of p < 0.02 was set to keep a list of 1,851 genes with the 
lowest p-values. The IPA software then performed an enrichment detection algorithms 
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to obtain sets of gene networks which showed over-representation in the differentially 
expressed genes. The top canonical pathways (Fig. 5.19) and the number of their 
shared genes (Fig. 5.20) are shown. Among these pathways are EIF2 signaling and 
regulation of eIF4 and p70S6K signaling pathways, both are comprised of numerous 
ribosomal proteins and translation initiation factors. TIA-1 function has been largely 
linked to its interaction with translation initiation complex, and eIF-2α has been shown to 
be both necessary and sufficient for TIA-1-mediated assembly of stress granules 253,254. 
The presence of translation initiation complex components in the dataset further support 
the specificity of the observed genetic alterations in TIA-1 knockout brain. Higher-level 
analyses of upstream regulatory networks and molecular and cellular functional 
pathways were also performed via IPA (Table 5.11 and Fig. 5.20). Pathways of protein 
and RNA metabolism including RNA post-transcriptional modification, protein synthesis, 
protein degradation, post-transcriptional modification, and gene expression were among 
the top of the list. 
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Fig. 5.18 Top 10 canonical pathways altered in KO. Yellow dots indicate the ratio of genes in the 
dataset over genes in the pathway. Blue bars indicate the negative logarithm transformation of the fisher’s 
exact test p-values. Only pathways with –log(p-value) > 3.15 are shown.  
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Fig. 5.19 Overlapping of the top 10 canonical pathways altered in KO. Red boxes indicate the top 10 
significant pathways. Numbers indicate the number of shared genes between two pathways connected by 
blue lines. 
 
Table. 5.11 Top 20 upstream regulators 
 
Upstream Regulator Molecule Type p-value of overlap 
RICTOR other 8.44E-12 
ST1926 chemical drug 8.46E-10 
MYCN transcription regulator 2.66E-09 
L-dopa chemical - endogenous mammalian 4.33E-08 
CD 437 chemical drug 8.04E-08 
sirolimus chemical drug 0.00000193 
KLF3 transcription regulator 0.00000459 
5-fluorouracil chemical drug 0.00000645 
HNF4A transcription regulator 0.0000191 
GnRH analog biologic drug 0.0000342 
CDK2AP1 other 0.0000869 
IL3 cytokine 0.0000933 
1,2-dithiol-3-thione chemical reagent 0.0000936 
TCR complex 0.000119 
RRP1B transcription regulator 0.000165 
ZFHX3 transcription regulator 0.000206 
HRAS enzyme 0.000321 
ciprofloxacin chemical drug 0.00036 
beta-1,3-glucan chemical drug 0.000417 
lanthanum chloride chemical reagent 0.000493 
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Fig. 5.20 Top molecular and cellular functional pathways altered in KO. Blue bars indicate the 
negative logarithm transformation of the fisher’s exact test p-values. Only pathways with –log(p-value) > 
1.3 are shown.  
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 Similar gene network analysis was performed on the gene list generated from t-
test between the KO-PTZ and WT-PTZ groups. A threshold of p < 0.02 was set to keep 
the top 906 genes with the lowest p-values. The top canonical pathways (Fig. 5.21) are 
shown. Among these pathways are synaptic long term potentiation and calcium 
signaling pathways, both are comprised of numerous protein phosphatase subunit 
genes. 
Fig. 5.21 Top canonical pathways altered in KO PTZ. Blue bars indicate the negative logarithm 
transformation of the fisher’s exact test p-values. Yellow dots indicate the ratio of genes in the dataset 
over genes in the pathway. Only pathways with –log(p-value) > 2.72 are shown. 
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5.5 Discussion 
 To date, several attempts have been made to investigate the transcriptome 
profile alterations in kindling using global expression profiling techniques, mainly via 
microarray. However, among the thousands of genes that have been identified to be 
differentially expressed in all studies, only a small proportion (~3%) showed changes in 
more than two publications 322. This could be due to the variation in kindling models 
(electrical or chemical), stimulation of distinct brain sub-regions (hippocampus or 
amygdala) or different treatment paradigm and animal species (mouse or rat). Most 
importantly, significant variations exist in microarray studies even under the same 
experimental conditions. Compared to the microarray technique, RNA-Seq data 
generated from Illumina sequencing platform has been shown to be highly reproducible, 
with relatively little technical variation 323. Therefore, in the present study I chose to use 
next-generation sequencing technique to study transcriptome alteration. 
 RNA-seq analysis detected a significant upregulation of Tia1 mRNA levels in 
knockout animals, regardless of their treatment group (Fig. 5.17). This observation is in 
good agreement with a previous study 269 where TIA-1 mRNA was found increased in 
spinal cord and cerebellum of TIA-1 knockout brain. In this study, TIA-1 oligonucleotides 
covering exons 9–11 detected significant upregulation of expression, whereas 
oligonucleotide corresponding to sequences at exon 4 was found to be absent from the 
knockout samples, consistent with my finding that the peak corresponding to exon 4 of 
TIA-1 mRNA is missing (Fig. 5.17). These results together are consistent with the 
original report describing the generation of TIA-1 knockout mice stating that the 
homologous recombination to delete exon 4 of TIA-1 mRNA resulting in shortened 
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stable mRNA and absent TIA-1 protein 241. In other words, the mouse line is a protein 
but not RNA knockout mutant. In addition, the increased expression of TIA-1 mRNA in 
knockout transcriptome suggests that the mutant TIA-1 mRNAs escape from 
surveillance mechanism in the cells (discussed in section 6.3.3).  
 TIA-1 is a key component in stress granule assembly. As a consequence, one 
might expect that an alteration of expression levels of other SG components after the 
loss of TIA-1 in the hippocampus. In cells undergoing different types of stresses, α-
subunit of eukaryotic translation initiation factor 2 (eIF2α) was phosphorylated at serine 
51 by various type of stress-activated kinases 237. Phosphorylation of eIF2α blocks 
translation initiation by preventing formation of eIF2-GTP-Met-tRNAi ternary complex 
and the further assembly of 43S pre-initiation complex. Instead of the ternary complex, 
TIA-1 and other RNA binding proteins interact with mRNA in the 43S complex, resulting 
in the formation of a non-canonical 48S complex that is translationally suppressed. 
Meanwhile, self-oligomerization of TIA1 or other RNA binding proteins then promotes 
the aggregation of these 48S complexes into stress granules. In the present study, eIF2 
signaling pathway was significantly altered between wild-type and knockout 
hippocampus. It is worth noting that the majority of these genes, including many 
translation initiation factors and small ribosomal subunit genes, are slightly reduced in 
their mRNA levels. It is possible that without TIA-1, a global translation disinhibition 
occurs which then triggers a feedback regulation mechanism to down-regulate genes 
that are associated with translational initiation. Moreover, although preliminary results 
fail to detect stress granule formation in kindled brains (Fig.4.4 and 4.5), it would be 
necessary to confirm whether stress granules are indeed formed in the process of 
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kindling. However, it is worth mentioning that stress granule may be assembled without 
eIF2α phosphorylation. For example, pharmacological inhibition of eIF4A inhibited 
translation initiation and initiate stress granule assembly independently of eIF2α 
phosphorylation324.  
 Other than altered expression in mRNA levels of genes from eIF2 pathway, there 
was no obvious dysregulation for any other known SG components. Possible 
explanations for this are: 1) the loss of TIA-1 might be compensated by expression 
changes in other genes. Upregulation of related genes, such as the RBP TIAR, may 
occur as a direct consequence of the loss of TIA-1 protein function (section 6.3.3); 2) 
knockout of Tia1 may have resulted in changes on the localization of SG components 
without influencing their expression levels; or 3) Tia1 deletion might only have an effect 
on SG gene expression levels under acute stress, which was absent from the current 
kindling model used in the study. Thus, I was unable to detect TIA-1-positive SG in 
hippocampus of brains that undergone convulsive seizure activities (Chapter 3) or of 
kindled brain (Chapter 4), suggesting kindling may not induce prolonged aggregation of 
TIA-1 protein and other SG components (discussed in section 6.3.1). 
 Another important finding of the present study is that the vast majority of altered 
transcripts are identified by the comparison between knockout group and wild-type 
group, rather than by the comparison between saline and PTZ treated groups (Fig. 
5.16). It is possible that the shortened 10-day PTZ injection paradigm is not sufficient 
enough to induce transcriptome-wide alteration in the brains, especially considering that 
we removed animals that had any convulsive seizures during the paradigm. Therefore, 
knockout animals may already possess alterations in gene expression levels under 
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basal condition. These alterations may have occurred during development and 
contribute to the regulation of neuroplasticity under pathological conditions such as 
epileptogenesis. Indeed, many of the altered transcripts that were identified in knockout 
brains (Table 5.10) are important regulators of physiological and pathological brain 
functions (discussed in section 6.3.3). For example, genes that regulate synaptic 
neurotransmission such as Vamp2, Napb and Aak1 (described in detail in section 6.3.3) 
were identified in the transcriptome analysis, implying a dysfunction in neurotransmitter 
releasing and recycling. Alteration in mRNA expression levels of genes that regulate 
cytoskeleton dynamics such as Ldb3 and Magi1 is consistent with previous findings that 
TIA-1 proteins can function as long-term regulators of the β-actin mRNA metabolism in 
mouse and human cells250. This result suggests the role of TIA-1 in synaptic plasticity 
and/or axonal cytoskeleton rearrangement. Indeed, disruption of axonal cytoskeleton-
dependent processes has been identified in many neurodegenerative diseases and 
affects axonal transport, outgrowth, targeting and synapse functioning325. 
 In conclusion, my data showed that loss of TIA-1 in mice led to altered 
expression levels of mRNA processing machinery, of specific eIF2 pathway 
components, and of various regulators of physiological and pathological brain functions. 
These findings may be relevant to elucidate the downstream regulators of TIA-1 in 
regulating epileptogenesis and in aberrant RNA processing mediated via TIA-1 in motor 
neuron diseases and neurodegenerative diseases. 
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CHAPTER 6 Discussion 
6.1 Main findings 
 In the present study, COX-2 mRNA was found to be highly expressed in cerebral 
cortex (Chapter 2) in vivo and in cultured cortical neurons in vitro. In addition, 
expression of COX-2 mRNA in cortical neurons correlated with neuronal activity and 
with NMDAR expression. NMDAR activity was found to be required for maintaining 
constitutive COX-2 mRNA levels, as well as for maintaining COX-2 mRNA stability. It is 
hypothesized that activity-dependent expression of COX-2 in neurons is regulated by 
RNA binding proteins. In particular, it is posited that loss of TIA-1, an RNA binding 
protein that suppresses COX-2 mRNA translation by binding to its 3’UTR, will lead to 
enhancement of COX-2 expression in neurons. 
 However, through the course of studying whether TIA-1 regulates COX-2 
expression and in turn modulates seizure threshold in the brain (Chapter 3), I did not 
observe a changed COX-2 protein level in TIA-1 deficient brain under basal conditions, 
suggesting that TIA-1 does not contribute to regulation of COX-2 protein expression in 
neurons. The acute PTZ-induced seizure threshold was also unchanged in mice lacking 
TIA-1 protein, indicating that this RNA binding protein does not influence the innate 
seizure threshold. However, I discovered novel roles of TIA-1 in brain plasticity during 
epileptogenesis (Chapter 4). Mutant mice lacking TIA-1 exhibited significantly higher 
kindling incidence relative to their wild-type littermates (+/+). Moreover, a higher 
mortality rate was associated with convulsions during kindling acquisition in -/- mice 
relative to +/+. Interestingly, whereas a lower kindling dose of PTZ yielded similar 
kindling incidences, enhanced mortality was still detected in mutant vs. wild-type mice. 
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Together, these results suggest that TIA-1 functions to antagonize the progressive 
changes in neuroplasticity associated with kindling development. 
 Finally, transcriptome alteration in TIA-1 knockout brains after a 10-day PTZ 
injection paradigm was analyzed (Chapter 5). After correction for biased expression of 
ChP genes, I found that the majority of differentially expressed genes between all 
experimental groups were between knockout vs wild-type genotypes, rather than 
between PTZ vs saline treatment. Moreover, transcripts from eIF2 signaling pathway 
are among the most significantly altered pathways in knockout transcriptome. 
6.2 Mechanisms that regulate neuronal COX-2 expression 
 This section is devoted to discussing the question as to how COX-2 expression 
in neurons may be regulated, specifically via NMDAR activity.  
6.2.1 Evoked and spontaneous release of glutamate in neurons 
 The amino acid, glutamic acid, is the primary excitatory neurotransmitter of the 
CNS. It is vital to the transmission and processing of information, and consequently, to 
key functions of the CNS, including cognitive processes, sensory perception, affective 
behaviors, and motor control.326-328 Glutamate is stored in synaptic vesicles. Some of 
these vesicles are found in active zones located in the axon termini of glutamatergic 
neurons. Active zones are specialized structures where activity-dependent exocytosis of 
vesicles occurs. These zones are juxtaposed with dendritic protrusions, or spines, on 
the target neuron.329 Spines are dynamic structures that harbor postsynaptic densities 
(PSDs),330,331 the electron dense signaling scaffolds where glutamate receptors are 
concentrated across from the active zones. Together, the axon termini and dendritic 
spines form the excitatory synapse between the presynaptic and the postsynaptic 
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neurons, respectively. Activity-dependent release of glutamate triggered by action 
potentials in the presynaptic neuron activates ionotropic glutamate receptors in the PSD 
of the postsynaptic neuron. Key among these is the NMDAR subtype.332 This receptor is 
a heteromeric complex composed primarily of GluN1 (NR1) and GluN2 (NR2), which 
form a ligand- and voltage-gated ion channel.333 NMDAR activation allows Na+ and Ca2+ 
entry into the cell down their concentration gradients.334 This contributes to synaptic 
transmission by producing an excitatory postsynaptic potential (EPSP) which makes the 
postsynaptic neuron more likely to fire an action potential. Thus, the influx of the ions 
that causes EPSP is called an excitatory postsynaptic current (EPSC). The increase in 
intracellular Ca2+ can also drive persistent changes in the physiology of the 
synapse.335,336  
 Although action potential-driven evoked neurotransmitter release as described 
above has been extensively studied, the release of neurotransmitters from presynaptic 
cells can be spontaneous and does not require action potential in presynaptic neurons, 
a mechanism that is poorly understood functionally and mechanistically. This so called 
spontaneous neurotransmitter release typically occurs with a low probability when a 
single vesicle is released into the synapse, generating miniature EPSPs (mEPSPs). The 
quantal nature of synaptic transmission was revealed first by Bernard Katz at 
the neuromuscular junction in 1951337.  
6.2.2 Functional roles of spontaneous glutamate release 
 Whether this extremely low-frequency communication between neurons carries 
information or merely represents “noise” has been debated since its discovery. Recent 
studies have provided substantial evidence that these spontaneously release events 
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can indeed modulate or even drive action potential firing in neurons, similar to their 
evoked counterpart. In rat cerebellar stellate cells, individual quanta strongly influences 
firing338. Specifically, an excitatory quantum increases the peak firing rate of these 
neurons, and the sizes of quanta are positively correlated with their ability to rapidly 
trigger an action potential. Similarly, in hippocampus, a prolonged activation of nicotinic 
acetylcholine receptors at presynaptic mossy fibers caused a burst of high-frequency 
and large-amplitude glutamatergic mEPSCs in postsynaptic pyramidal cells339. These 
large amplitude mEPSCs are consistent with the synchronized release of glutamate 
from the mossy fiber terminals and are sufficient to drive the postsynaptic pyramidal cell 
above its firing threshold. These results support the hypothesis that spontaneous 
neurotransmission can actually contribute to electrical signaling in neuronal networks. In 
addition, an increasing number of studies have also revealed that spontaneous release 
events trigger biochemical signaling leading to development of synaptic network and 
local protein synthesis in dendrites, thus regulating synaptic plasticity. For instance, in 
CA1 pyramidal cells, blocking both spontaneous and evoked glutamate release led to 
loss of dendritic spines, an effect that was not seen when blocking evoked glutamate 
release alone340. Moreover, AMPA receptor activation by spontaneous vesicular 
glutamate release is sufficient to maintain dendritic spines. Interestingly, blocking 
evoked neurotransmitter release in mice did not impair normal brain development 341. 
However, deletion of Munc18-1 protein in mice, resulting in complete loss of 
neurotransmitter secretion including spontaneous release of synaptic vesicles341, led to 
wide spread neurodegeneration after assembly of synaptic network, suggesting that the 
		165	
maintenance of synaptic connectivity requires spontaneous secretion of 
neurotransmitters.  
 Spontaneous neurotransmission not only contributes to both the firing of action 
potentials and the formation of synaptic network, but also activates different 
downstream signaling pathways compared to evoked neurotransmission. In cultured 
hippocampal neurons, prolonged blocking of all neurotransmission diminished protein 
synthesis in dendrites, whereas blocking of only the spontaneous neurotransmission 
enhances protein synthesis342. This suppression of miniature synaptic events on local 
protein synthesis in neurons is rapid and can occur in both dendritic and somatic 
compartments, revealing its role in the acute regulation of local dendritic protein 
synthesis in neurons. Furthermore, it has also been shown that spontaneous 
neurotransmitter release, rather than evoked release, specifically suppressed dendritic 
protein translation by phosphorylating and inactivating a critical catalytic factor for 
ribosomal translocation, eukaryotic elongation factor-2 (eEF2), during protein 
synthesis343. 
6.2.3 Regulation of COX-2 expression by spontaneous glutamate release via 
NMDAR activity, a hypothesis 
 The Results described above raise the question as to whether signaling by 
mEPSCs mechanistically differs from that triggered by evoked release of glutamate. 
Studies have shown that differential regulation of synaptic plasticity by evoked or 
spontaneous neurotransmission may be mediated by differential glutamate receptor 
activation. It has been shown that spontaneous neurotransmission activated a distinct 
pool of NMDARs and/or AMPAR with unique physiological functions compared with 
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receptors activated via evoked neurotransmission344,345. For example, application of 
NMDAR antagonist MK-801 at rest led to rapid reduction of NMDAR-mediated 
mEPSCs, which did not significantly hinder receptor activation in response to 
subsequent evoked release, suggesting that evoked and spontaneous release of 
glutamate activate largely non-overlapping populations of NMDAR345. Another example 
is that brief blockade of NMDAR-mediated miniature synaptic events induced a protein 
synthesis-dependent synaptic insertion of AMPARs that lack the GluR2 subunit344.  
 In summary, spontaneous glutamate release regulates local gene expression in 
postsynaptic dendrites, possibly via targeting a distinct group of NMDARs. Linking back 
to my findings in Chapter 2 that tetanus toxin blocked neither constitutive nor activity-
induced COX-2 mRNA levels and that NMDAR activity was both sufficient and required 
in regulating COX-2 mRNA levels, it is entirely possible that spontaneous synaptic 
activity regulates basal and activity-induced neuronal COX-2 mRNA expression via 
activating NMDAR. Whether this regulation is on the transcriptional level (mRNA) only 
or on the post-transcriptional level (protein) is not known as COX-2 protein expression 
was not measured herein. However, based on known distribution profile of COX-2 
mRNA and protein, it is reasonable to hypothesize that spontaneous synaptic activity 
regulates both. Under basal condition in glutamatergic neurons, COX-2 protein was 
primarily detected in cell soma and dendrites compared to synapses346. In other studies, 
COX-2 protein has been shown to be co-localized with postsynaptic markers but not 
presynaptic markers, suggesting the presence of COX-2 protein in postsynaptic 
dendritic spines74,347. Interestingly, it has been shown that mPGES-1 and mPGES-2 
were co-localized with the same postsynaptic marker346, suggesting that these 
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sequential biosynthetic enzymes are present in the same subcellular compartment and 
together regulate PGE2 production in a tight and efficient manner. An unanswered 
question is the discrepancy between COX-2 mRNA and protein subcellular distribution. 
COX-2 mRNA expression levels are substantially elevated by convulsive stimuli in 
hippocampus348. However, the induced COX-2 mRNA is confined to the cell bodies. 
Among the same cell population, it has been shown that COX-2 protein was induced by 
convulsive stimuli in the dendritic molecular layer of DG66. These results suggest that 
activity-induced COX-2 protein is most likely translated in cell bodies and that dendritic 
COX-2 protein may be products of selective transportation. Although this remains to be 
shown, it is highly possible since dendritic COX-2 protein was detected near 
endomembranes in dendritic spines346.  
6.3 The role of TIA-1 in regulating epileptogenesis 
 As discussed above, neuronal COX-2 expression may be subjected to NMDAR 
activity-dependent regulation via spontaneous release of glutamate. This regulation 
could be at the transcriptional level, or on post-transcriptional level via mediating local 
protein synthesis or more likely, selective transportation of COX-2 protein to dendrites. 
What may be the downstream regulators of NMDAR activity-dependent COX-2 protein 
expression remains a question.  
 RBPs are regulatory proteins that are involved in pre-mRNA processing, 
transport, stability and translation (section 1.3). In fact, it has been shown that many 
RBPs are direct mediators of gene expression in response to NMDAR activity (section 
6.4.5), raising the hypothesis that the expression of COX-2, among other genes, are 
subjected to the regulation of RBPs under the control of NMDAR. One of the RBP that 
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was examined in the present study is TIA-1. Although TIA-1 does not seem to regulate 
neuronal COX-2 protein expression (Chapter 3), I discovered its novel role in 
epileptogenesis. 
 In the past, evidence has suggested that under pathological condition such as 
epileptogenesis, RBPs may contribute positively or negatively towards disease 
progression. Such examples include the Hu/Elavl family of RBPs. Acute change of Hu 
family proteins and their targets has been found using different seizure models. Brain 
HuR/Elavl1 and HuD/Elav4 levels were found increased 24 hours after pilocarpine-
induced status epilepticus, most prominently in hippocampus 349. HuD mRNA levels 
increased dramatically in hippocampus 24 hours after kainic acid injection, coupled with 
an increased mRNA level of GAP-43, an important protein in synaptic remodeling 350. 
This increased GAP-43 level was blocked in HuD knockout brain. Interestingly, 
HuB/Elavl2, on the contrary showed a decreased protein level in hippocampus acutely 
after kainic acid induced seizure, along with a decreased GAP-43 mRNA350. These 
results suggest a regulatory role of Hu protein on GAP-43 mRNA levels after convulsive 
challenge. In hippocampus, hundreds of putative ligands of HuR have been identified 
with some showing differential expression acutely after PTZ-induced seizures 351. 
Among transcripts that show differential expression levels in DG of mice with 
spontaneous seizures induced by unilateral kainic acid injection, there was a significant 
overlapping of known targets of HuR and HuD352. Interestingly, many transcripts 
showed enhanced expression or altered polyadenylation profile, correlating with the role 
of HuD in stabilizing mRNAs and regulating their polyadenylation. Moreover, altered 
responses to convulsive stimuli has been noted in knockout animals of Hu genes. 
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Conditional knockout of HuR in hippocampal neurons showed diminished kainic acid-
induced seizure responses but exacerbated neurodegeneration after glutamatergic 
excitation353. Lack of HuC/Elavl3 gene led to spontaneous epileptic seizure activity 
represented by bilaterally synchronous sharp cortical spike discharges measured in 
electroencephalographic recording 354. HuD knockout mice showed increased 
susceptibility to auditory-induced seizures 355. In summary, the Hu RBP family plays an 
important role in seizure generation, probably through regulating immediate early genes 
or genes that control synaptic plasticity and thus seizure threshold. 
 Although evidence exists that RBP such as Hu/Elavl family regulates seizure 
threshold, deletion of TIA-1 does not seem to alter acute seizure generation (Chapter 
3). Rather, TIA-1 deletion leads to increased risk of kindling acquisition. The following 
sections discuss the possible mechanisms through which deletion of TIA-1, an 
important stress granule protein and essential RNA binding protein, may lead to altered 
progression of epilepsy. 
6.3.1 The roles of stress granule in seizure generation and epileptogenesis 
 TIA-1 is best known for its role under conditions of cellular stress, during which it 
facilitates formation of stress granules (SGs). SGs are large complexes of proteins and 
translationally silent mRNAs that reprogram translation under cellular stress conditions 
254. SGs are thought to be an adaptive response to pathological conditions where cells 
may be subjected to oxidative or endoplasmic reticulum stress 356. TIA-1 plays a 
prominent role in stress granule formation in mammalian cell lines 237,254. TIA-1 and 
stress granule formation are associated with a number of stress conditions in neurons 
as well. This includes conditions of acute oxidative and endoplasmic reticulum stress 
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356,357 as well as in neurodegenerative models, where stress granule formation 
progresses with the severity of the disease and contributes to neurodegeneration 94,266. 
In the CNS, TIA-1 mediates the stress responses associated with brain 
ischemia, tauopathies, and other neurological disease models 94,262,266,267.  
 It is known that oxidative stressors such as arsenite induce SGs in cultured 
hippocampal neurons 358. In the meantime, oxidative stress, measured by increased 
lipid peroxidation and altered activity of anti-oxidant enzymes such as superoxide 
dismutase (SOD), has been found after acute seizures and in kindled brains 293-296. 
Thus, it becomes an important question that whether oxidative stress and stress 
granules contribute to the progression kindling. To date, the assembly of SGs in the 
development of kindling has not yet been elucidated. In the present study, we failed to 
detect TIA-1-positive SG in hippocampus of brains that undergone convulsive seizure 
activities (Chapter 3) or of kindled brain (Chapter 4), suggesting kindling does not 
induce prolonged aggregation of TIA-1 protein. However, it would be necessary to 
examine SG formation using other SG markers, on a more carefully design time frame 
after acute seizure, to confirm whether seizure activity is sufficient to induce SGs. It 
should also be noted that neither PTZ-induced acute seizures nor kindling are 
associated with a frank neuroinflammatory response or overt neurodegeneration 181. It is 
possible, however, that TIA-1 and SGs contribute to other models of temporal lobe 
epileptogenesis, such as that induced by status epilepticus, which do involve a 
prominent neuroinflammatory response and hippocampal sclerosis. 
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6.3.2 Mechanism of TIA-1 deletion-mediated enhanced mortality during kindling 
 In the present study, a higher mortality rate was associated with convulsions 
during kindling acquisition in -/- mice relative to +/+. Whether any TIA-1 binding target 
are relevant to the role of TIA-1 in suppression of lethality during kindling acquisition will 
be the focus of future research. Alternatively, TIA-1 has an extensive proteome, binding 
to many proteins in the normal brain 267. It is possible that protein-protein interactions 
may be significant. Tau, a microtubule assembly and stabilizing factor 359, interacts with 
TIA-1 and influences its binding to a subset of proteins in the TIA-1 proteome 267. 
Interestingly, tau has been implicated in the hyperexcitability and lethality associated 
epileptogenesis in mice lacking Kcna1 360. Thus, deletion of tau in these mice 
attenuates both phenotypes. This raises the possibility that TIA-1 may function to 
suppress tau function in kindling-associated lethality. Additionally, it will be important to 
identify the location of action of TIA-1. If it is in the brain, in what structure (i.e., 
brainstem).   
 Regardless of the molecular and cellular mechanism, the role of TIA-1 in 
suppression of lethality during epileptogenesis suggests a heretofore unrecognized 
molecular influence in Sudden Unexpected Death in Epilepsy (SUDEP). This phenotype 
resembles the Kcna1 mutation mouse model of epilepsy and SUDEP 360. Lethality in 
this model begins early in the third week of life and progresses through early adulthood. 
This appears to corresponded to the period of epileptogenesis, as spontaneous 
seizures develop. It is relevant to mention that all lethality during kindling acquisition in 
TIA-1 deficient mice occurred during tonic-clonic seizure events, suggesting that 
convulsive seizures were the trigger. In wild-type animals during kindling paradigm, 
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tonic hind limb extensions were also observed but are rarely followed by death, 
suggesting that increased mortality may not due to an enhanced seizure activity in 
knockouts, but rather due to altered downstream pathway induced by spreading seizure 
activity. Cardiac abnormalities including tachycardia and bradycardia are often induced 
in seizures. Meanwhile, intrinsic heart abnormalities such as QT prolongation and heart 
rate variability, in turn, were proposed to contribute to SUDEP361. Tia1-/- animals are 
initially reported with a high macrophagocytic TNFα expression and a higher lethality 
rate upon LPS-induced endotoxin shock 241. Since both LPS and TNFα have been 
shown to induce cardiodepression 362, it is possible that lack of TIA-1 in heart leads to 
cardiac dysfunctions which contribute to lethality in both endotoxin shock and our 
kindling model. Indeed, TIA-1 deletion in heart has been associated with altered 
contractile performance of cardiomyocytes 301, although in this particular case TIA-1 
deletion resulted in better recovery from ischemia. 
6.3.3 Possible downstream effectors of TIA-1 deletion-mediated phenotypes in 
kindling 
 To identify possible downstream regulators of TIA-1 deletion-mediated 
phenotypes in kindling progression, kindling-induced transcriptome alterations in -/- and 
+/+ hippocampi were examined by RNA sequencing analysis. Results confirmed that 
exon 4 of TIA-1 coding sequences is missing in the knockout transcriptome. However, 
full length TIA-1 mRNA was detected in knockout, with an increase in TIA-1 mRNA 
levels. The existence of TIA-1 mRNAs in knockout transcriptome suggests they are not 
subjected to surveillance mechanisms such as nonsense-mediated decay (NMD, 
described later in section 6.4.5.4). NMD gets rid of aberrant mRNAs that have acquired 
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premature translation termination codons (PTCs) 363. PTCs are likely generated by 
faulty or alternative splicing. However, preliminary results using quantitative 
visualization of RNA sequencing read alignments (data not shown) showed that despite 
the lacking of exon 4, TIA-1 mRNAs in knockout remain their normal splicing patterns, 
suggesting that they may not harbor PTCs and thus are not subjected to NMD. In 
addition, it is known that not all PTCs trigger NMD 363. Nevertheless, the mechanism 
through which mutant TIA-1 mRNAs escape surveillance mechanisms is not fully 
understood. On the other hand, increased TIA-1 mRNA levels in knockout transcriptome 
could be explained by genetic compensation in response to gene knockout. 
Upregulation of related genes following a gene knockout may be a direct consequence 
of the loss of protein function. In fact, evidence exist that TIA-1 and TIAR are able to 
utilize feedback regulation to adjust the expression levels or their own. It has been 
shown that overexpression of TIA-1 and TIAR induces splicing of TIA-1 mRNA using 
novel alternative splicing sites, possibly resulting in frame shift or nonsense-mediated 
decay of TIA-1 mRNA 238. In addition, TIAR depletion results in increased ratio of TIA-
1b/a, while TIA-1b is believed to encode the active form of TIA-1 that has enhanced 
splicing stimulatory activity 240. Whether these up-regulated TIA-1 mRNAs have 
biological consequences remains elusive. Studies on other genes reveals that mutated 
mRNAs that evade surveillance can possess biological functions. In the case of β-globin 
gene, nonsense mutations occurred within its last exon do not activate NMD and yield a 
stable mRNA that directs the synthesis of C-terminally truncated polypeptides. These 
aberrant translation products act in a dominant negative fashion, resulting in a rare form 
of symptomatic heterozygous β-thalassemia (a blood disorder that reduces the 
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production of hemoglobin)364. To date, however, it is not known that whether TIA-1 
mRNA, rather than protein, is participating in any biological event.   
 In addition to altered expression levels of TIA-1 mRNA itself in knockout 
transcriptome, a global reduction of mRNA levels was seen in knockouts. Specifically, 
among all differentially expressed transcripts between knockout and wild-type groups, 
the majority of these transcripts are found to be reduced in knockout transcriptome. This 
phenomenon is likely due to the role of TIA-1 and SG in stabilizing associated mRNA 
targets. During cellular stress, protein synthesis is severely reduced and bulk mRNA is 
recruited to SGs. Depletion of proteins that are stably associated with SGs during its 
assembly enhances the degradation of target mRNAs365. This finding indicates that the 
stabilization of mRNAs during cellular stress is facilitated by the formation of stable 
mRNPs, which may be impaired in TIA-1 knockout brain. If this is true, however, the 
involvement of SG in acute seizure generation and epileptogenesis needs to be 
thoroughly investigated to identify when and where SGs are formed and how they may 
contribute to mRNA stability under these pathological conditions. 
 Notably, a vast majority of altered transcripts in knockout hippocampus are 
identified by the comparison between knockout group and wild-type group only. This 
finding suggests that knockout animals possess alterations in gene expression levels 
that are already occurred under basal condition. Many of these genes have been found 
in brains and are important regulators of physiological and pathological brain functions. 
For example, AP2 Associated Kinase 1 (Aak1) gene encodes a member of the Prk/Ark 
family of serine/threonine kinases, which plays an essential role during receptor-
mediated endocytosis. The formation of coated vesicles is an essential step for 
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receptor-mediated endocytosis. Two oligomeric protein complexes, clathrin and the 
adaptor protein 2 (AP2) complex, constitute the major coat proteins of these endocytic 
vesicles. AP2 complexes are recruited to plasma membrane and interact directly with 
motifs on the cytoplasmic domains of receptors366. Further assembly of clathrin into this 
complex then initiates the invagination of plasma membrane and facilitates vesicle 
formation 367. In non-neuronal cells, AAK1 has been shown to directly bind to clathrin 
and AP2 complex and specifically phosphorylates the μ subunit of the AP2 complex in 
vitro368. The phosphorylation results in suppressed internalization membrane proteins. It 
is intriguing that in hippocampal neurons, AAK1 was found to be enriched at presynaptic 
terminals368, suggesting that AAK1 may play a regulatory role in recycling of synaptic 
vesicles after neurotransmission. In addition, AAK1 contributes to dendrite growth 
regulation in hippocampal neurons by limiting the branching and length of dendrites369. 
In the present study, a decrease in AAK1 mRNA (~1.2 fold) was seen in TIA-1 knockout 
hippocampus compared to wild-type. In the meantime, other regulators of synaptic 
neurotransmission were also identified in the transcriptome analysis including Vamp2 
and Napb (both are slightly but significantly increased in knockout brains), implying a 
dysfunction in neurotransmitter recycling and releasing.  
6.4 Limitations and future directions 
6.4.1 To investigate how neuronal activity regulates cPLA2α mRNA levels 
 Throughout the course of examining neuronal activity-mediated regulation of 
COX-2 expression, it is intriguing to identify a correlation between decreased neuronal 
activity and increased mRNA levels of cPLA2α. Specifically, antagonism of NMDAR 
activity resulted in increased mRNA levels of cPLA2α in PNCs (Chapter 2), whereas 
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cPLA2α mRNA expression levels decreased significantly in hippocampus 3 hours after 
convulsive stimuli (Chapter 3). Phospholipase A2 enzymes encompass a superfamily 
that hydrolyze the sn-2 fatty acyl bonds of phospholipids to yield fatty acids and 
lysophospholipids. The Ca2+-dependent and cytosolic isoform cPLA2α has been shown 
to regulate NMDAR-mediated AA release71. Either blocking cPLA2α or NMDAR activity, 
or removing extracellular Ca2+ diminishes NMDA-induced prostaglandin production. Not 
only the activity of cPLA2α is coupled to NMDAR, its expression levels has also been 
shown to be correlated with increased neuronal activity. Protein expression levels of 
cPLA2α are found to elevate in hippocampal neurons in models of epileptogenesis196. 
mRNA expression levels of cPLA2α has also been found to increase after repeat 
electroconvulsive stimuli in hippocampus370. Notably in both cases, expression levels 
are positively correlated with neuronal activity, in contrary to the negative correlation 
found in my results. This discrepancy is likely explained by the difference in treatment 
paradigm. It is hypothesized that neuronal expression levels of cPLA2α are enhanced by 
prolonged elevation of neuronal activity, whereas acute increase of neuronal activity 
activates the enzyme, but in the meantime, down-regulates its expression as a 
feedback regulation in response to increased production of AA. A previous study 
measured cPLA2α expression in hippocampal tissue within 24 hours after a single 
administration of kainic acid did not see significant change in either protein or mRNA 
expression levels of cPLA2α165, further support the notion that repeat convulsive stimuli 
is required to up-regulate cPLA2α expression. In future studies, it is necessary to 
determine the precise window of acute alteration in both protein and mRNA expression 
levels of cPLA2α, and whether this acute alteration is dependent on NMDAR activity. 
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6.4.2 To identify COX-2 binding proteins using a novel approach 
 An ARE located within the proximal region of COX-2 3’UTR has been identified 
as a key RBP recognition site and a number of mRNA RBPs are known to bind to and 
regulate COX-2 mRNA stability or translation 89. In the present study, an attempt was 
made to identify neuronal specific RBPs that are able to bind COX-2 3’UTR and 
regulate its stability or translation via an NMDAR activity-dependent mechanism. 
Unfortunately, the specificity and abundancy of proteins that were pulled down by an 
RNA probe of the proximal region of COX-2 3’UTR were not sufficient for downstream 
high throughput analysis. Although the same approach has been used to successfully 
extract COX-2 mRNA binding proteins in macrophages previously84, it was not efficient 
in extracting RBPs in neurons herein possibly due to an altered or missing secondary 
structures in the short RNA probe compared to the native neuronal-specific COX-2 
mRNA, as intrinsic RNA secondary structure has been suggested to affect the binding 
of RBP to their target, such as in the case of HuR371. Therefore, an alternative future 
approach is proposed herein. This approach is similar to that used by others372 and was 
based on mRNA tagging technique using the MS2 bacteriophage system373. In this 
method, the bacteriophage MS2 coat protein (MCP) binds to a unique RNA hairpin 
sequence (MS2-binding site) which can be cloned into the mRNA of choice. These 
mRNAs, when transcribed in cells, can then be pulled-down with MCP proteins, 
preferably fused with tags such as fluorescence or enzymes. Briefly, MS2-MBP 
(Maltose binding protein) fusion protein in plasmid will be expressed in Escherichia coli 
(E. coli) and purified on an amylose column. A construct containing full length COX-2 
3’UTR will be cloned into the 3’ end of the luciferase gene in a luciferase vector. Six 
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tandem MS2 stem loops will be cloned out from a MS2-containing plasmid by PCR and 
inserted between the 3’ end of the luciferase coding sequence and the beginning of 
COX-2 3’UTR fragment. Cultured primary cortical neurons will be transfected with the 
COX-2 3’UTR construct. Mock transfected cells will serve as the negative control. Cells 
will then be lysed and supernatant lysate will be collected and quantitated. MS2-MBP 
fusion protein will be added to pre-washed amylose beads and allowed to bind. 
Immobilized MS2-MBP beads will then be added to cell lysate, incubated and washed 
extensively before sending for liquid chromatography–tandem mass spectrometry 
(LC/MS/MS) analysis. By using this approach, RBPs that bind to endogenous full-length 
COX-2 3’UTR may be identified with a better specificity. 
6.4.3 To investigate TIA-1 function in astrocytes 
 Results in chapter 4 showed that TIA-1 deletion leads to enhanced kindling 
acquisition (Fig. 4.1) and increased mortality in kindling model (Fig. 4.3). In addition, no 
trace of TIA-1 containing SG was found in neurons in kindled brain (Fig. 4.4 and 4.5), 
suggesting the negative phenotypes in Tia1-/- may not result from neuronal deletion of 
TIA-1. In fact, TIA-1 was found in cultured cortical astrocytes and in astrocytes within 
hippocampus (Fig. 3.1 and 3.5), suggesting a functional role of TIA-1 in astrocytes. 
Morphological changes marked by increased GFAP and vimentin immunereactivity in 
astrocytes was observed in epileptic patients and animal models for epileptogenesis 
including kindling 19. The effect of reactive astrocytes on seizure activity is still under 
debate. Ablation of reactive astrocytes in a model of traumatic brain injury resulted in 
markedly worsened neural damage and increased leukocyte infiltration 374, suggesting 
protective role of reactive gliosis. On the other hand, activated glia may exacerbate 
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seizure activity through increased production of cytokines, through reduced glutamine 
synthase which in turn leads to accumulated extracellular glutamate, and through 
impaired water redistribution 375. In future studies, it will be necessary to determine if 
astrocytic TIA-1 plays a role in epileptogenesis progression. It would also be necessary 
to investigate the genome wide alteration after TIA-1 deletion in neurons and astrocytes 
as two separate populations. 
6.4.4 Limitations of transcriptome analysis in TIA-1 deleted brains 
 In the present study, it was found that three knockout animals that received PTZ 
exhibit extremely high level of ChP genes. Although it is possible that the unexpected 
abundance of the ChP-specific genes is an artifact introduced by tissue preparation, the 
other possibility that it indeed has a biological basis associated with TIA-1 deletion 
cannot be ruled out. ChP epithelial cells are known to have a primary role in the 
secretion of CSF376, as well as mediating the isolation between CSF and blood albeit 
allowing the transportation of small molecules. Transport across the ChP epithelium 
extends beyond ions to proteins, nutrients and metabolic precursors. Importantly, ChP 
epithelial cells are known to mediate uptake of prostaglandins. Locally produced PGE2 
are taken by ChP epithelial cells via organic anion transporter 3 (OAT3), acting as a 
cerebral clearance pathway377. Myo-inositol is another molecule that is actively 
transported across ChP epithelium and serves as the precursor for many signaling 
molecules. Knockout of potassium channel subunits Kcne2, which regulates the myo-
inositol transportation, leads to low levels of myo-inositol in the CSF and increased 
susceptibility to stress and seizures 378. Although numerous case reports 379 suggest 
that choroidal fissure cyst, a cyst at the level of the choroidal fissure (where ChP is 
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attached to) is associated with seizure activities, very few study investigate the function 
of ChP in seizure generation and epileptogenesis or seizure-induced gene regulation in 
ChP. Indeed, chronic stress was able to induce alteration of many ChP genes380 and 
although CPECs normally have a slow turnover rate, they were able to proliferate in 
response to external stimuli such as injury and/or growth factors381. In future, it will be 
necessary to confirm whether morphological alteration or gene expression profile 
change were induced by kindling in TIA-1 knockout ChP. 
 TIA-1 has been shown as a multi-functional RBP that regulates alternative 
splicing, mRNA stability as well as translation. In the future, it would be necessary to 
revisit the transcriptome data to investigate the differential expression of alternative 
spliced transcripts that are potentially targets of TIA-1 regulation. On the other hand, 
proteome analysis will be performed to determine the role of TIA-1 in global translation 
of mRNA in the brain during epileptogenesis. 
6.4.5 Regulation of neuronal gene expression via NMDAR activity-responsive 
RNA binding proteins 
 Although TIA-1 does not appear to regulate COX-2 protein expression in 
neurons, other RBPs have been implicated in the control of activity-dependent local 
translational changes mediated by activation of NMDAR, thus become potential targets 
in the future. The following sections will focus on the mRNA granules containing 
cytoplasmic polyadenylation element binding proteins (CPEB), zipcode binding protein 1 
(ZBP1), Smaug1 or XRN1. These four proteins, among several other RBPs are 
responsive to NMDAR activity and can regulate mRNA silencing, transportation and/or 
translation.  
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6.4.5.1 Cytoplasmic polyadenylation element binding proteins (CPEB) 
 Cytoplasmic polyadenylation is one of many cellular mechanisms that modulate 
mRNA poly(A) tail length and thus translation. Cytoplasmic polyadenylation is regulated 
by the cytoplasmic polyadenylation element (CPE) binding proteins, or CPEBs, which 
recognize the consensus CPE sequence (UUUUUAU) in mRNA 3’- untranslated regions 
(UTRs). The CPEB RBP family has four members in vertebrates (CPEB1–4). All CPEB 
proteins have two RRMs and two zinc fingers, with CPEB1 (will be referred to as CPEB 
herein) showing less structural similarity to CPEB2-4. It is the only CPEB member that 
presents a high affinity to CPE.382 This biochemical discrepancy suggests non-
redundant function of CPEBs, which was confirmed by studies using knockout mouse 
lines383-385.  
 In Xenopus oocytes, elongation of poly(A) tails of masked mRNAs promotes their 
translation. This happens when cells re-enter meiotic division from an arrested stage, a 
process where the key machinery of cytoplasmic polyadenylation is identified (reviewed 
elsewhere386,387). Briefly, in the nucleus, target pre-mRNAs contain a CPE, which is 
within close proximity upstream of the AAUAAA poly(A) sites. CPEB and cleavage and 
polyadenylation specificity factor (CPSF) bind to CPE and AAUAAA respectively and 
escort mRNA during nucleus exportation. In cytoplasm, the complex recruits poly(A) 
polymerase germline development 2 (Gld2) and the deadenylating enzyme, poly(A) 
ribonuclease (PARN), where PARN activity dominates over Gld2 leading to shortening 
of the poly(A) tail. CPEB also binds Maskin, which prevents the assembly of the 
translation initiation complex. Following hormone stimulation, the kinase Aurora A is 
activated and phosphorylates CPEB, leading to expulsion of PARN and elongation of 
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poly(A) tail by Gld2. ePAB, a variant of poly(A) binding protein then replaces Maskin 
and promotes translation initiation. This CPEB-mediated polyadenylation and translation 
has been found for many CPE-containing mRNAs during oocyte maturation.388,389 
CPEB, along with most of the Xenopus cytoplasmic polyadenylation machinery 
components were later found in neurons.390-392 Maskin was not found in neurons, but its 
function was largely duplicated by neuroguidin (Ngd),393 a CPEB binding protein that 
also inhibits translation initiation.  
 In non-neuronal cells, CPEB has been found in both SGs and P-bodies, 
potentially acting as a link between the dynamic transitions of the two RNA granules394. 
CPEB mRNA was also found in the normal rodent brain, where it is conspicuously 
enriched in neurons of the hippocampal formation and cortical layers 2/3, 5 and 6, and 
mitral and Purkinje cells of the olfactory bulb and cerebellum, respectively.395 In 
glutamatergic excitatory neurons, CPEB-containing RNP granules were found in 
dendrites and are enriched in PSDs.390,391,396 
 In neurons, CPEB activity is tightly regulated by NMDAR activity. The association 
between NMDAR activity and CPEB function was first described in CaMKIIα 
(Ca2+/calmodulin-dependent protein kinase IIα) mRNA polyadenylation in synaptosome 
preparations from cultured rat hippocampal neurons.391 Glutamate stimulated 
phosphorylation of CPEB in synaptosomes, which was blocked by inhibition of NMDAR, 
but not by other glutamate receptors. This is linked to NMDAR activation since direct 
activation of NMDAR resulted in CPEB phosphorylation and CaMKIIα mRNA 
polyadenylation. CPEB-dependent dendritic transportation of CaMKIIα mRNA has been 
found to occur before its polyadenylation,397 with the presence of CPE in mRNA being 
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both necessary and sufficient for this process. Moreover, CPEB-containing particles 
contained dynein and kinesin and were transported in a microtubule-dependent manner 
at an average velocity of 4–8 μm/minute. These results suggest that CPEB escorts 
dormant mRNAs to dendrites where they are later released for translation by NMDAR 
activation. The mechanism of NMDAR/CPEB-dependent regulation of polyadenylation 
was well characterized in hippocampal neurons.393 NMDAR activation induced CPEB 
phosphorylation, dissociation of PARN, and dendritic mRNA polyadenylation. It also 
induced Gld2-dependent polyadenylation and translation. Interestingly, CPEB interacted 
with the mRNA of NMDAR subunit GluN2A through a 3’ CPE in its 3’UTR and regulated 
its dendritic localization398. These findings imply the association between CPEB-
dependent polyadenylation and synaptic plasticity through regulation of NMDAR subunit 
composition. This hypothesis was further confirmed in cultured rat hippocampal 
neurons,398 where glycine increased the surface expression of GluN2A-containing 
NMDAR via a protein synthesis-dependent mechanism. 
 The NMDAR activity-dependent regulation of important synaptic mRNAs 
including CaMKII and NMDAR subunit provides the molecular basis for earlier findings 
of altered neural plasticity in CPEB knockout animals.399-402 In neuroscience, a well-
established measurement for synaptic plasticity is the persistent strengthening (long-
term potentiation, LTP) or weakening (long-term depression, LTD) of synapses induced 
by high (LTP) or low (LTD) frequency trains of stimuli on pre-synaptic compartment. 
LTP or LTD induced within the Schaffer collateral-commissural pathway (SCCP) of the 
hippocampus is NMDAR-dependent. Mice lacking CPEB had deficiencies in LTP but 
LTD in SCCP399 appeared facilitated. Although maintenance of LTP/LTD generally 
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requires protein synthesis, some forms of LTP/LTD induced by distinct stimulation 
patterns do not. Interestingly, CPEB gene deletion only altered selected forms of protein 
synthesis-dependent LTP/LTD, suggesting the critical role of CPEB-mediated 
translation is stimulus-dependent.399 Besides SCCP, altered synaptic plasticity has also 
been found in other neuronal pathways, as CPEB in Purkinje neurons was required for 
cerebellar LTD and motor coordination.401 Finally, altered synaptic plasticity may 
eventually contribute to altered behaviors, such as reduced extinction of hippocampal 
memories in CPEB knockouts.402  
 In addition to CPEB, CPEB3 has also been linked with synaptic plasticity. 
NMDAR activation facilitated nuclear translocation of CPEB3 in cultured neurons.403 
CPEB3 binds GluA1 and A2 (AMPAR subunits) mRNAs and repressed their 
translation.382,404 Knockout of CPEB3 resulted in translational elevation of plasticity-
related proteins including PSD95, NMDAR and AMPARs and CaMKIIα,383 which may 
contribute to defects in a specific form of NMDAR-dependent synaptic de-potentiation405 
and an enhanced hippocampus-dependent memory.383 The mechanism through which 
CPEB3 functions is still not fully understood. Yet, it is at least independent of 
polyadenylation of mRNA targets, due to the inability of CPEB3 to bind CPE.382  
6.4.5.2 Zipcode binding protein 1 (ZBP1) 
 ZBP1 (zipcode binding protein 1) is an RBP that belongs to a family of 
evolutionarily related proteins found in many species from Drosophila to humans.406 
Expression levels are highest during development and much lower in adult tissues 
indicative of its importance during development. ZBP1 is widely expressed in 
developing tissues, including heart, lung, liver, intestine, epidermis and reproductive 
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organs, suggesting a broad role in development.407-409 In Drosophila, ZBP1 is expressed 
in the developing CNS, including brain and ventral nerve cord,410 and in fetal mice, it is 
highly expressed in neurons of the CNS.  
 ZBP1 protein has two RRMs and four hnRNP K homology (KH) domains. The KH 
domains 2 and 4 of RBP1 possess nuclear localization signals (NLS) that allow it to 
enter the nucleus, where it binds to its mRNA cargo.411-413 This association masks these 
signals allowing the complex to exit the nucleus. KH domains 3 and 4 bind mRNA 
transcripts that possess 54 nucleotide-long sequence, named zipcode cis element, in 
the 3’UTR proximal to the stop codon of target mRNAs.414-417 In fact, ZBP1 is identified 
and cloned using this element.414 An analysis of embryonic brain tissue from humans 
and mice identified this element in 114 conserved mRNAs.411 Among these is β-actin 
mRNA. β-actin is a cytoskeletal protein that is critical for the proper growth, arborization, 
and guidance of axons and/or dendrites during development.418 It is found in RNPs in 
both axon growth cones and dendrite filipodia, the leading edge of the growing neurites.  
 The interaction of ZBP1 with β-actin mRNA is well characterized. ZBP1-
containing RNPs carry the translationally repressed mRNA along microtubules to axon 
growth cones and dendrite filopodia, where it can be translated into protein.418-420 This 
transport is mediated by the molecular motors myosin Va and kinesins.412,421,422 Thus, 
ZBP1 functioned in the localization of specific subsets of mRNA to the growing edge of 
the neurites and their local translation.412,423-425 The importance of RBP1 function is 
supported by evidence from several studies. For example, depletion of ZBP1 or 
blocking its interaction with β-actin mRNA in cultured hippocampal neuron decreased 
local β-actin mRNA levels and impaired guidance of axonal growth cones and 
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aborization of dendrites.418,420 Similarly, expression of an engineered mRNA containing 
the β-actin 3’UTR bound ZBP1 and reduced endogenous mRNA dendritic 
localization.426 Translation is not allowed until the ZBP1-mRNA complex reaches its 
destination, where ZBP1 is phosphorylated at Tyr396 by Src.412,420 Phosphorylation 
reduces its affinity for the zipcode elements thereby releasing the mRNA for translation. 
The sequential binding and releasing of ZBP1 enable spatial and temporal control over 
beta-actin mRNA translation, which is an essential mechanism to regulate neurite 
growth. 
 In mature neurons, the actin-rich dendritic spines serve as the postsynaptic loci 
for excitatory transmission and synaptic plasticity. In cultured rat hippocampal neurons, 
ZBP1 granules were observed in dendritic shafts and spines that have synaptic 
connections.425 KCl-induced depolarization of the neurons caused an increase in the 
dendritic localization of ZBP1 granules and β-actin mRNA. An inhibitor of NMDAR 
attenuated these changes indicating that they resulted from KCl-induced excitatory 
neuronal activity. Interestingly, only a fraction of β-actin mRNA co-localized with ZBP1 
granules and vice versa. Also, the NMDAR inhibitor did not block the increase 
completely.  Together, these results suggest that other RBPs may be involved in 
activity-induced β-actin transport.  
 The zipcode element is recognized by other RBPs as well, such as HuD. For 
example, both ZBP1 and HuD bind to the zipcode element in the 3’UTR of rat β-actin 
mRNA. ZBP1 binds the core ACACCC motif and exhibits a unique specificity for the 
secondary structure of the sequence, whereas HuD binds the U-rich sequence following 
the core motif.427 This competition is restricted to mammals, as rat HuD did not bind to 
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chicken β-actin mRNA, which lacks the U-rich sequence.427 The biological implication of 
this competition remains unknown. Interestingly, HuD/ZBP1 interaction has been 
reported in other cases where the two work in synergy. HuD and ZBP1 both bind to 
GAP-43 mRNA, which has no clear zipcode element, and guide its axonal 
localization.428 Interaction between HuD and ZBP1 is also identified in differentiated P19 
neuronal cells where both were shown to bind Tau mRNA and regulated its trafficking to 
distal axons.429  
 In total, although ZBP1 function has been explored extensively in growing 
neurites, much remains unknown about the signal transduction mechanism that links 
ZBP1 to NMDAR-dependent transport and local translation. It is also necessary to 
identify novel targets of ZBP1 other than β-actin and to unravel protein/protein 
interaction between ZBP1 and other RBPs. Finally, ZBP1 is not restricted to RNPs as it 
was found in dendritic P-bodies and SGs,430-433 suggesting non-overlapping roles in 
these functionally distinct RNA granules.  
6.4.5.3 Smaug1 
 Smaug is an RBP that is identified as a key determinant of gene expression 
during Drosophila development.434,435 Smaug protein harbors one sterile alpha motif 
(SAM) domain, which recognizes binding elements in target mRNAs, named Smaug-
recognition element (SRE). This element possesses a stem-loop structure containing 
the conserved motif, CUGGC, within the loop.435,436 During oogenesis and early 
embryogenesis, gene transcription is silenced and development is dependent on gene 
products derived from the maternal transcriptome. Expression during these 
developmental periods is controlled by post-transcriptional mechanisms. However later 
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during maternal-to-zygotic transition, translation of zygotic mRNAs is initiated, 
accompanied by silencing or destruction of maternal mRNA, which is mediated by 
Smaug.437 On one hand, Smaug blocks translation initiation of SRE-containing mRNAs 
by recruiting Cup, an eIF4E binding protein that prevents the association of eIF4E with 
eIF4G.438 On the other hand, Smaug mediates mRNA destruction by recruiting the 
CCR4-NOT complex to induce de-adenylation as the first step in mRNA decay.439,440  
 Two Smaug homologs (Smaug1 and 2) are contained in the mammalian 
genome.436,441 In mice, Smaug1 is expressed in the brain, where it is a key component 
of a specific neuronal RNP, termed S-foci.442 S-foci has been shown to be present in the 
PSD-enriched fraction of glutamatergic synaptoneurosomes and co-localized with 
PSD95 in dendritic spines of hippocampal neurons, suggesting that they are involved in 
regulating translation in spines. S-foci in neurons are distinct from other RNPs found in 
dendrites. Thus, S-foci in neurons lacked the SG components, eIF3η translation 
initiation and TIA-1 translational silencer.95 This contrasts with heterologous expression 
in non-neuronal cells. Further co-localization studies indicated that S-foci are distinct 
from granules that contain FMRP, SMN, and Staufen 1. Neuronal S-foci also do not 
contain DCP1a (a decapping enzyme and an obligatory component of P-body), a P-
body marker, and were shown to be functionally distinct from P-bodies. Additionally, 
they differ from SX-bodies because they lack XRN1 5’-3- exoribonuclease, a key 
component of these RNPs.443 However, like SX-bodies, S-foci are dynamic structures 
that are strongly coupled with excitatory activity.95 Depolarization of cultured rat 
hippocampal neurons by KCl significantly reduced the number of synapses containing 
S-foci.95 Inhibition of NMDA but not AMPARs completely blocks this reduction, 
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indicating that it is linked to excitatory neuronal activity, potentially by blocking Ca2+-
dependent signal transduction via Phosphoinositide 3-kinase (PI3K). Assembly of S-foci 
seems to be dependent on availability of transcripts, but not synthesis of new Smaug1 
molecules. Thus, NMDAR activation induces polysome assembly, whereas inhibition 
redirects these mRNAs to S-foci. Upon NMDAR activation, association between S-foci 
and CaMKIIα mRNA is reduced, suggesting that activity-dependent disassembly of S-
foci may have physiological impact on synaptic plasticity. Interestingly, while NMDAR 
activation releases certain transcripts from S-foci (e.g., CaMKIIα), it induces general 
translational silencing in dendrites. Finally, knockdown of Smaug1 affects synapse 
formation by altering dendritic spine morphology and synaptic responses to repeated 
depolarizing stimuli.   
 Besides Smaug1, at least two other Smaug-related proteins are found in 
neurons.444,445 Smaug1 ∆EIII is a Smaug1 variant that lacks the third exon, which codes 
for 10 amino acids in its SAM. Yet Smaug1 ∆EIII is still capable of RNA-binding and 
shows repressor activity comparable to Smaug1.444  Smaug2, a homologous gene to 
Smaug1 in mammals, plays an important role in cortical neurogenesis, being both 
sufficient and necessary for cortical stem cell renewal.445 Although all three major 
Smaug isoforms are capable of forming aggregations,444 their functional redundancy in 
synaptic S-foci is currently unknown. 
6.4.5.4 XRN1 
 In addition to regulation of mRNA translation, expression from many genes is 
controlled at the level of mRNA stability. In fact, the two posttransciptional control 
mechanisms are often coordinated.446 One prominent pathway of mRNA degradation 
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involves the XRN family of 5’ → 3’ exoribonucleases.447 Two paralogs of XRNs, XRN1 
and XRN2, are present in eukaryotic cells. Both require an exposed 5’ monophosphate 
group on RNA substrates that is dictated by structural features of a highly conserved 
catalytic domain.448 However, the two XRNs differ in their subcellular location, function, 
and protein structure. Whereas XRN2 is a nuclear protein that serves critical roles in 
RNA polymerase II transcription and precursor mRNA processing, XRN1 is a cytosolic 
protein that is a major contributor to post-transcriptional mRNA processing. Substrate 
transcripts can be generated by three distinct pathways: 1) decapped mRNAs 
generated in deadenylation-dependent decay pathway, 2) endonucleolytic cleavage-
mediated mRNA decay, and 3) mRNA nonsense-mediated decay. However, XRN1 
deletion affects specific subsets of transcripts, consistent with its substrate specificity.449 
In this regard, evidence suggests that XRN1 can bind to select mRNAs that possess 
stable stacked planar structures, called G-quartets, which are formed by hydrogen 
bonds between four guanine ribonucleotides.450,451 Such cis-acting elements can be 
found throughout the transcripts but are most frequently located within the 5’ or 3’ 
UTRs, which are key points of mRNA function and regulation.452 Among the known 
functions of G-quartets are sorting/trafficking and translation of mRNAs. With respect to 
trafficking, G-quartets play an important role in dendritic targeting of mRNAs including 
PSD95 and CaMKIIα to postsynaptic sites.452 Finally, in addition to differences in 
subcellular distribution and function, XRN1 protein also possess an extended carboxyl 
terminus that is not found in XRN2. This domain likely contributes to distinct functional 
characteristics of XRN1.453 In addition to influencing RNA binding or self-
aggregation,208,454,455 it harbors several short regions enriched in lysine and/or glutamic 
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acid that may provide a platform for recruiting various different protein binding 
partners.456 
 XRN1 is generally considered to be a co-activator of P-body assembly together 
with DCP1a. In addition to DCP1a, XRN1 interacts with other P-body-specific enzymes, 
including the helicase DDX6 and the deadenylase CCR4-CAF1-NOT complex447 in the 
degradation of sequestered mRNAs. In cultured hippocampal neurons, XRN1 formed 
synaptic granules that are different from the canonical P-bodies.443 In these neurons, 
XRN1 localized in the post-synaptic compartment and exhibited minimal overlap with 
DCP1a, which was found in the dendritic shafts. The XRN1 containing granules, termed 
SX-bodies, show little or no co-localization with other important dendritic RBPs including 
FMRP, Smaug1, and SMN, suggesting that they are unique RNA granules that may 
have distinct regulatory roles in synaptic mRNA regulation. XRN1 was also found in 
SGs.212 Thus, bulk mRNA decay may not be the only activity of this enzyme. 
SX-bodies at the synapse are thought to be temporary RNA storage sites that respond 
to synaptic stimulation.443,455 SX-bodies contain mRNAs that are translationally 
repressed, resistant to 5’ → 3’ decay, and can resume translation upon dissolution of 
the granules443. The formation of SX-bodies negatively correlates with local protein 
synthesis. Dendritic translation in cultured neurons was blocked by NMDAR 
activation95,342 but was stimulated by metabotropic glutamate receptors (mGluR) 
activation.457,458 The size and number of SX-bodies increase when local protein 
synthesis is repressed by NMDAR stimulation, whereas stimulation of mGluR leads to 
an opposite effect on SX-bodies formation. Furthermore, knock down of XRN1 blocks 
NMDA-induced translational repression, suggesting SX-bodies are necessary for 
		192	
activity-induced local translation inhibition. Interestingly, this non-canonical regulatory 
role of XRN1 was also observed in yeast where under glucose exhaustion, XRN1 
accumulated in a plasma membrane-associated compartment that is segregated from 
the rest of the mRNA-decay machinery.459 This XRN1-mediated redistribution of 
mRNAs may function as a regulatory mechanism in metabolism reprogramming. Based 
on the evidence showing substrate specificity of XRN1 discussed above, future studies 
will be necessary to identify the complement of mRNAs that are repressed in these non-
canonical XRN1-containing granules, which will lead to a better understanding of the 
physiological role of SX-bodies in synaptic plasticity. 
6.4.5.5 Survival of motor neuron (SMN) protein 
 Among its multiple functions, SMN is necessary for axonal growth cone and 
dendritic filipodia maturation during development of spinal motor neurons. Two nearly 
identical copies of the SMN gene, SMN1 and SMN2, are present in the human genome. 
Mutations in the SMN1 gene together with deficiencies in SMN2 protein led to spinal 
muscular atrophy (SMA), an autosomal recessive neuromuscular disease that 
selectively disrupts spinal motor neuron development, maturation,460,461 and survival. 
Variable numbers of SMN2 gene copies are possible in the human genome and SMA 
disease severity correlates inversely with SMN2 copy number, suggesting that this SMN 
paralog can compensate for loss of SMN1. In contrast to human, the mouse genome 
has only one SMN gene.462 Inactivation of SMN gene in mice was embryonic lethal, 
whereas mutant mice with a human SMN2 transgene survived but died postnatally via 
an SMA-like phenotype.463,464 Like SMA in humans, severity correlated inversely with 
hSMN2 copy number further suggesting the apparent redundancy. 
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 SMN is an essential component of RNPs that control pre-RNA splicing in the 
nucleus and mRNA transport to axons and dendrites during spinal neuron 
development.465-467 β-actin mRNA is one such transcript, which may at least partly 
explain the role of SMN in neurite development.468 SMN is also a silencer of mRNA 
translation.469 Although it may have some capacity for RNA binding itself, it lacks known 
RNA binding domains and thus, mainly functions through interaction with other RBPs, 
such as ZBP1 (above) and HuD (below).466 SMN function is influenced by excitatory 
neuronal activity via the NMDAR. In cultured cerebellar granule cells, for example, the 
presence of SMN-positive nuclear granules coincided with NMDAR development.470 
Additionally, NMDAR activation increases SMN-positive granules in the nucleus and 
enhances transcription of SMN,470,471 which is mediated through the PI3K-AKT pathway 
downstream of Ca2+ influx.472 Moreover, NMDAR induced transcription from the human 
SMN2 transgene in mice lacking SMN and this suppressed the SMA phenotype.472 On 
the other hand, impairment of NMDAR activity in these mice blocked exercise-induced 
motor unit maturation and neuroprotection.473 Thus, in contrast to other RBPs discussed 
herein, NMDAR activity can effect mRNA processing, transport, and translation via 
enhanced transcription of SMN. In addition to spinal motor neurons and cultures of 
cerebellar granule cells, various neuron populations of the adult human and mouse 
CNS also express SMN474. However, its function in the adult remains to be elucidated.  
6.4.5.6 Heterogeneous nuclear ribonucleoproteins (hnRNP) A1 
 A large fraction of SMN2 mRNA (>75%) innately lacks exon 7 as a result of exon 
skipping, leading to the translation of an unstable protein,475 which is thought to be the 
basis of SMA.476 Evidence indicates that lack of exon 7 disrupted the ability of SMN2 to 
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translocate from the nucleus to the cytoplasm,477 where it assembled into tRNPs that 
transport mRNAs, including β-actin, to axons and dendrites. SMN2 exon 7 skipping or 
inclusion is a complex process, involving a number of RBPs.478 Among these is 
heterogeneous nuclear ribonucleoproteins A1 (hnRNP A1), which suppresses exon 7 
splicing.479 hnRNP A1 binds to specific motifs found in many pre-mRNAs in addition to 
SMN2 and regulates their splicing to mature mRNAs.480 Relevant to the focus of this 
discussion, KCl-induced depolarization of cultured cortical neurons increased binding of 
hnRNP A1 to the pre-mRNA of GluN1, an obligate subunit NMDAR. GluN1 pre-mRNA 
has 22 exons and 8 different splice variants.481 hnRNPA1 splices exon 21482 (C1 
cassette), which codes for 37 amino acids in the carboxy terminal intracellular tail of 
GluN1. Interestingly, splicing of exon 21 by hnRNPA1 was linked to NMDAR-dependent 
Ca2+ signaling, and since the presence or absence of exon 21 appears to affect 
subcellular distribution or cell surface expression483-485, activity-dependent induction of 
hnRNPA1 splicing may serve to regulate excitatory neurotransmission. While much is 
unknown about the influence of hnRNPA1 on CNS function, it is worth noting that 
environmental stimuli, such as lead poisoning and perhaps drug addiction, are known to 
affect splicing of the carboxy terminal exons of GluN1, raising the possibility that 
NMDAR-dependent hnRNPA1 exon splicing is indeed as an adaptive response486,487. 
6.4.5.7 TAR DNA-binding protein 43 (TDP-43) 
 In contrast to hnRNPA1, TDP-43, a multi-functional RBP, promotes exon 7 
inclusion in the SMN2 transcript. TDP-43 is a member of the hnRNP family that binds 
specifically to UG-rich sequence488. It functions as a pre-RNA splicer and has been 
linked with alternative splicing of multiple disease-related genes, including SMN489. This 
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RBP also functions in the entire life cycle of mRNA and in non-coding RNA 
processing490. In neurons, it was found in the nucleus, cytoplasm and dendrites491 and 
has been implicated in SG formation490. In dendrites of cultured hippocampal neurons, 
NMDA stimulation led to decreased co-localization of TDP-43 with RNA, whereas KCl 
greatly enhanced this association491. KCl also enhanced the co-localization of TDP-43 
with Staufen1 and FMRP. These results suggest TDP-43 responds differently to distinct 
neuronal activities, and may cooperate with other activity-dependent RBPs in mRNA 
transportation and local translation. The level of TDP-43 in the nucleus is also coupled 
with NMDAR activity. In cortical neurons, extracellular glutamate accumulation induced 
elevated nuclear TDP-43 protein levels through activation of NMDAR containing 
GluN2A subunit492. This increased nuclear TDP-43 was required for neuronal survival 
against glutamate accumulation, suggesting distinct activity-dependent roles of TDP-43 
in the nucleus versus dendrites. 
6.4.5.8 ARE/poly(U)-binding/degradation factor 1 (AUF1) 
 AUF1, also known as hnRNP D, is an RBP primarily targeting 
adenylate/uridylate-rich elements (AU-rich elements or AREs) located within mRNA 
3’UTR. AUF1 binding may lead to mRNA decay through a yet to be fully characterized 
mechanism493. In brain, AUF1 expression is primarily found in the nucleus92,494 and 
negatively correlates with NMDAR activity92. In cultured cerebellar granule cells, NMDA 
induced a decrease in the level of nuclear AUF1 through nitric oxide (NO) production. 
This led to mRNA stabilization of one specific AUF1 target, α2 subunit of NO-sensitive 
guanylyl cyclase, and subsequent production of cGMP92. It is unclear whether the 
decreased AUF1 level releases bound mRNA and leads to competitive binding of 
		196	
stabilizing RBPs such as HuR. The extent to which AUF1 regulates stability of other 
mRNAs in neurons remains to be determined. 
6.4.5.9 HuD/embryonic lethal abnormal vision-like 4 (elavl4) 
 Hu (Elavl) proteins belong to a family RBPs comprised of HuR (HuA/Elavl1), HuB 
(Elavl2), HuC (Elavl3), HuD (Elavl4).495,496  These RBPs bind to AU-rich elements (ARE) 
of target mRNAs and regulate pre-RNA processing, mRNA stability, and translation. 
Whereas HuR is expressed ubiquitously, expression of HuB, HuC, and HuD is restricted 
to neurons under normal conditions. HuD has been found in dendrites of neurons, 
where it associates with neuronal mRNAs including neuritin, Homer1a, GAP-43, 
Neuroligins, Verge and CAMKIIα.497 Dendritic HuD expression was increased upon 
neuronal depolarization, accompanied by increased association of HuD mRNA binding 
and their translation, and an NMDAR antagonist blocked this activity-induced increase. 
Consistently, knockout of GluN1 subunit of NMDAR led to decreased HuD expression in 
brain. Polysome profiling experiments showed an increase in association between HuD 
and poly-A-binding protein (PABP) in polysomes following neuronal stimulation. These 
results suggest that HuD mediates NMDAR activity-dependent re-distribution of bound 
mRNAs to dendrites and regulates their translation by bringing these mRNAs into active 
polysomes. In the developing brain, the transport of HuD and its mRNA cargo is 
dependent on SMN, at least in spinal motor neurons, and this is likely due to a 
necessary role of SMN for the integration of HuD into tRNPs498,499.    
6.4.5.10 CArG Box binding factor A (CBF-A) 
 CBF-A belongs to the hnRNP A/B family of RNPs, which included hnRNP A1 
(see above).500 These RBPs recognize cis-element located in the 3’UTR of target 
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mRNAs termed A2RE (hnRNP A2 response element) This RBP has been identified in 
various cell types, including neurons of rodent brain.500,501 In neurons, CBF-A protein is 
found in the nucleus and in mRNA granules in axons and dendrites100 or more generally 
bound to the RTS (RNA trafficking sequence), located within the 3’UTR of a number of 
neuronal transcripts.100,501 CBF-A positive granules contain important dendritic mRNAs 
including Arc, BDNF and CaMKIIα, which were bound by CBF-A directly at their RTS. 
Interestingly, NMDAR stimulation led to accumulation of CBF-A granules and bound 
mRNAs in dendrites,100 suggesting that the interplay between CBF-A and RTS elements 
is correlated with the function of excitatory synapses. Accordingly, CBF-A silencing 
impaired the dendritic localization of CaMKIIα mRNA. The involvement of CBF-A in 
development of excitatory synapses and neuronal plasticity is yet to be determined. 
6.4.5.11 Staufen1 
 The Staufen (Stau) family of double-stranded RNA-binding proteins (dsRBPs) 
bind specifically to a collection of double-stranded RNA secondary structures termed 
Stau-recognized structures (SRS).502 Staufen1 is found in neurons and is involved in 
mRNA stability, dendritic transportation, and translation. Growing evidence suggests 
that Staufen1 plays an important role in dendrite development and synaptic plasticity. In 
the latter case, in NMDAR-dependent long-term memory formation in Drosophila, 
Staufen1 transcription was induced in a CREB (cAMP response element binding 
protein)-dependent manner.503 This induction was not observed in flies expressing a 
defective NMDAR and this was presumed to be due to the loss of NMDAR-dependent 
suppression of basal expression of a CREB repressor.504 In hippocampal organotypic 
cultures, Staufen1 knockdown led to altered dendritic spine length and shape of CA1 
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neurons, whereas NMDAR blockage prevented these changes.505 These results 
suggest Staufen1 contributes to NMDAR-dependent plasticity via alteration in dendritic 
spine morphology. 
6.4.5.12 Fragile X mental retardation protein (FMRP) 
 FMRP is an RBP encoded by FMR1 gene located on the X chromosome. It binds 
to a variety of cis-elements in mRNAs,506 including a G-quadruplex (a structure motif 
composed of spaced GG dinucleotides).507 Mutations causing extensive expansion of a 
CGG trinucleotide-repeat sequence located in the 5’UTR of FMR1, lead to epigenetic 
silencing of the gene. This loss of function of FMR1 is known to be the cause of fragile 
X mental retardation syndrome, a heritable cognitive disorder similar to autism spectrum 
disorder.508 FMRP can shuttle between the nuclear and cytoplasmic compartments in 
neurons,509 but is found at post-synaptic sites of excitatory synapses as well. 
Depolarization of glutamatergic neurons, which stimulates synaptic release of 
glutamate, transiently increases trafficking of FMRP and its mRNA transcript to 
dendrites and post-synaptic sites. This effect is likely due to activation of mGluR5, a G-
protein-coupled mGluR.510 It is posited that these effects may be relevant to the well-
established role of FMRP in mGluR-dependent synaptic plasticity.508 Additional 
evidence from studies in the sensory cortex suggests that FMRP expression level is 
coupled to NMDAR activity as well. In this regard, FMRP protein expression has been 
found to be induced in the barrel cortex of the rat by unilateral whisker stimulation, a 
model of experience-dependent plasticity.511 This increase is blocked by inhibition of 
either mGluR or NMDAR. Similarly, in mice that were reared in the dark, FMRP levels 
increased post-transcriptionally in the cell bodies and dendrites of visual cortical 
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neurons following a short-term light exposure.512 This increase was also blocked by 
NMDAR inhibition. These data suggests that FMRP may act through NMDAR in 
experience-dependent synaptic plasticity. 
6.4.6 Hypothetical model of NMDAR-responsive RBP-mediated regulation of 
neuronal gene expression 
 As discussed above, evidence suggests the presence of RBPs that are 
responsive to altered NMDAR activity. A conceptual view of the possible relationships 
between NMDAR activity and dendritic translation is shown in Figure 6.1. This 
schematic divides the relationship into two classes. Class A NMDAR activity-responsive 
(Nar) RBPs are constitutively transported to dendritic sites, where they store 
translationally silent mRNAs in tRNPs. NMDAR activation during excitatory transmission 
stimulates disassembly of the granules releasing the mRNAs, thus initiating their 
translation into protein (A1, e.g., Smaug1). Alternatively, mRNAs may acquire increased 
stability due to exosome dissociation (A2, e.g., AUF1), thus allowing them to be 
transported. Class B Nar RBPs do not bind mRNA (or bind at minimal level) 
constitutively but are induced to bind their targets by increased NMDAR activity (i.e., 
excitatory neurotransmission). Upon binding, target mRNAs can be transported to 
dendrites (B1, e.g., CBF-A, ZBP1), translationally silenced (B2, e.g., XRN1), or become 
translationally active (B3, e.g. CPEB, HuD). Modification such as phosphorylation may 
contribute to these changes (e.g., CPEB, ZBP1). Finally, NMDAR activity may induce 
changes in mRNA splicing leading to alternatively spliced transcripts (B4, e.g., hnRNP-
A1).  
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Fig. 6.1 NMDAR-responsive RNA binding proteins 
 
 In summary, the above sections present a hypothetical model in which gene 
expression levels are regulated via RBPs under the control of activated NMDAR (by 
spontaneous/evoked glutamate release). Whether COX-2 gene expression is regulated 
through these Nar RBPs and if so, through which RBP(s) and during which steps of the 
RNA life cycle it is regulated remain interesting questions to ask in the future.  
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6.5 Overall significance 
 The present study investigated how COX-2 mRNA levels are regulated by 
excitatory neuronal activity in cultured cortical neurons. It also examined how COX-2 
protein levels are regulated by convulsive stimuli in the brain. Specifically, the present 
study found that TIA-1, an RBP that has been shown to regulate COX-2 expression in 
non-neuronal cell, does not appear to regulate COX-2 protein expression in neurons, 
arguing that COX-2 expression is regulated differently in brain. Since enhancing 
neuronal COX-2 expression can raise the innate seizure threshold of the brain, a better 
understanding of COX-2 regulation in the brain may facilitate development of novel 
antiepileptic approaches based on augmenting neuronal COX-2 expression and/or 
activity. The present study is also the first to show that disrupting TIA-1 function can 
enhance the risk of epileptogenesis, possibly due to an alter transcriptome in 
hippocampus. Since various RBPs have been shown to react to altered neuronal 
activity and are hypothesized to contribute to the progression of epilepsy, the discovery 
of TIA-1 as a regulator of epileptogenesis supports this theory and provides novel 
targets for anti-epileptic strategies.  
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APPENDIX TABLE 1. Effect of COX-2 inhibition on seizure and epileptogenesis 
 
*, i.m., intramuscular. #, i.p., intraperitoneal. $, The term anticonvulsant is used here to describe the effects of COX-2 inhibition in studies involving 
an acute seizure model (non-epileptic) whereas antiepileptic is used for studies involving an epileptogenesis model where the animals were 
analyzed for spontaneous recurrent seizures or kindling acquisition.  
Pharmacologi
cal or genetic 
modification 
of COX-2 
Dose and 
route of 
COX-2 
inhibitor 
Dosing 
paradigm Convulsant 
Seizure or 
epileptogen
esis models 
Species, strain 
and gender of 
mice 
Major effects Summary 
Ibuprofen; 
Diclofenac; 
Indomethacin; 
Flurbiprofen; 
10mg/kg, i.m.* 2h prior to PTZ PTZ (100mg/kg, i.p.#) Acute seizure 
Adult male 
NMRI mice 
All NSAID decreased LD50 of 
PTZ;  
Diclofenac, Indomethacin and 
Flurbiprofen shortened onset 
time of acute seizure 
Aggravated 
seizure 
activities69 
Indomethacin 5mg/kg, i.p.  2h prior to grabbing 
Moderate 
environmental 
stress (Grab) 
Acute seizure Adult Gerbil of either sex 
Increased severity and 
incidence of 2nd seizure 15min 
after 1st seizure 
Aggravate 
seizure 
activities67 
Indomethacin 10mg/kg, i.p. 30min prior to Tacrine 
LiCl (12mEq/kg, 
i.p.) 24h prior 
Tacrine (5mg/kg 
i.p.) 
Acute seizure Adult male Wistar Rat 
Abolished seizure and 
hippocampal damage 
Anticonvulsa
nt effect $ 
 
Neuronal 
protective 
effect 513 
Indomethacin; 
Celecoxib; 
NS-398; 
Aspirin; 
10mg/kg, i.p. 30min prior to kainic acid 
kainic acid 
(50mg/kg, i.p.) 
Status 
epilepticus 
Adult male 
Mice (spicies 
not specified) 
All aggravated seizure activity 
and mortality;  
Indomethacin and NS-398 
aggravated neuronal death 
Aggravated 
seizure 
activities 
 
Aggravated 
neuronal 
injury 174 
Indomethacin; 
Nimesulide; 
Ketoprofen; 
Celecoxib; 
10mg/kg, i.p. 
(Indomethacin
, Nimesulide, 
Ketoprofen); 
10mg/kg, p.o. 
(Celecoxib) 
1h prior to or 
15min after 
kainic acid 
kainic acid 
(10mg/kg, i.p.) Acute seizure 
Adult male ICR 
mice 
All aggravated kainic acid-
induced seizure activity; 
Indomethacin aggravated 
neuronal death 
Aggravated 
seizure 
activities 
 
Aggravated 
neuronal 
injury 168 
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Pharmacologi
cal or genetic 
modification 
of COX-2 
Dose and route of 
COX-2 inhibitor 
Dosing 
paradigm Convulsant 
Seizure or 
epileptog
enesis 
models 
Species, 
strain 
and 
gender of 
mice 
Major effects Summary 
SC560; 
Indomethacin; 
5 mg/kg, i.p. 
(SC560); 
10mg/kg, i.p. 
(Indomethacin) 
30min prior to 
stimulation 
Daily electrical 
stimuli to 
unilateral 
amygdala up to 
13 days 
Kindling 
Male 
C57BL/6J 
mice (age 
not 
specified) 
Reduced after-discharge duration 
and attenuated kindling progress 
Antiepileptic 
effect514 
Celecoxib; 
NS398; 
Celecoxib (7,20, 
30mg/kg, i.p.); 
NS398 (10, 30, 
90mg/kg, i.p.) 
Prior to 
stimulation 
Daily electrical 
stimuli to 
unilateral 
amygdala 
Kindling 
Male 
NMRI 
mice 
No effects on generation, spread 
and termination of seizure activity 
(After-discharge threshold and 
duration, seizure severity and 
duration) 
No effect515 
CAY10404 + 
rIL-1ra 
CAY10404 
(10mg/kg, i.p.) + 
rIL-1ra (100mg/kg, 
i.p.) 
Single dose 
immediate prior 
to pilocarpine;  
 
Single dose 
prior to 
pilocarpine + 
once daily for 
10 days after 
status 
epilepticus 
LiCl (3mg/kg, 
i.p.) 16-18h prior 
Pilocarpine 
(60mg/kg s.c.#) 
Status 
epilepticus 
P21 
Wistar rat 
(gender 
not 
specified) 
Single dose pretreatment did not 
have any antiepileptic effect; 10-
day treatment resulted in reduced 
frequency of spontaneous recurrent 
seizures and attenuated mossy 
fiber sprouting 
Antiepileptic 
effect194 
Indomethacin 140 µg/day 
4-week 
continuous 
administration 
Weekly Tossing Kindling* 
Adult 
male EL 
mice 
No change in seizure threshold; 
Better seizure recover and 
attenuated seizure duration 
Antiepileptic 
effect178 
Rofecoxib; 
Nimesulide; 
Naproxen; 
Aspirin; 
Rofecoxib (1-
4mg/kg,p.o.$); 
Nimesulide (1-
5mg/kg, p.o.); 
Naproxen (7 and 
14mg/kg, p.o.); 
Aspirin (10 and 
20mg/kg, p.o.); 
45min prior to 
PTZ 
PTZ (80 mg/kg, 
i.p.) 
Acute 
seizure 
Male 
Albino 
(Laka) 
mice 
All drugs dose-dependently 
reduced mortality, increased 
seizure onset time, decreased 
seizure duration. Some drugs 
potentiated protective effects of 
subprotective dose of muscimol 
and diazepam 
Anticonvulsa
nt effect191 
*, EL is an inbred albino strain that has multiple genetic loci that contributing to its recurrent seizure phenotype. Recurrent seizure can be induced 
by rhythmic stimulation in young EL mice, which is a process similar to kindling. 
#, sc., subcutaneous. $, po., per os.   
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Pharmacologi
cal or genetic 
modification 
of COX-2 
Dose and route of 
COX-2 inhibitor 
Dosing 
paradigm Convulsant 
Seizure or 
epileptoge
nesis 
models 
Species, 
strain 
and 
gender of 
mice 
Major effects Summary 
Rofecoxib 1-5mg/kg, i.p. 45 min prior to PTZ 
PTZ (80 mg/kg, 
i.p.) 
 
Acute 
seizure 
Male 
Albino 
(Laka) 
mice 
Increased the mean onset time of 
clonus;  
Reduced seizure duration; 
Accelerated recovery to normal 
behavior and activity after PTZ 
seizures;  
Rofecoxib at a dose of 0.5mg/kg 
potentiated subprotective dose of 
tiagabine 
Anticonvulsa
nt effect179 
 
Rofecoxib 2 or 5 mg/kg, p.o. 
45min prior 
to PTZ 
daily 
PTZ, (40 
mg/kg, i.p. 
daily) 
Kindling 
Male 
Albino 
(Laka) 
mice 
Significant decrease in PTZ-
induced kindling score (since 
1st day); 
Reduced oxidative stress 
Antiepileptic 
effect197 
nimesulide; 
rofecoxib; 
 
nimesulide (2.5 
mg/kg; ip); 
rofecoxib (2 
mg/kg, ip); 
 
45min prior 
to 
convulsant 
stimulus 
Bicuculline 
(4 mg/kg; 
ip), 
picrotoxin (8 
mg/kg; ip) 
electroshoc
k (60 mA for 
0.2 sec); 
Acute 
seizure 
Male 
Albino 
(Laka) 
mice 
Prolonged mean onset time of 
convulsions, decreased duration of 
clonus and decreased mortality rate 
against bicuculline and picrotoxin-
induced convulsions; Ineffective 
towards maximal electroshock-
induced convulsions; 
Anticonvulsa
nt effect192 
Nimesulide 2.5 or 5mg/kg, p.o. 
45min prior 
to PTZ 
daily 
PTZ, (40 
mg/kg, i.p. 
daily) 
Kindling 
Male 
Albino 
(Laka) 
mice 
Significant decrease in PTZ-
induced kindling score;  
Reduced oxidative stress 
Antiepileptic 
effect198 
Nimesulide 10mg/kg, i.p. twice daily 
From 1 day 
prior to 
kindling 
until 1day 
after 
kindling 
Multiple 
subconvulsi
ve electric 
shock daily 
for 4 days 
Kindling 
Adult 
male 
Wistar 
Rat 
Attenuated kindling development Antiepileptic effect196 
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Pharmacologi
cal or genetic 
modification 
of COX-2 
Dose and 
route of 
COX-2 
inhibitor 
Dosing 
paradigm Convulsant 
Seizure or 
epileptoge
nesis 
models 
Species, 
strain 
and 
gender of 
mice 
Major effects Summary 
Conditional 
genetic 
deletion of the 
PTGS2 gene 
limited to 
principal 
forebrain 
neurons 
(synapsin 1 
promoter) 
 
N/A N/A 
Methylscopolamine and 
terbutaline (2.5-3mg/kg, 
i.p.)15-30min prior 
Pilocarpine (364±33 
mg/kg i.p. for control, 
and 357±89 mg/kg for 
cKO), terminate 1h later 
by Pentobarbital 
(30mg/kg, i.p.) 
Status 
epilepticus  
Mice on 
C57BL/6 
backgrou
nd 
Unchanged latency, mortality, 
severity or EEG pattern; Early 
(1day after status epilepticus) 
aggravation but delayed (4days 
after status epilepticus) 
protective effects on CA1 
neuronal injury. Protective 
effects on somatostatin positive 
interneurons; 
No effect on 
acute seizure 
activities 
 
Delayed 
neuronal 
protective 
effects 183 
Same as above except 
for the concentration of 
Pilocarpine is 275-310 
mg/kg 
Reduced delayed mortality 
during 7 days after status 
epilepticus was found in cKO 
animals along with a modest 
improvement in Barnes maze 
test; 
Reduced 
mortality; 
Improved 
retrograde 
memory 516 
Celecoxib 
6 mg/kg, 
i.p., once 
daily for 5 
days or a 
single 
injection 
Prior to 
kainic acid 
injection 
kainic acid (12 or 6 
mg/kg, i.p.) 
Acute 
responses 
to kainic 
acid 
injection 
Male 
Wistar rat 
No improvement in object 
exploration deficit or hyperactivity in 
open field;  
No effect on neuronal loss in 
hippocampus; 
All determined 8 to 11 days post 
kainic acid injection. 
No effect on 
behavior 
consequence 
of seizures 
2 h after 
kainic acid 
injection 
Attenuation of the learning and 
object exploration deficits in MWM 
task and hyperactivity in open field; 
No effect on neuronal loss in 
hippocampus. 
All determined 8 to 11 days post 
kainic acid injection. 
Neuronal 
protective 
effect 201 
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Pharmacologi
cal or genetic 
modification 
of COX-2 
Dose and 
route of 
COX-2 
inhibitor 
Dosing 
paradigm Convulsant 
Seizure or 
epileptoge
nesis 
models 
Species, 
strain 
and 
gender of 
mice 
Major effects Summary 
Celecoxib 
20 mg/kg, 
p.o., once 
daily until 
the day of 
sacrifice 
Beginning 
24 h after 
Status 
epilepticus 
Lithium (127 mg/kg, i.p.) 
24 h prior to pilocarpine 
(30 mg/kg, i.p.), 
terminated 1h later by 
10mg/kg diazepam, i.p. 
Status 
epilepticus 
Male 
Sprague-
Dawley 
rat 
Reduction in the likelihood of 
developing spontaneous recurrent 
seizures and microglia activation.  
Inhibition of hippocampal cell 
proliferation, hilar neurogenesis and 
CA1 gliogenesis.   
Prevented neuronal loss and 
microglia activation in 
hippocampus. 
Antiepileptic 
effect 
 
Neuronal 
protective 
effect 199 
Celecoxib 
2 mg/kg, 
p.o., once 
1 h before 
PTZ 
injection 
PTZ (60 mg/kg, i.p.) Acute seizure 
Male 
Wistar rat 
Increased latency for the first clonic 
and generalized seizure induced by 
PTZ.  Decreased duration of 
generalized seizure. 
Anticonvusiv
e effect 
0.2 or 20 
mg/kg, p.o., 
once 
No effect on Seizure latency 
induced by PTZ. No effect 
182 
Rofecoxib 10 mg/kg, i.p. 
6 or 8 h 
after kainic 
acid 
injection, 
and twice 
daily for 2 
days 
kainic acid (10 
mg/kg, i.p.) 
Acute 
responses 
to kainic 
acid 
injection 
Male 
Sprague-
Dawley 
rat 
Neuroprotection in hippocampus, 
but not in thalamus, amygdala and 
piriform cortex 
Neuronal 
protective 
effect176 
Nimesulide 10 mg/kg, i.p. 
Alone with 
kainic acid 
injection 
kainic acid (10 
mg/kg, i.p.) 
Acute 
responses 
to kainic 
acid 
injection 
Male 
Sprague-
Dawley 
rat 
Augmented the toxic effects of 
kainic acid with more severe and 
longer lasting seizure symptoms. 
Significantly increased kainic acid-
induced mortality.  Less cell loss. 
Aggravates 
seizures193 
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Pharmacologi
cal or genetic 
modification 
of COX-2 
Dose and 
route of 
COX-2 
inhibitor 
Dosing 
paradigm Convulsant 
Seizure or 
epileptoge
nesis 
models 
Species, 
strain 
and 
gender of 
mice 
Major effects Summary 
Rofecoxib 4 mg/kg, i.p., once 
45 min 
before PTZ 
injection 
PTZ (i.v.*) Acute 
Male 
Albino 
mice 
Increased seizure threshold and 
thus decreased of the incidence of 
PTZ-induced convulsions 
Anticonvulsa
nt effect180 
Parecoxib 
(valdecoxib) 
10 mg/kg, 
i.p., twice 
daily for 17 
days 
1.5 h after 
Status 
epilepticus 
onset 
Lithium (127 mg/kg, 
i.p.) 12-17 h prior to 
pilocarpine (20-50 
mg/kg, i.p.), 
terminated 90min 
after by diazepam 
10mg/kg, i.p. 
Status 
epilepticus 
Female 
Sprague-
Dawley 
rat 
Reduction of PGE2 levels in 
hippocampus, frontal cortex, 
amygdala and piriform cortex. 
Reduction of the severity, but not 
the frequency and duration of 
spontaneous recurrent seizures.  
Neuroprotection in the 
hippocampus and piriform cortex. 
Moderate reduction of learning 
impairment and prevention of 
locomotor hyperactivity in the 
Morris water maze. 
Antiepileptic 
effect 
 
Neuronal 
protective 
effect200 
SC58125 
3 mg/kg, 
p.o., once 
1 h before 
kainic acid 
injection 
kainic acid (10 
mg/kg, s.c.) Acute 
responses 
to kainic 
acid 
injection 
Male 
Sprague-
Dawley 
rat 
Attenuation of kainic acid-induce 
rise in PGE2 level in the 
hippocampus. 
Not 
determined 
for acute 
seizures 
3 mg/kg, 
p.o., 3 times 
1 h before, 
24 and 48 
h after the 
kainic acid 
injection 
kainic acid (0.6 µg, 
i.c.v.# injection) 
Male 
Sprague-
Dawley 
rat 
Increased survival of hippocampal 
CA3 neurons one week after kainic 
acid exposure. 
Neuronal 
protective 
effect164 
NS398 
10 mg/kg, 
i.p., twice 
daily for 3 
days 
5 h after 
kainic acid 
injection kainic acid (1 µg, intra-
hippocampal injection) 
Acute /Not 
terminated 
for seizure 
Male 
Wistar rat 
Attenuation of kainic acid-induce 
rise in PGE2 level.  Increase in the 
number of surviving CA3 
hippocampal neurons. 
Neuronal 
protective 
effect 
5 mg/kg, 
i.p., once 
30 min 
before 
kainic acid 
injection 
Transient attenuation of kainic acid-
induce rise in PGE2 level and no 
neuroprotection in the CA3 
Not 
determined 
for acute 
seizures202 
*, i.v., intravenous injection. #, i.c.v., Intracerebroventricular injection.  
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Pharmacologi
cal or genetic 
modification 
of COX-2 
Dose and route of 
COX-2 inhibitor 
Dosing 
paradigm Convulsant 
Seizure or 
epileptoge
nesis 
models 
Species, 
strain 
and 
gender of 
mice 
Major effects Summary 
Nimesulide 10 mg/kg, p.o., once 
30 min 
before 
Status 
epilepticus 
-induction 
Electrical 
stimulation 
of 
hippocampu
s 
Rapid 
kindling 
C57BL/6J 
mice 
Attenuation of kindling-induced rise 
in PGE2 level.  Decrease in the total 
after discharge duration.  
Attenuation of recurrence of 
electrographic and behavioral 
seizures. 
Antiepileptic 
effect195 
SC58236 
10 mg/kg, p.o., 
once daily for 7 
days 
Start 4 h 
after Status 
epilepticus 
Electrical 
stimulation 
of 
hippocampu
s, status 
epilepticus 
terminated 
4h later by 
isoflurane 
Status 
epilepticus 
Male 
Sprague-
Dawley 
rat 
No effect on status epilepticus-
duration, latency to first seizure in 
epileptogenic phase, average 
number of seizures, microglial 
associated neuroinflammation, hilar 
cell loss or mossy fiber sprouting.  
Attenuation of seizure induce rise in 
PGE2 level in hippocampus 
No anti-
epileptic 
effect 517 
SC58236 
10 mg/kg, p.o., 
once daily for 3 
days or for 14 days 
Start 1 day 
before 
Status 
epilepticus 
-induction 
Electrical 
stimulation 
of 
hippocampu
s 
Status 
epilepticus 
Adult 
Male 
Sprague-
Dawley 
rat 
No effect on SE-duration, SE 
severity, hippocampal cell survival, 
microglial associated 
neuroinflammation or mossy fiber 
sprouting.  Increased mortality. 
Increase 
mortality518 
Valeryl 
salicylate 20 or 40mg/kg, s.c. 
30min 
before PTZ 
PTZ 
(60mg/kg, 
i.p.) 
Acute 
seizure 
Adult 
Male 
BALB/c 
Increased seizure severity Aggravate seizure519 
Celecoxib 6000ppm in diet water 
6 month 
before 
kainic acid kainic acid 
(10mg/kg, 
i.p,) 
Status 
epilepticus 
C57Bl/6-
129/Ola 
backgrou
nd 
 
Aggravated seizure intensity and 
neuronal injury 
Aggravate 
seizure 
 
Aggravate 
neuronal 
injury520 COX-2 knockout N/A N/A 
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Pharmacologi
cal or genetic 
modification 
of COX-2 
Dose and route of 
COX-2 inhibitor 
Dosing 
paradigm Convulsant 
Seizure or 
epileptoge
nesis 
models 
Species, 
strain 
and 
gender of 
mice 
Major effects Summary 
Celecoxib 10 or 20 mg/kg, p.o. 1h before 
Flurothyl 
(inhalant, 
0.1mL, 
10min) 
Acute 
neonatal 
seizure 
7 to 10 
days old 
Sprague-
Dawley 
rat 
Increased onset time of seizure Anticonvulsant effect521 
Rofecoxib 30mg/kg, p.o. 3h before PTZ 
PTZ 
(32mg/kg, 
i.p.) 
Acute 
seizure 
Adult 
male mice 
on 
C57BL/6 
backgrou
nd 
Increased acute seizure intensity 
and incidence 
Aggravate 
seizure68 
Rofecoxib 30mg/kg, diet water 5days before PTZ 
PTZ (40 or 
55mg/kg, 
i.p.) 
Acute 
seizure Male CD-
1 mice 
Unchanged seizure severity 
No effect181 PTZ 
(40mg/kg, 
i.p., daily) 
Kindling Unchanged progress of kindling 
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APPENDIX TABLE 2. NMDAR-responsive RNA binding proteins 
 
RNA 
binding 
protein 
Neuronal cellular 
distribution 
Neuronal RNA 
granule 
presented 
Cis-acting sequence on 
mRNAs 
NMDAR activation-
dependent change 
Activity-dependent 
functional in RNA 
processing 
CPEB 
Cell body, Synapse, 
enriched in post-
synaptic 
density390,391,396 
tRNP, SG, 
PB390,396,394 
Cytoplasmic polyadenylation 
element (CPE)382 Phosphorylation
391,393 
Polyadenylation-induced 
translation391,393,398 
 
AUF1 Primarily in the nucleus494 SG
522 AU rich element493 Down-regulation of protein level92 mRNA stabilization
92 
CBF-A 
Nucleus, 
cytoplasm, 
dendrites, pre- and 
post-synaptic 
sites100 
CBF-A+ RNP 
granule100,523 
hnRNP A2 response 
element/RNA trafficking 
sequence elements (RTS) 
100,501 
Accumulation in 
dendrites100 mRNA transportation
100 
Smaug1 Cytoplasm and dendrites95,442 S-foci
95 Smaug recognition element (SRE)436 Disassembly of S-foci
95 mRNA translation95 
HuD Cell body and dendrites349,497 
HuD+ RNP 
granule497 AU rich element
496 Increased expression
349; 
Dendritic redistribution497 mRNA translation
497 
SMN Cell body and dendrites466 tRNP, SG
466 Unknown Increased transcription470,472 Unknown 
Staufen Cytoplasm and dendrites524,525 tRNP
524 Various Stau-recognised structures (SRS)502 Not directly studied  Dendritic Morphology
505 
hnRNP-A1 Primarily in the nucleus480 SG
526 AU rich element; UAGA(G) motif480 
Increased binding to target 
pre-mRNA482 
Alternative pre-mRNA 
splicing482 
ZBP-1 Cell body, dendrites and axons425 
tRNP, SG, 
PB430-433 Zipcode element
416 Increased dendritic expression425 mRNA transportation
425 
XRN1 
Cell body, dendrites 
and post-synaptic 
sites443 
SG, PB, SX-
body212,443,447 G-quartets
450,451 Increased size and number of SX bodies443 
mRNA storage and 
silencing443 
TDP-43 Nucleus, cytoplasm and dendrites491 SG
490, PB491 UG-repeats488 Decreased binding to RNA in dendrites491 Unknown 
FMRP 
Nucleus and 
cytoplasm509, 
dendrites and 
synapses510 
tRNP510, SG527, 
PB431 
G-quadruplex507 and other 
motifs506 
Increased protein 
expression511,512  Unknown 
 
tRNP, transport ribonucleoprotein; SG, stress granule; PB, processing body; S-foci, Smaug1+ mRNA silencing granules; SX-body, XRN1+ synaptic 
granules. 
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APPENDIX TABLE 3. Raw read characteristics 
 
Mouse 
IDs Genotype Treatment 
Total 
Reads# 
Avg. 
read length 
Avg. 
read quality % N* % GC 
TA1_S11 KO Saline 67524832 74.46 33.21 0.01 49.03 
TA2_S12 KO PTZ 73285558 74.45 34.04 0.01 49.16 
TA5_S1 WT Saline 72046940 74.46 34.04 0.01 48.81 
TB2_S2 WT Saline 82177350 74.48 33.96 0.01 48.71 
TB3_S13 KO PTZ 71923278 74.45 33.97 0.01 48.95 
TB5_S3 WT Saline 66195524 74.47 33.81 0.01 49.07 
TC1_S4 WT PTZ 70995380 74.48 34.06 0.01 48.93 
TC2_S5 WT PTZ 43061028 74.48 34.03 0.01 48.91 
TC3_S14 KO PTZ 70713034 74.45 34.01 0.01 48.94 
TD3_S9 KO Saline 53928752 74.44 33.66 0.01 47.85 
TD4_S10 KO Saline 80880876 74.45 34.00 0.01 48.98 
TE2_S15 KO PTZ 79422620 74.45 33.93 0.01 48.93 
TE3_S16 KO PTZ 77200872 74.47 33.95 0.01 48.55 
TE5_S6 WT PTZ 70666828 74.48 33.85 0.01 48.94 
TF1_S7 WT PTZ 82127172 74.47 34.01 0.01 48.91 
TF4_S8 WT PTZ 78702894 74.48 34.00 0.01 48.86 
 
*, %N stands for the percentage of unidentified base call 
#, Total reads here represent all reads from the paired end sequencing (2 x 75bp) 
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APPENDIX TABLE 4. Raw read characteristics after trimming 
 
Mouse IDs Genotype Treatment 
Total 
reads# 
Avg. 
read length 
Avg. 
read quality % N % GC 
TA1_S11 KO Saline 33762483 74.37 33.22 0.01 49.04 
TA2_S12 KO PTZ 36642882 74.35 34.05 0.01 49.18 
TA5_S1 WT Saline 36023531 74.36 34.04 0.01 48.82 
TB2_S2 WT Saline 41088773 74.38 33.96 0.01 48.72 
TB3_S13 KO PTZ 35961719 74.34 33.97 0.01 48.96 
TB5_S3 WT Saline 33097874 74.37 33.81 0.01 49.08 
TC1_S4 WT PTZ 35497771 74.38 34.06 0.01 48.95 
TC2_S5 WT PTZ 21530550 74.38 34.04 0.01 48.93 
TC3_S14 KO PTZ 35356598 74.35 34.01 0.01 48.95 
TD3_S9 KO Saline 26964468 74.34 33.66 0.01 47.87 
TD4_S10 KO Saline 40440580 74.35 34.00 0.01 48.99 
TE2_S15 KO PTZ 39711471 74.35 33.93 0.01 48.94 
TE3_S16 KO PTZ 38600625 74.36 33.95 0.01 48.57 
TE5_S6 WT PTZ 35333489 74.38 33.85 0.01 48.96 
TF1_S7 WT PTZ 41063689 74.37 34.01 0.01 48.92 
TF4_S8 WT PTZ 39351573 74.38 34.01 0.01 48.87 
 
*, %N stands for the percentage of unidentified base call 
#, Total reads here represent unpaired reads after trimming (1 x 75bp), note the number reduced to ~1/2 
of paired total reads in Appendix Table 3 
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APPENDIX TABLE 5. Raw Gene Counts after quantification. 
 
Sample name Genotype Treatment Min Max Mean Median Q1 Q3 
TA1_S11 KO Saline 0 107876 933.01 74.00 0.00 767.00 
TA2_S12 KO PTZ 0 174552 1063.83 93.00 0.00 882.00 
TA5_S1 WT Saline 0 114010 1032.56 88.00 0.00 870.50 
TB2_S2 WT Saline 0 144024 1176.99 87.00 0.00 957.98 
TB3_S13 KO PTZ 0 287954 1025.22 102.00 0.00 875.00 
TB5_S3 WT Saline 0 165676 937.43 75.00 0.00 771.00 
TC1_S4 WT PTZ 0 122641 1025.23 80.00 0.00 840.43 
TC2_S5 WT PTZ 0 73725.3 617.67 48.00 0.00 507.00 
TC3_S14 KO PTZ 0 257812 1030.20 95.00 0.00 872.00 
TD3_S9 KO Saline 0 79873.4 716.80 51.02 0.00 588.50 
TD4_S10 KO Saline 0 119148 1167.10 109.00 0.00 993.00 
TE2_S15 KO PTZ 0 130780 1131.08 87.00 0.00 923.38 
TE3_S16 KO PTZ 0 128124 1100.12 91.00 0.00 908.00 
TE5_S6 WT PTZ 0 108485 999.70 88.00 0.00 842.00 
TF1_S7 WT PTZ 0 141710 1168.38 92.00 0.00 959.50 
TF4_S8 WT PTZ 0 141663 1124.50 87.00 0.00 920.50 
All samples   0 287954 1015.61 82.00 0.00 832.53 
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